CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><script src="https://cmp.osano.com/6olh2SicG0V81Mlk/1f9d883d-3834-40b9-9a96-6f89a1cda98b/osano.js"></script><title>Multiple Myeloma</title><meta name="description" content="The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."/><meta property="og:url" content="https://www.ajmc.com/compendium/multiple-myeloma "/><meta property="og:title" content="Multiple Myeloma"/><meta property="og:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta property="og:site_name" content="AJMC"/><meta property="og:description" content="The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Multiple Myeloma"/><meta name="twitter:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta name="twitter:site" content="@@AJMC_Journal"/><meta name="twitter:description" content="The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."/><meta name="robots" content="max-image-preview:large"/><meta name="robots" content="max-video-preview:-1"/><link rel="preconnect dns-prefetch" href="https://cmp.osano.com"/><link rel="preconnect dns-prefetch" href="https://res.lassomarketing.io"/><link rel="preconnect dns-prefetch" href="https://www.lightboxcdn.com"/><link rel="preconnect dns-prefetch" href="https://pub.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.segment.com"/><link rel="preconnect dns-prefetch" href="https://securepubads.g.doubleclick.net"/><link rel="preconnect dns-prefetch" href="https://pagead2.googlesyndication.com"/><link rel="preconnect dns-prefetch" href="https://cdn.sanity.io"/><link rel="preconnect dns-prefetch" href="https://www.google-analytics.com"/><link rel="preconnect dns-prefetch" href="https://www.googletagmanager.com"/><link rel="preconnect dns-prefetch" href="https://player.vimeo.com"/><link rel="preconnect dns-prefetch" href="https://youtube.com"/><link rel="preconnect dns-prefetch" href="https://connect.facebook.net"/><link rel="preconnect dns-prefetch" href="https://www.facebook.com"/><link rel="preconnect dns-prefetch" href="https://static.ads-twitter.com"/><link rel="preconnect dns-prefetch" href="https://ad.doubleclick.net"/><link rel="preload" href="https://securepubads.g.doubleclick.net/tag/js/gpt.js"/><link rel="preload" href="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"/><link rel="icon" href="/favicon.ico"/><script async="" src="https://securepubads.g.doubleclick.net/tag/js/gpt.js"></script><script src="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"></script><script src="https://one.ajmc.com/tagmanager/scripts/one.js"></script><script>window.dataLayer = window.dataLayer || []; window.dataLayer.push({ event: "page_dimensions", pageTitle: "Multiple Myeloma", dimension9: "compendium/multiple-myeloma", dimension11: "", dimension12: "", dimension13: "", dimension14: "", dimension15: "compendium/multiple-myeloma", dimension18: "", dimension19: "", dimension20: "", });</script><script type="module"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NK5KQXS'); </script><script type="module"> var ALGOLIA_INSIGHTS_SRC = "https://cdn.jsdelivr.net/npm/search-insights@2.4.0"; !function(e,a,t,n,s,i,c){e.AlgoliaAnalyticsObject=s,e[s]=e[s]||function(){ (e[s].queue=e[s].queue||[]).push(arguments)},i=a.createElement(t),c=a.getElementsByTagName(t)[0], i.async=1,i.src=n,c.parentNode.insertBefore(i,c) }(window,document,"script",ALGOLIA_INSIGHTS_SRC,"aa");</script><link rel="canonical" href="https://www.ajmc.com/compendium/multiple-myeloma"/><meta name="next-head-count" content="10"/><script async="" type="text/javascript" src="https://www.lightboxcdn.com/static/lightbox_mjh.js"></script><script defer="" src="https://res.lassomarketing.io/scripts/lasso-imp-id-min.js" type="text/javascript"></script> <script defer="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js"></script> <script type="module"> !function(){var analytics=window.analytics=window.analytics||[];if(!analytics.initialize)if(analytics.invoked)window.console&&console.error&&console.error("Segment snippet included twice.");else{analytics.invoked=!0;analytics.methods=["trackSubmit","trackClick","trackLink","trackForm","pageview","identify","reset","group","track","ready","alias","debug","page","once","off","on","addSourceMiddleware","addIntegrationMiddleware","setAnonymousId","addDestinationMiddleware"];analytics.factory=function(e){return function(){var t=Array.prototype.slice.call(arguments);t.unshift(e);analytics.push(t);return analytics}};for(var e=0;e<analytics.methods.length;e++){var key=analytics.methods[e];analytics[key]=analytics.factory(key)}analytics.load=function(key,e){var t=document.createElement("script");t.type="text/javascript";t.async=!0;t.src="https://cdn.segment.com/analytics.js/v1/" + key + "/analytics.min.js";var n=document.getElementsByTagName("script")[0];n.parentNode.insertBefore(t,n);analytics._loadOptions=e};analytics.SNIPPET_VERSION="4.13.1"; window.LassoImpressionID = lassoImpID(); analytics.load("BBbKMoOjmhsxPnbd2nO6osz3zq67DzuN"); analytics.page({ 'LassoImpressionID': window.LassoImpressionID }); }}(); </script> <link rel="preload" href="/_next/static/css/e5225e6dc4ca333b.css" as="style"/><link rel="stylesheet" href="/_next/static/css/e5225e6dc4ca333b.css" data-n-g=""/><link rel="preload" href="/_next/static/css/1fd9d1dcb68b7a42.css" as="style"/><link rel="stylesheet" href="/_next/static/css/1fd9d1dcb68b7a42.css" data-n-p=""/><link rel="preload" href="/_next/static/css/73c00cd95dc66651.css" as="style"/><link rel="stylesheet" href="/_next/static/css/73c00cd95dc66651.css" data-n-p=""/><link rel="preload" href="/_next/static/css/0f1de527bcd6b2b3.css" as="style"/><link rel="stylesheet" href="/_next/static/css/0f1de527bcd6b2b3.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="/_next/static/chunks/webpack-7bb91bc5bbba1ada.js" defer=""></script><script src="/_next/static/chunks/framework-45ce3d09104a2cae.js" defer=""></script><script src="/_next/static/chunks/main-c1ce322a402d266c.js" defer=""></script><script src="/_next/static/chunks/pages/_app-c3a05645a08041c3.js" defer=""></script><script src="/_next/static/chunks/8eec4907-bd18a9d50c17fbc1.js" defer=""></script><script src="/_next/static/chunks/065a3ddb-42216585c327b2a5.js" defer=""></script><script src="/_next/static/chunks/9814d858-cb162ab048445baf.js" defer=""></script><script src="/_next/static/chunks/69bd6bf3-c7219ac9ecb38ac9.js" defer=""></script><script src="/_next/static/chunks/f36c6662-e730e1316f9aa347.js" defer=""></script><script src="/_next/static/chunks/72585f70-0d4479e14d41a365.js" defer=""></script><script src="/_next/static/chunks/59b4e022-12a1c6f09c31aa87.js" defer=""></script><script src="/_next/static/chunks/aeb74aa0-4e0b515016d20a9f.js" defer=""></script><script src="/_next/static/chunks/e893f787-08b93252db7fc864.js" defer=""></script><script src="/_next/static/chunks/e1efa4cc-06e900eb45581c19.js" defer=""></script><script src="/_next/static/chunks/c8eae200-9f0c2beb62006a40.js" defer=""></script><script src="/_next/static/chunks/a29ae703-70c961c34719afa8.js" defer=""></script><script src="/_next/static/chunks/4592-37f767f9d2e595fc.js" defer=""></script><script src="/_next/static/chunks/1212-e69ee8c76b24c02a.js" defer=""></script><script src="/_next/static/chunks/4179-91956f2d2c4bf724.js" defer=""></script><script src="/_next/static/chunks/9879-c84885d45ee98d34.js" defer=""></script><script src="/_next/static/chunks/9355-c793747e2dd7fab4.js" defer=""></script><script src="/_next/static/chunks/3499-b4daf1c9382343af.js" defer=""></script><script src="/_next/static/chunks/4386-1eb6319d7e5f2437.js" defer=""></script><script src="/_next/static/chunks/8421-a4cb4c694745bc83.js" defer=""></script><script src="/_next/static/chunks/8412-bd07abe8ce76d08f.js" defer=""></script><script src="/_next/static/chunks/430-ec5773e97694cd78.js" defer=""></script><script src="/_next/static/chunks/173-0c8dbb3c1f76b4a8.js" defer=""></script><script src="/_next/static/chunks/7707-950f90aec08fbabe.js" defer=""></script><script src="/_next/static/chunks/475-90949f2271d616fd.js" defer=""></script><script src="/_next/static/chunks/9323-6b03066a987bc392.js" defer=""></script><script src="/_next/static/chunks/4978-ee388caa09ad5169.js" defer=""></script><script src="/_next/static/chunks/4063-ea283543a8930e92.js" defer=""></script><script src="/_next/static/chunks/pages/%5B...slug%5D-1b8b61a43bc98d83.js" defer=""></script><script src="/_next/static/jIKMoC-9mMyLq4v4Ma7Tv/_buildManifest.js" defer=""></script><script src="/_next/static/jIKMoC-9mMyLq4v4Ma7Tv/_ssgManifest.js" defer=""></script><style id="__jsx-1661e6713d4eb9b5">.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:90px;background:#fff}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5{}@media screen and (min-width:768px){.leader-fixed.jsx-1661e6713d4eb9b5{position:fixed;margin-top:1rem;z-index:999999}}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5 div[id*="google_ads_iframe"].jsx-1661e6713d4eb9b5:empty{height:0px!important}@media screen and (max-width:668px){.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:0px;position:fixed;background:white;left:0;right:0;top:55px;padding-top:.5rem;padding-bottom:.25rem;z-index:9999}}</style><style id="__jsx-1215160397">.bottomDiv.jsx-1215160397{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1215160397::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1215160397::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1215160397{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1215160397{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1215160397{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore0undefined.jsx-1215160397:hover{background:var(--secondary)}.view-more-wrap0undefined.jsx-1215160397{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap0undefined.jsx-1215160397:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1215160397{background-position:right bottom}.text-white.jsx-1215160397{color:var(--primary)}</style><style id="__jsx-1637274924">.bottomDiv.jsx-1637274924{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1637274924::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1637274924::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1637274924{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1637274924{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1637274924{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore1undefined.jsx-1637274924:hover{background:var(--secondary)}.view-more-wrap1undefined.jsx-1637274924{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap1undefined.jsx-1637274924:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1637274924{background-position:right bottom}.text-white.jsx-1637274924{color:var(--primary)}</style><style id="__jsx-286612495">.bottomDiv.jsx-286612495{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-286612495::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-286612495::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-286612495{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-286612495{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-286612495{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore2undefined.jsx-286612495:hover{background:var(--secondary)}.view-more-wrap2undefined.jsx-286612495{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap2undefined.jsx-286612495:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-286612495{background-position:right bottom}.text-white.jsx-286612495{color:var(--primary)}</style><style id="__jsx-2915913710">.bottomDiv.jsx-2915913710{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2915913710::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2915913710::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2915913710{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2915913710{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2915913710{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore3undefined.jsx-2915913710:hover{background:var(--secondary)}.view-more-wrap3undefined.jsx-2915913710{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap3undefined.jsx-2915913710:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2915913710{background-position:right bottom}.text-white.jsx-2915913710{color:var(--primary)}</style><style id="__jsx-2363373513">.bottomDiv.jsx-2363373513{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2363373513::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2363373513::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2363373513{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2363373513{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2363373513{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore4undefined.jsx-2363373513:hover{background:var(--secondary)}.view-more-wrap4undefined.jsx-2363373513{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap4undefined.jsx-2363373513:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2363373513{background-position:right bottom}.text-white.jsx-2363373513{color:var(--primary)}</style><style id="__jsx-19ede9f0a5a45918">.jsx-19ede9f0a5a45918::-webkit-scrollbar{display:none}</style><style id="__jsx-2785488040">.bottomDiv.jsx-2785488040{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2785488040::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2785488040::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2785488040{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2785488040{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2785488040{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore5undefined.jsx-2785488040:hover{background:var(--secondary)}.view-more-wrap5undefined.jsx-2785488040{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap5undefined.jsx-2785488040:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2785488040{background-position:right bottom}.text-white.jsx-2785488040{color:var(--primary)}</style><style id="__jsx-1434825611">.bottomDiv.jsx-1434825611{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1434825611::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1434825611::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1434825611{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1434825611{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1434825611{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore6undefined.jsx-1434825611:hover{background:var(--secondary)}.view-more-wrap6undefined.jsx-1434825611{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap6undefined.jsx-1434825611:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1434825611{background-position:right bottom}.text-white.jsx-1434825611{color:var(--primary)}</style><style id="__jsx-4064126826">.bottomDiv.jsx-4064126826{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-4064126826::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-4064126826::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-4064126826{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-4064126826{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-4064126826{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore7undefined.jsx-4064126826:hover{background:var(--secondary)}.view-more-wrap7undefined.jsx-4064126826{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap7undefined.jsx-4064126826:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-4064126826{background-position:right bottom}.text-white.jsx-4064126826{color:var(--primary)}</style><style id="__jsx-187450181">.bottomDiv.jsx-187450181{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-187450181::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-187450181::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-187450181{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-187450181{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-187450181{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore8undefined.jsx-187450181:hover{background:var(--secondary)}.view-more-wrap8undefined.jsx-187450181{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap8undefined.jsx-187450181:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-187450181{background-position:right bottom}.text-white.jsx-187450181{color:var(--primary)}</style><style id="__jsx-609564708">.bottomDiv.jsx-609564708{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-609564708::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-609564708::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-609564708{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-609564708{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-609564708{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore9undefined.jsx-609564708:hover{background:var(--secondary)}.view-more-wrap9undefined.jsx-609564708{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap9undefined.jsx-609564708:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-609564708{background-position:right bottom}.text-white.jsx-609564708{color:var(--primary)}</style><style id="__jsx-3886647465">.bottomDiv.jsx-3886647465{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-3886647465::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-3886647465::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-3886647465{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-3886647465{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-3886647465{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore0355d9b46-713d-4d48-84a7-2968d82157e5.jsx-3886647465:hover{background:var(--secondary)}.view-more-wrap0355d9b46-713d-4d48-84a7-2968d82157e5.jsx-3886647465{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap0355d9b46-713d-4d48-84a7-2968d82157e5.jsx-3886647465:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-3886647465{background-position:right bottom}.text-white.jsx-3886647465{color:var(--primary)}</style><style id="__jsx-3945728741">.bottomDiv.jsx-3945728741{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-3945728741::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-3945728741::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-3945728741{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-3945728741{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-3945728741{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore13b3937de-a7a5-4ebd-bb5c-6192a7da7102.jsx-3945728741:hover{background:var(--secondary)}.view-more-wrap13b3937de-a7a5-4ebd-bb5c-6192a7da7102.jsx-3945728741{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap13b3937de-a7a5-4ebd-bb5c-6192a7da7102.jsx-3945728741:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-3945728741{background-position:right bottom}.text-white.jsx-3945728741{color:var(--primary)}</style><style id="__jsx-3745364856">.bottomDiv.jsx-3745364856{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-3745364856::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-3745364856::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-3745364856{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-3745364856{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-3745364856{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore29453bbb8-c0d5-459e-9058-a97e9e0cdb97.jsx-3745364856:hover{background:var(--secondary)}.view-more-wrap29453bbb8-c0d5-459e-9058-a97e9e0cdb97.jsx-3745364856{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap29453bbb8-c0d5-459e-9058-a97e9e0cdb97.jsx-3745364856:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-3745364856{background-position:right bottom}.text-white.jsx-3745364856{color:var(--primary)}</style><style id="__jsx-2629720111">.bottomDiv.jsx-2629720111{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2629720111::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2629720111::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2629720111{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2629720111{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2629720111{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore354fbd28a-f02c-44b9-8d31-f0863e5d2455.jsx-2629720111:hover{background:var(--secondary)}.view-more-wrap354fbd28a-f02c-44b9-8d31-f0863e5d2455.jsx-2629720111{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap354fbd28a-f02c-44b9-8d31-f0863e5d2455.jsx-2629720111:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2629720111{background-position:right bottom}.text-white.jsx-2629720111{color:var(--primary)}</style><style id="__jsx-ad50481d5ee26850">@media(min-width:980px)and (max-width:1200px){.article-detail.jsx-ad50481d5ee26850{width:47%}}@media(min-width:1201px)and (max-width:1400px){.article-detail.jsx-ad50481d5ee26850{width:55%}}</style></head><body><div id="__next" data-reactroot=""><div class="-mb-6"><div id="frame-nav" class="sticky top-0 z-[999999]"><div class="h-full w-full"><nav role="navigation" class=" w-full mx-auto hidden lg:block bg-white shadow-md relative"><div class="bg-primary" id="topnav"><div class="container px-4 relative justify-between h-16 flex items-center md:items-stretch mx-auto "><div class="h-full flex items-center flex-1 justify-between mr-4"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></a><div class="hidden md:block"><div class="bg-primary py-2 whitespace-nowrap"><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 items-end"><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">News<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/news" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All News</a><a href="/press-release" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Press Releases</a><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Video<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/video-hub" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Video Types</a><a href="/interviews" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC TV</a><a href="/insights" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insights</a><a href="/onlocation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">OnLocation</a><a href="/payer-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Payer Perspectives</a><a href="/peer-exchange" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Peer Exchange</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a><a href="/stakeholder-summit" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Stakeholder Summit</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/podcasts">Podcasts</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Conferences<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/latest-conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Coverage</a><a href="/conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Listing</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Journals<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/publications" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Journals</a><a href="/publications/issue" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">The American Journal of Managed Care</a><a href="/publications/ajac" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health, Equity & Outcomes</a><a href="/publications/evidence-based-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Evidence-Based Oncology</a><a href="/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">About Supplements and Featured Publications</a><a href="/publications/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Supplements and Featured Publications Issues</a><a href="/submit-a-manuscript" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Submit a Manuscript</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Events<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/ivbmevents" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Institute for Value-Based Medicine</a><a href="https://pcoc.ajmc.com/" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Patient-Centered Oncology Care</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Resources<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/interactive-tools" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Interactive Tools</a><a href="/clinical-spotlight" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Clinical Spotlight</a><a href="/custom-email" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Microsites</a><a href="/sponsored" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sponsored Content</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/continuing-education">CE</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">About AJMC<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/editorial" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC Staff</a><a href="/anniversary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Anniversary</a><a href="/about/seema-sonnad-nomination" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Seema Sonnad Award</a><a href="/partners" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Strategic Alliance Partners</a></div></div></div></div></div></div></div><div class="md:flex items-center justify-end hidden"><div class="flex items-center"><div class="md:pr-10 lg:pr-0 h-full flex items-center"><button class="w-6 h-6 relative"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button><div class="hidden bg-secondary p-4 rounded shadow-lg top-16 right-0 overflow-hidden absolute grid place-items-center z-[99999] "><form method="GET" action="/search"><div class="relative"><div class="text-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6"><button aria-label="submit" type="submit" class="absolute block inset-0"><svg xmlns="http://www.w3.org/2000/svg" class="text-gray-600 stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button></div><input type="text" required="" name="searchTerm" class="block border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2" placeholder="Search"/></div></form></div></div></div><a href="https://one.ajmc.com/subscribe" class="bg-subscribe-btn rounded text-white py-1.5 px-3 text-[14px] ml-4 uppercase font-semibold">Subscribe</a></div></div></div><div class="bg-white" id="bottomnav"><div style="max-height:60px" class="px-4 transition-all container justify-between h-14 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-row gap-2 mr-4"><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</span><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</span><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</span><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lung Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</span><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div><div class="flex flex-1 items-center gap-3 overflow-hidden justify-start"><span class="text-md font-semibold whitespace-pre !text-primary filter brightness-75">Spotlight</span><ul id="spotlight-links" class="flex gap-2 h-4 overflow-hidden flex-wrap"><li class="text-xs pt-0.5 whitespace-pre cursor-pointer hover:underline text-gray-800"><a href="/ivbmevents?display=home">Free In-Person Regional Events Focused on Oncology and Population Health</a></li></ul></div></div></div></div></nav><nav class="lg:hidden"><div class="w-full shadow-md bg-primary sticky top-0 z-40"><div class="flex mx-auto container"><div class=" py-4 flex items-stretch justify-between mx-4 items-center w-full"><div class="flex items-center justify-end"><div class="flex items-center"><div class="h-full flex items-center"><button id="menu" aria-label="open menu" aria-expanded="false" class="focus:outline-none focus:ring-2 focus:ring-gray-700 rounded-md text-white"><svg width="30" height="30" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M21 10H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 6H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 14H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 18H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path></svg></button></div></div></div><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-10 w-40"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center" loading="lazy"/></noscript></span></a></div><div class="relative w-8 h-8 my grid items-center"><a class="absolute lg:hidden inset-0 mt-1" href="/search"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></a></div></div></div><div style="max-height:50px" class="bg-white px-4 transition-all h-12 md:items-stretch mx-auto" id="bottomnav-mobile"><div class="container justify-between h-12 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-1 justify-center xs:justify-start items-center relative group h-full z-50 gap-2"><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</span><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</span><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</span><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lung Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</span><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div></div></div></div></div><div class="fixed top-0 w-[85vw] h-full transform -translate-x-full z-40 transition duration-300 lg:hidden min-h-screen bg-primary shadow-lg" id="mobile-nav"><div class="w-full h-full shadow-lg z-40 fixed overflow-y-auto top-0 flex-col justify-between xl:hidden pb-4 transition duration-500 ease-in-out"><div class="px-5 h-full"><div class="flex flex-col justify-between h-full w-full"><div><div class="mt-6 flex w-full items-center justify-between"><div class="border-b border-gray-200 pb-2 flex items-center justify-between w-full"><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-16 w-40 "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></div><button aria-label="close menu" class="focus:outline-none focus:ring-2 rounded-md text-white pl-8 font-bold"><svg width="18" height="18" viewBox="0 0 14 14" fill="#fff" xmlns="http://www.w3.org/2000/svg"><path d="M13 1L1 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path><path d="M1 1L13 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path></svg></button></div></div><ul role="list" class="flex flex-1 flex-col gap-y-7 mt-6"><li><ul role="list" class="-mx-2 space-y-1"><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Spotlight</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>News</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Video</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/podcasts"><span>Podcasts</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Conferences</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Journals</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Events</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Resources</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/continuing-education"><span>CE</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>About AJMC</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="https://one.ajmc.com/subscribe"><span>Subscribe</span></a></li></ul></li></ul><div class="flex md:hidden mt-4 items-center gap-2 mt-6 pt-6 border-t"><a rel="noreferrer noopener" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="21" height="21" viewBox="12.65 12.65 118.02 118.02"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z" fill="#FFFFFF"></path></g></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="27" width="27" xmlns="http://www.w3.org/2000/svg"><path d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.instagram.com/ajmcjournal/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M224,202.66A53.34,53.34,0,1,0,277.36,256,53.38,53.38,0,0,0,224,202.66Zm124.71-41a54,54,0,0,0-30.41-30.41c-21-8.29-71-6.43-94.3-6.43s-73.25-1.93-94.31,6.43a54,54,0,0,0-30.41,30.41c-8.28,21-6.43,71.05-6.43,94.33S91,329.26,99.32,350.33a54,54,0,0,0,30.41,30.41c21,8.29,71,6.43,94.31,6.43s73.24,1.93,94.3-6.43a54,54,0,0,0,30.41-30.41c8.35-21,6.43-71.05,6.43-94.33S357.1,182.74,348.75,161.67ZM224,338a82,82,0,1,1,82-82A81.9,81.9,0,0,1,224,338Zm85.38-148.3a19.14,19.14,0,1,1,19.13-19.14A19.1,19.1,0,0,1,309.42,189.74ZM400,32H48A48,48,0,0,0,0,80V432a48,48,0,0,0,48,48H400a48,48,0,0,0,48-48V80A48,48,0,0,0,400,32ZM382.88,322c-1.29,25.63-7.14,48.34-25.85,67s-41.4,24.63-67,25.85c-26.41,1.49-105.59,1.49-132,0-25.63-1.29-48.26-7.15-67-25.85s-24.63-41.42-25.85-67c-1.49-26.42-1.49-105.61,0-132,1.29-25.63,7.07-48.34,25.85-67s41.47-24.56,67-25.78c26.41-1.49,105.59-1.49,132,0,25.63,1.29,48.33,7.15,67,25.85s24.63,41.42,25.85,67.05C384.37,216.44,384.37,295.56,382.88,322Z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="/rss"></a></div></div></div></div></div></div></nav></div></div><div class="container px-4 mx-auto pl-2 pr-2 sm:h-[98px] sm:w-[728px]"><div id="leaderboardWrapper" class="jsx-1661e6713d4eb9b5 leaderboardAdWrapper mx-auto mt-1 flex min-h-0 md:min-h-[90px] justify-center items-center flex-col relative z-[99999] "><div class="jsx-1661e6713d4eb9b5 bg-white md:-translate-x-4"><div class="jsx-1661e6713d4eb9b5 text-[8px] text-center text-gray-600 hidden relative">Advertisement</div><div id="div-gpt-ad-top" class="jsx-1661e6713d4eb9b5 AD728x90 mx-auto text-center x"></div></div></div></div><hr class="mt-8 pt-8 -mb-4 pb-0"/><div id="multiple-myeloma" class="container mx-auto flex m-1 min-h-[57vh] px-4"><div class="flex-auto w-[calc(100%-300px)] pr-0 md:pr-6 mt-16 sm:mt-0"><div class="pb-24 my-2"><div class="flex"><h1 class="text-[19px] mt-1 md:mt-0 md:text-3xl mb-2">Multiple Myeloma</h1><div class="flex justify-center px-0 -mt-1 sm:-mt-2 align-center"></div></div><div class="w-full mb-2 border border-secondary"></div><div id="description-summary" class="text-sm text-gray-500"><div class="blockText_blockContent__TbCXh"><p class="pb-2">The <em>AJMC</em><sup class="text-inherit">®</sup> Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.</p></div><div class="clear-both"></div></div><div class="border-b-[2px] border-[#EEE] "><div class="m-2"><div class="hidden xs:flex justify-between items-center"><h2 class="text-3xl">Latest News</h2></div><div class="xs:my-6 my-4 xs:block hidden"><div class="flex"><div class="flex sm:pr-[35px] pr-[20px] flex-col w-[40%] border-r-[2px] border-[#EEE]"><div class="lg:h-[220px] h-[170px] relative bg-default-logo-background "><a class="0 w-full" href="/view/balancing-life-and-myeloma-a-patient-centered-approach"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-contain" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-contain" loading="lazy"/></noscript></span></a></div><div class="border-t-gray-100 border-t-2 flex-auto py-2 "><span class="text-sm text-gray-500 py-2">November 22nd 2024</span><div class="py-3"><a class="lg:text-[20px] text-[19px] font-[500]" href="/view/balancing-life-and-myeloma-a-patient-centered-approach">Balancing Life and Myeloma: A Patient-Centered Approach</a></div><div class="pb-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/maggie-l-shaw"><i>Maggie L. Shaw</i></a></span></div></div><a href="/view/balancing-life-and-myeloma-a-patient-centered-approach"><a href="/view/balancing-life-and-myeloma-a-patient-centered-approach"><p class="mt-1 text-gray-800 text-[13px] line-clamp-6 text-hidden">In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.</p></a></a></div></div><div class="flex-wrap w-[60%] flex "><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/elevating-value-in-cancer-care-with-innovations-accessibility-equity"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/elevating-value-in-cancer-care-with-innovations-accessibility-equity"><span class="text-sm text-gray-500">November 21st 2024</span></a><div><a class="text-[14px]" href="/view/elevating-value-in-cancer-care-with-innovations-accessibility-equity"><p class="line-clamp-4 text-hidden font-[500]">Elevating Value in Cancer Care With Innovations, Accessibility, Equity</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/os-better-with-belantamab-mafodotin-triplet-vs-daratumumab-in-r-r-mm"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/os-better-with-belantamab-mafodotin-triplet-vs-daratumumab-in-r-r-mm"><span class="text-sm text-gray-500">November 19th 2024</span></a><div><a class="text-[14px]" href="/view/os-better-with-belantamab-mafodotin-triplet-vs-daratumumab-in-r-r-mm"><p class="line-clamp-4 text-hidden font-[500]">OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/jordyn-sava"><i>Jordyn Sava</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/elevating-myeloma-care-amidst-complex-treatment-choices"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/elevating-myeloma-care-amidst-complex-treatment-choices"><span class="text-sm text-gray-500">November 15th 2024</span></a><div><a class="text-[14px]" href="/view/elevating-myeloma-care-amidst-complex-treatment-choices"><p class="line-clamp-4 text-hidden font-[500]">Elevating Myeloma Care Amidst Complex Treatment Choices</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/maggie-l-shaw"><i>Maggie L. Shaw</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/eque-cel-car-t-shows-strong-results-for-multiple-myeloma"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/eque-cel-car-t-shows-strong-results-for-multiple-myeloma"><span class="text-sm text-gray-500">November 7th 2024</span></a><div><a class="text-[14px]" href="/view/eque-cel-car-t-shows-strong-results-for-multiple-myeloma"><p class="line-clamp-4 text-hidden font-[500]">Eque-Cel CAR T Shows Strong Results for Multiple Myeloma</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/maggie-l-shaw"><i>Maggie L. Shaw</i></a></span></div></div></div></a></div></div></div><div class="xs:hidden block"><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-full xs:my-6 my-4 #000 text-3xl">Latest News</div></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/balancing-life-and-myeloma-a-patient-centered-approach"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">November 22nd 2024</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Balancing Life and Myeloma: A Patient-Centered Approach</p></div><div class="jsx-1215160397 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/maggie-l-shaw"><i>Maggie L. Shaw</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/elevating-value-in-cancer-care-with-innovations-accessibility-equity"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fc93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">November 21st 2024</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Elevating Value in Cancer Care With Innovations, Accessibility, Equity</p></div><div class="jsx-1637274924 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/os-better-with-belantamab-mafodotin-triplet-vs-daratumumab-in-r-r-mm"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">November 19th 2024</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM</p></div><div class="jsx-286612495 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/jordyn-sava"><i>Jordyn Sava</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/elevating-myeloma-care-amidst-complex-treatment-choices"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">November 15th 2024</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Elevating Myeloma Care Amidst Complex Treatment Choices</p></div><div class="jsx-2915913710 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/maggie-l-shaw"><i>Maggie L. Shaw</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/eque-cel-car-t-shows-strong-results-for-multiple-myeloma"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd6cda65715e52774e2cab34d922cdd302167b243-1200x738.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">November 7th 2024</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Eque-Cel CAR T Shows Strong Results for Multiple Myeloma</p></div><div class="jsx-2363373513 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/maggie-l-shaw"><i>Maggie L. Shaw</i></a></span></div></div></div></div></a></div></div></div></div></div><div class="py-8 border-b-[2px] border-[#EEE]"><div class="relative w-full h-full max-w-[984px] rounded-md mx-auto"><div class="flex flex-col-reverse lg:flex-row items-center justify-center mx-auto rounded-md"><div class="w-full lg:w-[610px] xl:w-3/4 h-[280px] xs:h-[260px] sm:h-[250px] lg:h-[243px] xl:h-[311px] pb-[90px] pt-2 sm:pt-4 lg:pt-3 xl:pt-4 pl-3 xs:pl-4 sm:pl-6 pr-3 rounded-tl-none lg:rounded-tl-md rounded-bl-md rounded-br-md lg:rounded-br-none" style="background:var(--primary)"><h2 class="text-md sm:text-lg xl:text-xl leading-tight lg:leading-none xl:sleading-tight text-white font-bold font-lora my-2">EHA 2024: Highlights in Multiple Myeloma</h2><p class=" font-light font-rubik text-white text-xs xl:text-sm">Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.</p><div style="color:var(--primary)"><a class="font-bold font-rubik text-xs flex items-center gap-2 mt-2.5 xs:mt-4 lg:mt-2.5 xl:mt-3.5 py-2 px-3 cursor-pointer max-w-fit bg-white hover:bg-gray-300 rounded-md" href="https://bit.ly/4cuqjYm">Visit Now</a></div></div><div class="w-full max-h-[385px] lg:max-h-[243px] xl:max-h-[311px] overflow-hidden flex justify-center items-center rounded-br-none rounded-tr-md rounded-tl-md lg:rounded-r-md lg:rounded-tl-none pointer-events-none"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27959%27%20height=%27539.5%27/%3e"/></span><img alt="Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024." srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2c39f10d15ac4c73885940b5265e347b27a026ea-492x300.png&w=1080&q=75 1x, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2c39f10d15ac4c73885940b5265e347b27a026ea-492x300.png&w=1920&q=75 2x" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2c39f10d15ac4c73885940b5265e347b27a026ea-492x300.png&w=1920&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div></div><div class="absolute bottom-0 left-0 flex justify-between lg:justify-start gap-2 w-full lg:w-[22rem] xl:w-[27rem] px-3 xs:px-4 sm:px-6 pb-3 xs:pb-6 lg:pb-3 xl:pb-6"><button class="w-8 h-8 rounded-2xl flex items-center justify-center"><svg fill="none" height="32" viewBox="0 0 24 24" width="32" xmlns="http://www.w3.org/2000/svg"><g stroke="#fff" stroke-width="2"><circle cx="12" cy="12" r="10"></circle><path d="m13.5 8-4 4 4 4" stroke-linecap="round" stroke-linejoin="round"></path></g></svg></button><div class="flex items-center justify-around w-full gap-[3px]"><button class="flex-1 h-[3px] rounded-full bg-white"></button><button class="flex-1 h-[3px] rounded-full bg-white bg-opacity-40"></button></div><button class="w-8 h-8 rounded-2xl flex items-center justify-center"><svg fill="none" height="32" viewBox="0 0 24 24" width="32" xmlns="http://www.w3.org/2000/svg"><g stroke="#fff" stroke-width="2"><circle cx="12" cy="12" r="10"></circle><path d="m10.5 8 4 4-4 4" stroke-linecap="round" stroke-linejoin="round"></path></g></svg></button></div></div></div><div class="border-b-[2px] border-[#EEE] "><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Video Interviews</div><a href="/interviews" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/mrd-a-game-changer-in-multiple-myeloma"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg%2FSidana%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">October 24th 2024</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">MRD: A Game Changer in Multiple Myeloma</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/ims-2024-speakers-look-back-on-exciting-myeloma-updates"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png%2FIMS%2520-%25202024%2520Recap.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">October 1st 2024</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">IMS 2024 Speakers Look Back on Exciting Myeloma Updates</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/evaluating-t-cell-therapies-in-first-line-multiple-myeloma-treatment"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">September 26th 2024</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Evaluating T-Cell Therapies in First-Line Multiple Myeloma Treatment</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/creating-equitable-ai-models-for-multiple-myeloma"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png%2FScreenshot%25202024-09-19%2520at%252011.19.40%2520AM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">September 26th 2024</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Creating Equitable AI Models for Multiple Myeloma</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/mrd-as-a-new-paradigm-in-myeloma-treatment"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png%2FScreenshot%25202024-09-23%2520at%25202.24.02%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">September 26th 2024</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">MRD as a New Paradigm in Myeloma Treatment</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2785488040 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/new-car-t-trial-in-mm-aims-for-triple-receptor-targeting"><div class="jsx-2785488040 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2785488040 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fcda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg%2FLeland%2520Metheny%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2785488040 content-wrap"><span class="jsx-2785488040 py-3 text-sm text-gray-500 text-left"><i class="jsx-2785488040">August 24th 2024</i></span><div class="jsx-2785488040 w-full h-fit mb-4"><p class="jsx-2785488040 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">New CAR T Trial in MM Aims for Triple Receptor Targeting</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1434825611 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/beyond-eha-2024-promising-research-in-multiple-myeloma-to-watch"><div class="jsx-1434825611 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1434825611 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1434825611 content-wrap"><span class="jsx-1434825611 py-3 text-sm text-gray-500 text-left"><i class="jsx-1434825611">July 29th 2024</i></span><div class="jsx-1434825611 w-full h-fit mb-4"><p class="jsx-1434825611 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-4064126826 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/eha-2024-highlights-overcoming-challenges-with-bispecific-antibodies-in-rrmm"><div class="jsx-4064126826 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-4064126826 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png%2Fmikhael.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-4064126826 content-wrap"><span class="jsx-4064126826 py-3 text-sm text-gray-500 text-left"><i class="jsx-4064126826">July 24th 2024</i></span><div class="jsx-4064126826 w-full h-fit mb-4"><p class="jsx-4064126826 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-187450181 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/future-directions-in-the-management-of-multiple-myeloma"><div class="jsx-187450181 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-187450181 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-187450181 content-wrap"><span class="jsx-187450181 py-3 text-sm text-gray-500 text-left"><i class="jsx-187450181">July 24th 2024</i></span><div class="jsx-187450181 w-full h-fit mb-4"><p class="jsx-187450181 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Future Directions in the Management of Multiple Myeloma </p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-609564708 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/asco-2024-dreamm-8-study-of-belantamab-mafodotin-pomalidomide-and-dexamethasone"><div class="jsx-609564708 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-609564708 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png%2FGarfallHS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-609564708 content-wrap"><span class="jsx-609564708 py-3 text-sm text-gray-500 text-left"><i class="jsx-609564708">July 19th 2024</i></span><div class="jsx-609564708 w-full h-fit mb-4"><p class="jsx-609564708 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone</p></div></div></div></a></div></div></div><div class="border-b-[2px] border-[#EEE] my-4"><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Continuing Medical Education</div><a href="/continuing-education" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-3886647465 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/ash-annual-meeting-coverage-highlighting-the-recent-updates-in-tki-use-in-the-treatment-of-cml-insights-and-application-for-managed-care?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-3886647465 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-3886647465 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-3886647465 content-wrap"><span class="jsx-3886647465 py-3 text-sm text-gray-500 text-left"><i class="jsx-3886647465">November 23rd 2024</i></span><div class="jsx-3886647465 w-full h-fit mb-4"><p class="jsx-3886647465 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care</p></div><div class="jsx-3886647465 text-left text-[12px] text-[#000] py-6">December 18, 2024 | 1:00 PM & 8:00 PM ET</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-3945728741 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/recent-advances-in-bcma-directed-treatment-in-multiple-myeloma-insights-and-application-for-managed-care-enduring?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-3945728741 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-3945728741 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-3945728741 content-wrap"><span class="jsx-3945728741 py-3 text-sm text-gray-500 text-left"><i class="jsx-3945728741">November 23rd 2024</i></span><div class="jsx-3945728741 w-full h-fit mb-4"><p class="jsx-3945728741 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care</p></div><div class="jsx-3945728741 text-left text-[12px] text-[#000] py-6">1.0 Credits / Hematologic Cancer, Oncology</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-3745364856 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/keeping-pace-with-new-developments-in-multiple-myeloma-updates-and-strategies-to-optimize-bispecific-antibodies-and-car-t-cell-therapy-tcdv?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-3745364856 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-3745364856 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-3745364856 content-wrap"><span class="jsx-3745364856 py-3 text-sm text-gray-500 text-left"><i class="jsx-3745364856">November 23rd 2024</i></span><div class="jsx-3745364856 w-full h-fit mb-4"><p class="jsx-3745364856 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy</p></div><div class="jsx-3745364856 text-left text-[12px] text-[#000] py-6">1.5 Credits / Oncology, Hematology, Hematologic Cancer</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-2629720111 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/addressing-the-gaps-and-clinical-challenges-in-chronic-lymphocytic-leukemia-updates-and-strategies-for-managed-care-dxq5?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-2629720111 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2629720111 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2629720111 content-wrap"><span class="jsx-2629720111 py-3 text-sm text-gray-500 text-left"><i class="jsx-2629720111">November 23rd 2024</i></span><div class="jsx-2629720111 w-full h-fit mb-4"><p class="jsx-2629720111 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care</p></div><div class="jsx-2629720111 text-left text-[12px] text-[#000] py-6">1.5 Credits / Hematology, Hematologic Cancer, Oncology</div></div></div></a></div></div></div><div class="flex items-center space-x-4 border-0 border-b border-secondary select-none py-1"><h2 class="text-3xl text-primary">More News</h2></div><div class="flex flex-wrap w-full pb-4"><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-1"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/making-cancer-care-easier-with-community-bispecific-antibody-programs"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/4edd101225fd12036d64c1d3622149d3bddcd243-1280x719.png?fit=crop&auto=format" alt="Screenshot of an interview with Courtney VanHouzen, PharmD" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 15th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/making-cancer-care-easier-with-community-bispecific-antibody-programs">Making Cancer Care Easier With Community Bispecific Antibody Programs</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/alexandra-gerlach">Alexandra Gerlach</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/laura-joszt">Laura Joszt, MA</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/making-cancer-care-easier-with-community-bispecific-antibody-programs"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Allowing patients to stay in their homes to receive bispecific antibodies can make the whole cancer journey easier, explained Courtney VanHouzen, PharmD, of Cowell Family Cancer Center, Munson Healthcare.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg?fit=crop&auto=format" alt="Thomas Jefferson | Image: Thomas Jefferson University " width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 13th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy">Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/ryan-flinn">Ryan Flinn</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/delays-in-myeloma-oral-therapy-linked-to-race-age"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/75a045d91321b8483c43f41bf052203a0cb3f568-4397x3412.jpg?fit=crop&auto=format" alt="Health disparities word cloud | Image Credit: Colored Lights-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 11th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/delays-in-myeloma-oral-therapy-linked-to-race-age">Delays in Myeloma Oral Therapy Linked to Race, Age</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/delays-in-myeloma-oral-therapy-linked-to-race-age"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/isatuximab-approval-highlights-role-of-anti-cd38-antibody-in-myeloma-care"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg?fit=crop&auto=format" alt="Surbhi Sidana, MD, MBBS, Stanford University" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 2nd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/isatuximab-approval-highlights-role-of-anti-cd38-antibody-in-myeloma-care">Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/isatuximab-approval-highlights-role-of-anti-cd38-antibody-in-myeloma-care"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/varied-types-levels-of-support-needed-for-patients-with-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/7f842239e3b3b2e06a220dac987c201761de64b3-7073x3500.jpg?fit=crop&auto=format" alt="Multiple myeloma | Image credit: freshidea - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">September 20th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/varied-types-levels-of-support-needed-for-patients-with-multiple-myeloma">Varied Types, Levels of Support Needed for Patients With Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/julia-bonavitacola">Julia Bonavitacola</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/varied-types-levels-of-support-needed-for-patients-with-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/bridging-global-treatment-gaps-in-relapsed-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/cda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg?fit=crop&auto=format" alt="Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">September 17th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/bridging-global-treatment-gaps-in-relapsed-multiple-myeloma">Bridging Global Treatment Gaps in Relapsed Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/bridging-global-treatment-gaps-in-relapsed-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the world, explains Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-7"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/d-vrd-boosts-mrd-negativity-in-transplant-eligible-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/e8b89f6523b42f0e4eac2c396f686ac915160fbf-1200x738.jpg?fit=crop&auto=format" alt="Clinical trial results | Image Credit: Egor-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">September 12th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/d-vrd-boosts-mrd-negativity-in-transplant-eligible-multiple-myeloma">D-VRd Boosts MRD Negativity in Transplant-Eligible Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/chris-ryan">Chris Ryan</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/d-vrd-boosts-mrd-negativity-in-transplant-eligible-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/triple-target-car-t-cells-benefits-and-challenges"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/cda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg?fit=crop&auto=format" alt="Leland Metheny, MD, University Hospitals Seidman Cancer Center" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 30th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/triple-target-car-t-cells-benefits-and-challenges">Triple-Target CAR T Cells: Benefits and Challenges</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/triple-target-car-t-cells-benefits-and-challenges"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-issues-crl-for-linvoseltamab-in-r-r-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/cdc10674fe8a1ccf14048f3b60b2e86e3ffe8bb1-5000x3337.jpg?fit=crop&auto=format" alt="Regeneron logo | Image credit: Casimiro – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 21st 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-issues-crl-for-linvoseltamab-in-r-r-multiple-myeloma">FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/hayden-e-klein">Hayden E. Klein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-issues-crl-for-linvoseltamab-in-r-r-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/second-asct-extends-survival-in-relapsed-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/8caf2ee1f420c7185048fb92441c1b5b881d218a-1200x738.jpg?fit=crop&auto=format" alt="stem cells | Image Credit: jarun011-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 20th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/second-asct-extends-survival-in-relapsed-multiple-myeloma">Second ASCT Extends Survival in Relapsed Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/second-asct-extends-survival-in-relapsed-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/challenges-with-pomalidomide-for-patients-with-comorbid-rrmm-ckd"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/568bbc1591d5d6400d39c9416b6235ce6dfcf018-1200x738.jpg?fit=crop&auto=format" alt="MM treatment | Image Credit: Dzmitry-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 14th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/challenges-with-pomalidomide-for-patients-with-comorbid-rrmm-ckd">Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/challenges-with-pomalidomide-for-patients-with-comorbid-rrmm-ckd"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/novel-therapies-needed-for-older-patients-with-rrmm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/0636f60ec186da460f794acfef0878325c54f9ec-1200x738.jpg?fit=crop&auto=format" alt="MM blood test | Image Credit: luchschenF-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 6th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/novel-therapies-needed-for-older-patients-with-rrmm">Novel Therapies Needed for Older Patients With RRMM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/novel-therapies-needed-for-older-patients-with-rrmm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-13"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/daratumumab-and-hyaluronidase-fihj-based-quadruplet-approved-in-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/f2d1812ac576b862153d30d4fe7e135bec6ddffc-1200x738.jpg?fit=crop&auto=format" alt="FDA | Image Credit: ra2studio-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 31st 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/daratumumab-and-hyaluronidase-fihj-based-quadruplet-approved-in-mm">Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/daratumumab-and-hyaluronidase-fihj-based-quadruplet-approved-in-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/dual-target-car-t-cells-achieve-100-response-rate-in-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/a8ce964403b3f6531ee8a6c5d1ff46969a56666b-1200x728.jpg?fit=crop&auto=format" alt="CAR T in MM | Image Credit: LASZLO-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 25th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/dual-target-car-t-cells-achieve-100-response-rate-in-mm">Dual-Target CAR T Cells Achieve 100% Response Rate in MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/dual-target-car-t-cells-achieve-100-response-rate-in-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/eha-2024-teclistimab-in-high-risk-relapsed-refractory-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/f6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png?fit=crop&auto=format" alt="Joseph Mikhael, MD, an expert on multiple myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 19th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/eha-2024-teclistimab-in-high-risk-relapsed-refractory-multiple-myeloma">EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/joseph-mikhael-md">Joseph Mikhael, MD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/eha-2024-teclistimab-in-high-risk-relapsed-refractory-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/use-of-prophylactic-tocilizumab-with-teclistamab-takeaways-from-asco-2024"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png?fit=crop&auto=format" alt="Alfred L. Garfall, MD, an expert on multiple myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 17th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/use-of-prophylactic-tocilizumab-with-teclistamab-takeaways-from-asco-2024">Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/alfred-l-garfall-md">Alfred L. Garfall, MD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/use-of-prophylactic-tocilizumab-with-teclistamab-takeaways-from-asco-2024"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/treatment-in-early-relapse-multiple-myeloma-takeaways-from-eha-2024"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/f6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png?fit=crop&auto=format" alt="Joseph Mikhael, MD, an expert on multiple myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 17th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/treatment-in-early-relapse-multiple-myeloma-takeaways-from-eha-2024">Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/joseph-mikhael-md">Joseph Mikhael, MD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/treatment-in-early-relapse-multiple-myeloma-takeaways-from-eha-2024"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Dr. Mikhael discusses treatment in early relapse of multiple myeloma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/myeloma-survivorship-program-findings-and-future-steps"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/266dba9b57f0c1e1669791ffd8130eef47282a33-1200x728.jpg?fit=crop&auto=format" alt="Support group image | Image Credit: Tom Merton/KOTO-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 17th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/myeloma-survivorship-program-findings-and-future-steps">Myeloma Survivorship Program: Findings and Future Steps</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/myeloma-survivorship-program-findings-and-future-steps"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Peer and survivorship support are lacking for patients living with multiple myeloma, leading investigators to evaluate a group-focused multidisciplinary intervention that encompassed physical and mental activities. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-19"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/final-griffin-trial-data-confirm-daratumumab-benefit-against-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/5cba2040fb990cdd20d42e332cc21083c9a38581-1200x728.jpg?fit=crop&auto=format" alt="Multiple myeloma | Image Credit: Felipe Caparrós-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 10th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/final-griffin-trial-data-confirm-daratumumab-benefit-against-mm">Final GRIFFIN Trial Data Confirm Daratumumab Benefit Against MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/final-griffin-trial-data-confirm-daratumumab-benefit-against-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Patient outcomes in this trial were compared between the regimens of lenalidomide, bortezomib, and dexamethasone and daratumumab, lenalidomide, bortezomib, and dexamethasone for use against multiple myeloma (MM). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/game-changing-strategies-for-early-relapsed-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/23b8d7cf863336087bed8bb220c2d6e7aaf9050e-1200x675.jpg?fit=crop&auto=format" alt="Interview with Joseph Mikhael, MD, MEd, FRCPC, FACP" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 7th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/game-changing-strategies-for-early-relapsed-myeloma">Game-Changing Strategies for Early-Relapsed Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/brooke-mccormick">Brooke McCormick</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/game-changing-strategies-for-early-relapsed-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/advancements-and-challenges-in-treating-relapsed-refractory-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/366bb84a36b5bbb43be763745d5d1de6601b8e61-3750x2000.png?fit=crop&auto=format" alt="AJMC with Dr Suzane Lentzsch | Background image credit: ipopba - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 2nd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/advancements-and-challenges-in-treating-relapsed-refractory-multiple-myeloma">Advancements and Challenges in Treating Relapsed/Refractory Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/brooke-mccormick">Brooke McCormick</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/advancements-and-challenges-in-treating-relapsed-refractory-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-generates-durable-responses-in-functionally-high-risk-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/b3dd27f5b3c839de0cc4b205d4e44336b925b677-1200x728.jpg?fit=crop&auto=format" alt="multiple myeloma | Image Credit: ibreakstock-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 28th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-generates-durable-responses-in-functionally-high-risk-myeloma">Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/ariana-pelosci">Ariana Pelosci</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-generates-durable-responses-in-functionally-high-risk-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In April, the FDA approved decabtagene vicleucel (ide-cel) for earlier treatment of relapsed/refractory multiple myleoma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/the-tremendous-complexity-of-treating-rrmm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/23b8d7cf863336087bed8bb220c2d6e7aaf9050e-1200x675.jpg?fit=crop&auto=format" alt="Joseph Mikhael, MD, MEd, FRCPC, FACP" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 27th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/the-tremendous-complexity-of-treating-rrmm">The Tremendous Complexity of Treating RRMM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/brooke-mccormick">Brooke McCormick</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/the-tremendous-complexity-of-treating-rrmm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In this interview from our coverage of the European Hematology Association 2024 Congress, Joseph Mikhael, MD, MEd, FRCPC, FACP, International Myeloma Foundation, discusses the complex principles that underlie treating multiple myeloma (MM) in the US.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/dr-suzanne-lentzsch-highlights-promising-linvoseltamab-results-in-treating-rrmm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/366bb84a36b5bbb43be763745d5d1de6601b8e61-3750x2000.png?fit=crop&auto=format" alt="AJMC with Dr Suzane Lentzsch | Background image credit: ipopba - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 21st 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/dr-suzanne-lentzsch-highlights-promising-linvoseltamab-results-in-treating-rrmm">Dr Suzanne Lentzsch Highlights Promising Linvoseltamab Results in Treating RRMM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/brooke-mccormick">Brooke McCormick</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/dr-suzanne-lentzsch-highlights-promising-linvoseltamab-results-in-treating-rrmm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Suzanne Lentzsch, MD, PhD, of Columbia University, presented promising results of linvoseltamab for treating relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association 2024 Congress.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-25"></div></div></div><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/mrd2stop-promise-in-halting-myeloma-maintenance-therapy"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/0b344275aab19e5e3756affd170b28a5f881845f-1200x628.jpg?fit=crop&auto=format" alt="multiple myeloma diagnosis | Image Credit: shidlovski-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 13th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/mrd2stop-promise-in-halting-myeloma-maintenance-therapy">MRD2STOP: Promise in Halting Myeloma Maintenance Therapy</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/mrd2stop-promise-in-halting-myeloma-maintenance-therapy"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">One patient died during this study, which used PET/CT, flow cytometry, and next-generation sequencing to define measurable residual disease negativity.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/imroz-adding-isatuximab-to-soc-in-transplant-ineligible-newly-diagnosed-multiple-myeloma-cut-risk-of-disease-progression-or-death-40-"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/6f74eb3d8d988ca4cbf715879d1b287fdd803e01-968x508.jpg?fit=crop&auto=format" alt="Sarclisa packaging | Image credit: Sanofi" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 4th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/imroz-adding-isatuximab-to-soc-in-transplant-ineligible-newly-diagnosed-multiple-myeloma-cut-risk-of-disease-progression-or-death-40-">IMROZ: Adding Isatuximab to SOC in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Cut Risk of Disease Progression or Death 40%</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/imroz-adding-isatuximab-to-soc-in-transplant-ineligible-newly-diagnosed-multiple-myeloma-cut-risk-of-disease-progression-or-death-40-"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Combining the anti-CD38 monoclonal antibody with a standard backbone triplet should be the new standard of care for newly diagnosed patients not eligible for transplant, said lead investigator Thierry Facon, MD.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/future-indications-and-frontline-potential-of-cilta-cel-in-multiple-myeloma-insights-from-dr-binod-dhakal"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/4287639dedc490b040e69194f9d38464eb6444a1-1200x724.jpg?fit=crop&auto=format" alt="Binod Dhakal, MD" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 24th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/future-indications-and-frontline-potential-of-cilta-cel-in-multiple-myeloma-insights-from-dr-binod-dhakal">Future Indications and Frontline Potential of Cilta-Cel in Multiple Myeloma: Insights From Dr Binod Dhakal</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/future-indications-and-frontline-potential-of-cilta-cel-in-multiple-myeloma-insights-from-dr-binod-dhakal"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In the final part of our interview with Binod Dhakal, MD, lead investigator of the CARTITUDE-4 study, he looks to the future of earlier treatment for relapsed/refractory multiple myeloma. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/raymond-thertulien-md-phd-on-how-abnormalities-drive-treatment-choices-in-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/41eb5a69edf2fc2a89c1ae52b03d0593bfb6d266-230x284.jpg?fit=crop&auto=format" alt="Raymond Thertulien, MD, PhD | Image credit: LinkedIn" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 20th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/raymond-thertulien-md-phd-on-how-abnormalities-drive-treatment-choices-in-multiple-myeloma">Raymond Thertulien, MD, PhD, on How Abnormalities Drive Treatment Choices in Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/raymond-thertulien-md-phd-on-how-abnormalities-drive-treatment-choices-in-multiple-myeloma"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/car-t-proves-effective-and-safe-for-refractory-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/489f3675b313076477343c9a9201cf95dd28fc06-1200x800.jpg?fit=crop&auto=format" alt="MM image | Image Credit: Svetlana-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 15th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/car-t-proves-effective-and-safe-for-refractory-multiple-myeloma">CAR T Proves Effective and Safe for Refractory Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/car-t-proves-effective-and-safe-for-refractory-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/dr-binod-dhakal-the-importance-of-patient-monitoring-with-cilta-cel-treatment"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/4287639dedc490b040e69194f9d38464eb6444a1-1200x724.jpg?fit=crop&auto=format" alt="Binod Dhakal, MD" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 6th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/dr-binod-dhakal-the-importance-of-patient-monitoring-with-cilta-cel-treatment">Dr Binod Dhakal: The Importance of Patient Monitoring With Cilta-Cel Treatment</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/dr-binod-dhakal-the-importance-of-patient-monitoring-with-cilta-cel-treatment"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In part 2 of our interview with Binod Dhakal, MD, he addresses how CARTITUDE-4 study findings help to advance the clinical understanding of ciltacabtagene autoleucel (cilta-cel) and the importance of vigilance and education on the treatment’s adverse effects. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div></div><div class="w-full text-center flex justify-center pb-24"><a class="px-4 py-2 border-y border-r bg-primary text-white" href="/compendium/multiple-myeloma?page=1">1</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=2">2</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=3">3</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=4">4</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=5">5</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=6">6</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=7">7</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=8">8</a><div class="px-4 py-2 border-y border-r">...</div><a class="px-4 py-2 border-y border-r" href="/compendium/multiple-myeloma?page=10">10</a><a class="px-4 py-2 border-y border-r" href="/compendium/multiple-myeloma?page=2">></a></div></div></div><div class="flex-none w-[300px] z-[9999] relative hidden md:block"><div style="top:5rem" class="sticky custom-spacing"><div class="collapse-container " style="overflow:hidden;max-height:900px;transition:max-height .4s ease-in-out"></div></div></div></div><div id="div-gpt-ad-pixel" style="width:1px;height:1px" class=""></div><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NK5KQXS" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="footerOuterWrap" class=" mx-auto flex"><div class="bg-[#00598D] xl:w-[70%] w-[70%] py-12 pl-auto"><div class="xxl:w-[75%] w-[90%] ml-auto"><div><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27300%27%20height=%2744%27/%3e"/></span><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" srcSet="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=384&q=75 1x, /_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75 2x" src="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div><div class="flex"><div class="flex justify-between pt-6"><div class="w-[40%]"><div class="text-footer-text-color text-xs"><p>2 Commerce Drive<br/>Suite 100<br/>Cranbury, NJ 08512</p></div><div class="self-start py-6" style="display:flex;flex-wrap:wrap"><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='facebook' fill='#FFFFFF' fillRule='nonzero'> <path d='M512,256 C512,114.6 397.4,0 256,0 C114.6,0 0,114.6 0,256 C0,397.4 114.6,512 256,512 C257.5,512 259,512 260.5,511.9 L260.5,312.7 L205.5,312.7 L205.5,248.6 L260.5,248.6 L260.5,201.4 C260.5,146.7 293.9,116.9 342.7,116.9 C366.1,116.9 386.2,118.6 392,119.4 L392,176.6 L358.4,176.6 C331.9,176.6 326.7,189.2 326.7,207.7 L326.7,248.5 L390.2,248.5 L381.9,312.6 L326.7,312.6 L326.7,502.1 C433.7,471.4 512,372.9 512,256 Z' id='Path' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="25" height="25" viewBox="1.41 1.41 252.9 252.9"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><polygon points="24.89,23.01 57.79,66.99 65.24,66.99 32.34,23.01" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)"></polygon><path d="M 45 0 L 45 0 C 20.147 0 0 20.147 0 45 v 0 c 0 24.853 20.147 45 45 45 h 0 c 24.853 0 45 -20.147 45 -45 v 0 C 90 20.147 69.853 0 45 0 z M 56.032 70.504 L 41.054 50.477 L 22.516 70.504 h -4.765 L 38.925 47.63 L 17.884 19.496 h 16.217 L 47.895 37.94 l 17.072 -18.444 h 4.765 L 50.024 40.788 l 22.225 29.716 H 56.032 z" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)" stroke-linecap="round"></path></g></svg></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='linkedin' fill='#FFFFFF' fillRule='nonzero'> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M181.609375,387 L119.261719,387 L119.261719,199.425781 L181.609375,199.425781 L181.609375,387 Z M150.4375,173.8125 L150.03125,173.8125 C129.109375,173.8125 115.578125,159.410156 115.578125,141.410156 C115.578125,123.003906 129.523438,109 150.851562,109 C172.179688,109 185.304688,123.003906 185.710938,141.410156 C185.710938,159.410156 172.179688,173.8125 150.4375,173.8125 Z M406.421875,387 L344.082031,387 L344.082031,286.652344 C344.082031,261.433594 335.054688,244.234375 312.496094,244.234375 C295.273438,244.234375 285.015625,255.835938 280.507812,267.035156 C278.859375,271.042969 278.457031,276.644531 278.457031,282.25 L278.457031,387 L216.113281,387 C216.113281,387 216.929688,217.023438 216.113281,199.425781 L278.457031,199.425781 L278.457031,225.984375 C286.742188,213.203125 301.566406,195.023438 334.644531,195.023438 C375.664062,195.023438 406.421875,221.832031 406.421875,279.445312 L406.421875,387 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.instagram.com/ajmcjournal/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='instagram' fill='#FFFFFF' fillRule='nonzero'> <path d='M305,256 C305,283.0625 283.0625,305 256,305 C228.9375,305 207,283.0625 207,256 C207,228.9375 228.9375,207 256,207 C283.0625,207 305,228.9375 305,256 Z' id='Path' /> <path d='M370.59375,169.304688 C368.238281,162.921875 364.480469,157.144531 359.597656,152.402344 C354.855469,147.519531 349.082031,143.761719 342.695312,141.40625 C337.515625,139.394531 329.734375,137 315.402344,136.347656 C299.898438,135.640625 295.25,135.488281 256,135.488281 C216.746094,135.488281 212.097656,135.636719 196.597656,136.34375 C182.265625,137 174.480469,139.394531 169.304688,141.40625 C162.917969,143.761719 157.140625,147.519531 152.402344,152.402344 C147.519531,157.144531 143.761719,162.917969 141.402344,169.304688 C139.390625,174.484375 136.996094,182.269531 136.34375,196.601562 C135.636719,212.101562 135.484375,216.75 135.484375,256.003906 C135.484375,295.253906 135.636719,299.902344 136.34375,315.40625 C136.996094,329.738281 139.390625,337.519531 141.402344,342.699219 C143.761719,349.085938 147.515625,354.859375 152.398438,359.601562 C157.140625,364.484375 162.914062,368.242188 169.300781,370.597656 C174.480469,372.613281 182.265625,375.007812 196.597656,375.660156 C212.097656,376.367188 216.742188,376.515625 255.996094,376.515625 C295.253906,376.515625 299.902344,376.367188 315.398438,375.660156 C329.730469,375.007812 337.515625,372.613281 342.695312,370.597656 C355.515625,365.652344 365.648438,355.519531 370.59375,342.699219 C372.605469,337.519531 375,329.738281 375.65625,315.40625 C376.363281,299.902344 376.511719,295.253906 376.511719,256.003906 C376.511719,216.75 376.363281,212.101562 375.65625,196.601562 C375.003906,182.269531 372.609375,174.484375 370.59375,169.304688 L370.59375,169.304688 Z M256,331.484375 C214.308594,331.484375 180.511719,297.691406 180.511719,256 C180.511719,214.308594 214.308594,180.515625 256,180.515625 C297.6875,180.515625 331.484375,214.308594 331.484375,256 C331.484375,297.691406 297.6875,331.484375 256,331.484375 Z M334.46875,195.171875 C324.726562,195.171875 316.828125,187.273438 316.828125,177.53125 C316.828125,167.789062 324.726562,159.890625 334.46875,159.890625 C344.210938,159.890625 352.109375,167.789062 352.109375,177.53125 C352.105469,187.273438 344.210938,195.171875 334.46875,195.171875 Z' id='Shape' /> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M402.113281,316.605469 C401.402344,332.253906 398.914062,342.9375 395.28125,352.289062 C387.644531,372.035156 372.035156,387.644531 352.289062,395.28125 C342.941406,398.914062 332.253906,401.398438 316.609375,402.113281 C300.933594,402.828125 295.925781,403 256.003906,403 C216.078125,403 211.074219,402.828125 195.394531,402.113281 C179.75,401.398438 169.0625,398.914062 159.714844,395.28125 C149.902344,391.589844 141.019531,385.804688 133.675781,378.324219 C126.199219,370.984375 120.414062,362.097656 116.722656,352.289062 C113.089844,342.941406 110.601562,332.253906 109.890625,316.609375 C109.167969,300.929688 109,295.921875 109,256 C109,216.078125 109.167969,211.070312 109.886719,195.394531 C110.597656,179.746094 113.082031,169.0625 116.714844,159.710938 C120.40625,149.902344 126.195312,141.015625 133.675781,133.675781 C141.015625,126.195312 149.902344,120.410156 159.710938,116.71875 C169.0625,113.085938 179.746094,110.601562 195.394531,109.886719 C211.070312,109.171875 216.078125,109 256,109 C295.921875,109 300.929688,109.171875 316.605469,109.890625 C332.253906,110.601562 342.9375,113.085938 352.289062,116.714844 C362.097656,120.40625 370.984375,126.195312 378.328125,133.675781 C385.804688,141.019531 391.59375,149.902344 395.28125,159.710938 C398.917969,169.0625 401.402344,179.746094 402.117188,195.394531 C402.832031,211.070312 403,216.078125 403,256 C403,295.921875 402.832031,300.929688 402.113281,316.605469 L402.113281,316.605469 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="/rss"><p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:svgjs="http://svgjs.com/svgjs" version="1.1" width="25px" height="25px" x="0" y="0" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512" xml:space="preserve"> <g> <path xmlns="http://www.w3.org/2000/svg" d="m437.019531 74.980469c-48.351562-48.351563-112.640625-74.980469-181.019531-74.980469s-132.667969 26.628906-181.019531 74.980469c-48.351563 48.351562-74.980469 112.640625-74.980469 181.019531s26.628906 132.667969 74.980469 181.019531c48.351562 48.351563 112.640625 74.980469 181.019531 74.980469s132.667969-26.628906 181.019531-74.980469c48.351563-48.351562 74.980469-112.640625 74.980469-181.019531s-26.628906-132.667969-74.980469-181.019531zm-267.757812 292.957031c-13.730469 0-24.90625-11.171875-24.90625-24.90625s11.175781-24.90625 24.90625-24.90625c13.734375 0 24.90625 11.171875 24.90625 24.90625s-11.171875 24.90625-24.90625 24.90625zm80.277343 4.925781c-8.28125 0-15-6.714843-15-15 0-44.171875-35.9375-80.109375-80.109374-80.109375-8.285157 0-15-6.71875-15-15 0-8.285156 6.714843-15 15-15 60.714843 0 110.109374 49.394532 110.109374 110.109375 0 8.285157-6.714843 15-15 15zm67.09375 0c-8.285156 0-15-6.714843-15-15 0-81.167969-66.035156-147.203125-147.203124-147.203125-8.285157 0-15-6.714844-15-15s6.714843-15 15-15c97.710937 0 177.203124 79.492188 177.203124 177.203125 0 8.285157-6.714843 15-15 15zm66.292969 0c-8.28125 0-15-6.714843-15-15 0-117.722656-95.773437-213.496093-213.496093-213.496093-8.285157 0-15-6.714844-15-15 0-8.285157 6.714843-15 15-15 65.039062 0 126.1875 25.328124 172.179687 71.316406 45.988281 45.992187 71.316406 107.140625 71.316406 172.179687 0 8.285157-6.714843 15-15 15zm0 0" fill="#ffffff" data-original="#000000" style=""/> </g> </svg></p></a></div><div class="text-footer-text-color text-xs"><p>© 2024 MJH Life Sciences<sup>®</sup> and AJMC®.<br/> All rights reserved.</p></div></div><div class="flex flex-row flex-wrap self-start w-[60%]"><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/about-us">About</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/contactus">Contact</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/editorial-boards">Editorial Boards</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/advertise">Advertise</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_blank" href="https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com">Do Not Sell My Information</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/terms">Terms & Conditions</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/privacy">Privacy Policy</a></div></div><div class="flex items-start mr-6 lg:mr-10"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27251%27%20height=%2768%27/%3e"/></span><img alt="AJMC Managed Markets Network Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="AJMC Managed Markets Network Logo" srcSet="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=256&q=75 1x, /_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75 2x" src="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div></div></div></div></div><div class="w-[30%] bg-[#003767] flex items-center justify-center "><div class="flex flex-col justify-between "><a target="_self" rel="noopener noreferrer" class="my-2 px-8" href="/topic/center-on-health-equity-and-access"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="CH Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="CH Logo" srcSet="/_next/image?url=%2FCHA_Logo.png&w=384&q=75 1x, /_next/image?url=%2FCHA_Logo.png&w=640&q=75 2x" src="/_next/image?url=%2FCHA_Logo.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a><a target="_blank" rel="noopener noreferrer" class="my-2 px-8" href="https://www.centerforbiosimilars.com/"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="Center for Biosimilars Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="Center for Biosimilars Logo" srcSet="/_next/image?url=%2FCB.png&w=384&q=75 1x, /_next/image?url=%2FCB.png&w=640&q=75 2x" src="/_next/image?url=%2FCB.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a></div></div></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"pageProps":{},"cache":{"main_menu":[{"sortOrder":1,"navParent":null,"_type":"mainNavigation","name":"News","_id":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_updatedAt":"2020-04-14T13:26:21Z","is_active":true,"_createdAt":"2020-04-14T13:26:14Z","_rev":"Yw6MEKZDMdk6hC2JCRdGN7","subQuery":[{"url":"/news","is_active":true,"_updatedAt":"2020-04-14T13:30:35Z","children":[],"navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_rev":"sBk7YzjWMuBuhiatU3YIhQ","_type":"mainNavigation","_id":"1376963d-32e8-4647-bb5e-59c984e35893","_createdAt":"2020-04-14T13:30:35Z","name":"All News"},{"_updatedAt":"2020-04-14T13:30:57Z","is_active":true,"name":"Press Releases","_id":"2af5da5e-78c2-42c8-90b8-3900f8c89889","url":"/press-release","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_createdAt":"2020-04-14T13:30:57Z","_rev":"QxOJBWa4XErmibN6Cb5OcA","children":[],"_type":"mainNavigation"},{"name":"Product Approvals and Launches","url":"/approvals-launches","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_createdAt":"2021-07-29T12:15:49Z","_rev":"jvOgZ3KZdbRHfWlt9ePmOA","_type":"mainNavigation","_updatedAt":"2022-01-07T20:44:44Z","is_active":true,"_id":"854a1ad1-9831-4387-bda9-ffb93a074ace","children":[]}]},{"_id":"821e259a-db55-4862-985a-5cd089bbf894","navParent":null,"subQuery":[{"_type":"mainNavigation","_updatedAt":"2024-05-24T16:52:54Z","sortOrder":1,"_rev":"rcwwj6TiN2Q0ymhqDzJ8ty","_id":"f51d85fa-cabc-4c7d-85d0-11301088b7f6","name":"All Video Types","url":"/video-hub","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_createdAt":"2024-05-24T16:37:06Z","children":[]},{"is_active":true,"_rev":"LJrwYxwtzLC9JsOYMk8TBr","name":"AJMC TV","_id":"a99a3683-5173-46b3-94b0-21b7d6b06a24","_createdAt":"2024-05-24T16:38:14Z","url":"/interviews","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_type":"mainNavigation","_updatedAt":"2024-05-28T19:38:54Z","children":[]},{"is_active":true,"url":"/insights","_updatedAt":"2020-04-14T13:43:45Z","_createdAt":"2020-04-14T13:43:45Z","children":[],"navParent":{"_type":"reference","_ref":"821e259a-db55-4862-985a-5cd089bbf894"},"_rev":"Yw6MEKZDMdk6hC2JCRda8Z","_type":"mainNavigation","name":"Insights","_id":"b03ccbf6-6387-48de-8edc-4f1f23debe40"},{"url":"/onlocation","_rev":"k6N5FycA5UhVnvpzSEa3Rp","_type":"mainNavigation","name":"OnLocation","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"children":[],"_id":"f3d69d10-636b-4927-8ff4-4f54fabc940a","_updatedAt":"2020-04-14T13:44:19Z","_createdAt":"2020-04-14T13:44:19Z","is_active":true},{"name":"Payer Perspectives","_id":"d4e3d69c-8a07-4191-af89-27d7e838af08","_type":"mainNavigation","url":"/payer-perspectives","children":[],"_updatedAt":"2022-10-05T15:29:11Z","_createdAt":"2022-10-05T15:29:11Z","_rev":"37PW14Mg02p9z7FTF1SGE9","is_active":true,"navParent":{"_type":"reference","_ref":"821e259a-db55-4862-985a-5cd089bbf894"}},{"_createdAt":"2020-04-14T13:44:43Z","_id":"8f602f1e-1840-4c32-8cdb-9a26d6c0e873","_type":"mainNavigation","navParent":{"_type":"reference","_ref":"821e259a-db55-4862-985a-5cd089bbf894"},"_rev":"VdTcsTJkAuZveXGf2i9Pes","name":"Peer Exchange","children":[],"_updatedAt":"2020-04-14T13:44:43Z","url":"/peer-exchange","is_active":true},{"_updatedAt":"2024-05-24T18:27:43Z","_type":"mainNavigation","is_active":true,"_id":"0f532685-cd4c-4350-89cd-b8a388e6495b","name":"Post Conference Perspectives","url":"/post-conference-perspectives","navParent":{"_type":"reference","_ref":"821e259a-db55-4862-985a-5cd089bbf894"},"_createdAt":"2024-05-24T18:27:43Z","_rev":"Jz2W7keLhiw1UYkGHgA51N","children":[]},{"_rev":"y3lsbm3yQTliOnC9CU5TiR","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"children":[],"url":"/stakeholder-summit","_id":"bbc55ff8-1532-475e-9f51-f9d5eb39e369","_type":"mainNavigation","_createdAt":"2020-12-01T22:43:10Z","_updatedAt":"2020-12-01T22:43:26Z","name":"Stakeholder Summit"}],"sortOrder":2,"_rev":"rcwwj6TiN2Q0ymhqDzIFjO","_type":"mainNavigation","name":"Video","_updatedAt":"2024-05-24T16:36:15Z","is_active":true,"_createdAt":"2020-04-14T13:26:30Z"},{"name":"Podcasts","_rev":"rcwwj6TiN2Q0ymhqDzIUb7","url":"/podcasts","navParent":null,"sortOrder":3,"_type":"mainNavigation","_id":"4939ee15-ae6f-4aba-8481-9ee27ce729d3","_updatedAt":"2024-05-24T16:41:18Z","subQuery":[],"is_active":true,"_createdAt":"2024-05-24T16:40:58Z"},{"name":"Conferences","_updatedAt":"2024-05-24T16:41:40Z","is_active":true,"_createdAt":"2020-04-14T13:27:01Z","_rev":"rcwwj6TiN2Q0ymhqDzIVAU","navParent":null,"subQuery":[{"_rev":"pI9SawGKsTP14Lioy589Kx","_type":"mainNavigation","_createdAt":"2020-06-12T15:17:29Z","_updatedAt":"2020-08-21T22:11:23Z","children":[],"_id":"f45b532b-23e3-4b44-8d7f-2f3c13c9ae81","sortOrder":1,"name":"Conference Coverage","url":"/latest-conference","is_active":true,"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"}},{"_createdAt":"2020-06-12T15:18:28Z","_rev":"FxFuWbqTkFGbPWgBBSR6xp","_updatedAt":"2020-06-12T15:19:26Z","sortOrder":2,"children":[],"_type":"mainNavigation","name":"Conference Listing","url":"/conference","_id":"004461ae-46cb-45ef-916e-f03c6d99d6d3","is_active":true,"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"}},{"_rev":"ZU3dXbR1BZtBbbPuRGxz53","is_active":true,"name":"Post Conference Perspectives","_updatedAt":"2024-07-03T19:00:13Z","url":"/post-conference-perspectives","navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"_createdAt":"2024-07-03T19:00:13Z","sortOrder":3,"children":[],"_type":"mainNavigation","_id":"a006d0df-0cc9-4386-abfb-b1931a3918d4"}],"_id":"6841664a-93f2-4f56-8760-836ec9c7b483","sortOrder":4,"_type":"mainNavigation"},{"navParent":null,"subQuery":[{"name":"All Journals","_updatedAt":"2024-05-24T16:42:23Z","url":"/publications","sortOrder":1,"children":[],"_id":"48193abd-ecf4-4c90-b0ae-984ca2be88c9","_rev":"rcwwj6TiN2Q0ymhqDzIVyQ","_type":"mainNavigation","is_active":true,"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2020-05-04T21:06:00Z"},{"_updatedAt":"2024-05-24T16:42:39Z","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"sortOrder":2,"url":"/publications/issue","is_active":true,"children":[],"_id":"08081ddf-ffd8-4b17-a2ff-dfe6a0ac64a3","_rev":"rcwwj6TiN2Q0ymhqDzIWug","name":"The American Journal of Managed Care","_createdAt":"2020-04-14T13:55:29Z","_type":"mainNavigation"},{"_id":"47782239-2714-4bd1-99e6-750443bd39ea","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"children":[],"_type":"mainNavigation","name":"Population Health, Equity \u0026 Outcomes","is_active":true,"_createdAt":"2020-04-14T13:56:01Z","sortOrder":3,"_updatedAt":"2024-09-16T13:23:11Z","url":"/publications/ajac","_rev":"4fso9RuTzczLhlxmnMQ1bu"},{"url":"/publications/evidence-based-oncology","_rev":"uJbbwQWkLESsncBrcLL4uf","_updatedAt":"2024-05-24T16:43:12Z","children":[],"is_active":true,"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2020-04-14T13:56:21Z","_id":"b99cc54f-5801-46e9-bd20-e690623ed12c","name":"Evidence-Based Oncology","sortOrder":4,"_type":"mainNavigation"},{"is_active":true,"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_id":"6e7e3485-ef8b-40e3-8320-3c434df6bbb5","url":"/supplement","children":[],"_createdAt":"2024-05-23T20:59:41Z","_rev":"rcwwj6TiN2Q0ymhqDzIY1L","_type":"mainNavigation","name":"About Supplements and Featured Publications","sortOrder":5,"_updatedAt":"2024-05-24T16:43:26Z"},{"_rev":"uJbbwQWkLESsncBrcLL5w0","sortOrder":6,"_updatedAt":"2024-05-24T16:43:32Z","children":[],"_id":"a2112c87-8e92-4b64-b42d-3117117f67a3","url":"/publications/supplement","_type":"mainNavigation","name":"Supplements and Featured Publications Issues","is_active":true,"navParent":{"_type":"reference","_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150"},"_createdAt":"2020-04-14T13:56:51Z"},{"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDzIYDp","is_active":true,"_createdAt":"2023-03-14T13:29:11Z","name":"Submit a Manuscript","url":"/submit-a-manuscript","sortOrder":7,"_type":"mainNavigation","_id":"fa8c9edc-3d32-4e9e-b68b-47d5c15694a5","_updatedAt":"2024-05-24T16:43:38Z","children":[]}],"_updatedAt":"2024-05-24T16:41:49Z","is_active":true,"_createdAt":"2020-04-14T13:27:20Z","sortOrder":5,"name":"Journals","_id":"94f13109-c3cc-47b5-bf49-96ed727c8150","_rev":"uJbbwQWkLESsncBrcLL0hr","_type":"mainNavigation"},{"is_active":true,"navParent":null,"sortOrder":6,"_updatedAt":"2020-05-08T20:03:10Z","url":"/events","_type":"mainNavigation","name":"Events","_rev":"8ZvheBjSwe5Dc4gCmgsR0M","_createdAt":"2020-04-14T13:27:17Z","subQuery":[{"_rev":"Jz2W7keLhiw1UYkGHgA4Yf","_type":"mainNavigation","children":[],"navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"},"url":"/ivbmevents","name":"Institute for Value-Based Medicine","_id":"de4fe195-3db9-4d12-842d-f26100fbea5b","_updatedAt":"2024-05-24T18:26:23Z","is_active":true,"_createdAt":"2024-05-24T16:44:43Z"},{"_type":"mainNavigation","navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"},"is_active":true,"_createdAt":"2024-05-24T16:45:02Z","name":"Patient-Centered Oncology Care","_updatedAt":"2024-05-24T18:26:42Z","children":[],"_id":"dddfc37d-8958-4e0a-91e3-0634bb6502a3","url":"https://pcoc.ajmc.com/","_rev":"Jz2W7keLhiw1UYkGHgA4eP"}],"_id":"ad5c19be-040c-4ea8-b639-807f54c9a1aa"},{"_updatedAt":"2024-05-24T16:45:37Z","is_active":true,"_createdAt":"2020-04-14T13:29:34Z","navParent":null,"subQuery":[{"url":"/interactive-tools","is_active":true,"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_type":"mainNavigation","name":"Interactive Tools","_id":"4a08b5fc-379c-4952-bec1-0d9dacb11170","_createdAt":"2020-04-14T13:51:39Z","_rev":"rcwwj6TiN2Q0ymhqDzIfXP","sortOrder":1,"_updatedAt":"2024-05-24T16:46:13Z","children":[]},{"_rev":"rcwwj6TiN2Q0ymhqDyFVrf","name":"Clinical Spotlight","_updatedAt":"2024-05-23T20:32:07Z","url":"/clinical-spotlight","is_active":true,"_createdAt":"2020-10-16T13:03:47Z","_id":"43960f88-0c8d-404b-b9d9-d90432c2c516","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"children":[],"_type":"mainNavigation"},{"_rev":"rcwwj6TiN2Q0ymhqDzIhDR","url":"/custom-email","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_id":"38aa3af0-8a34-4ae6-898c-37214580d384","children":[],"_type":"mainNavigation","name":"Microsites","_updatedAt":"2024-05-24T16:46:44Z","is_active":true,"_createdAt":"2024-05-24T16:46:44Z"},{"_createdAt":"2024-05-24T16:47:05Z","name":"Sponsored Content","_id":"d0b0683f-18e1-4e75-89fd-fb4e578a562f","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"url":"/sponsored","children":[],"_rev":"rcwwj6TiN2Q0ymhqDzIiDr","is_active":true,"_type":"mainNavigation","_updatedAt":"2024-05-24T16:47:05Z"}],"name":"Resources","_id":"86b03e38-f3d2-41d1-89e7-c3175c571a55","sortOrder":7,"_rev":"rcwwj6TiN2Q0ymhqDzIdco","_type":"mainNavigation"},{"_rev":"LtkInV1jlQdtEIFjVpi9sG","_updatedAt":"2024-08-27T15:31:04Z","_createdAt":"2020-04-14T14:00:08Z","subQuery":[],"_id":"621fccf5-dcdb-40a9-af70-9bf3ccf79278","url":"/continuing-education","is_active":true,"sortOrder":8,"_type":"mainNavigation","name":"CE","navParent":null},{"_createdAt":"2024-05-24T16:48:11Z","sortOrder":9,"_type":"mainNavigation","navParent":null,"is_active":true,"subQuery":[{"name":"AJMC Staff","_id":"be637b3b-f72a-4049-91b8-409809b2d815","_updatedAt":"2024-05-24T19:05:57Z","_createdAt":"2024-05-24T19:05:57Z","_type":"mainNavigation","_rev":"Jz2W7keLhiw1UYkGHgBp6D","url":"/editorial","children":[],"is_active":true,"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"}},{"is_active":true,"_createdAt":"2024-05-24T16:48:30Z","_type":"mainNavigation","_updatedAt":"2024-05-24T16:48:30Z","url":"/anniversary","navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDzIn5Y","name":"Anniversary","_id":"5298152f-5135-4c2c-a46e-a14ad0300bf4","children":[]},{"children":[],"_createdAt":"2024-05-24T18:24:23Z","_type":"mainNavigation","_updatedAt":"2024-07-23T13:38:48Z","navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_rev":"AGf4LvcO2r7q1La1cjR7dD","_id":"28d33143-d9a9-45bd-af63-bed8d2198118","url":"/about/seema-sonnad-nomination","is_active":true,"name":"Seema Sonnad Award"},{"_id":"acb7dc53-dfab-462a-b2e9-b0cfc8675da4","url":"/partners","is_active":true,"children":[],"_rev":"uJbbwQWkLESsncBrcLLVEZ","name":"Strategic Alliance Partners","navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_type":"mainNavigation","_updatedAt":"2024-05-24T16:49:00Z","_createdAt":"2024-05-24T16:49:00Z"}],"_rev":"rcwwj6TiN2Q0ymhqDzIlc0","name":"About AJMC","_id":"c14e4637-909c-4bf6-bf81-64eeb6005352","_updatedAt":"2024-05-24T16:48:11Z"},{"subQuery":[],"blank":true,"_updatedAt":"2024-03-11T14:58:15Z","is_active":true,"_createdAt":"2020-06-22T20:56:33Z","_rev":"gFXie0Ldruy1o91XppbLLd","_type":"mainNavigation","navParent":null,"name":"Subscribe","_id":"1e279576-0b33-4e57-8782-b6b1edbf68da","sortOrder":9,"url":"https://one.ajmc.com/subscribe"}],"sub_menu":[{"name":"Specialty Area","_updatedAt":"2024-05-24T05:08:37Z","_createdAt":"2020-04-14T14:04:25Z","sortOrder":1,"_type":"subNavigation","subQuery":[{"_rev":"Jz2W7keLhiw1UYkGHfbM3A","is_active":true,"_updatedAt":"2024-05-24T05:06:44Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"url":"/compendium/biosimilars","children":[],"_createdAt":"2024-05-24T05:06:44Z","_type":"subNavigation","name":"Biosimilars","_id":"aa3904f3-c0d8-495d-a77f-afcc41f27045"},{"_rev":"G7uWgc8ggxb5zBvm8zNQqB","name":"Cardiorenalmetabolic","_id":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","is_active":true,"_createdAt":"2024-05-24T05:30:27Z","_type":"subNavigation","_updatedAt":"2024-06-11T20:17:38Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"_rev":"Jz2W7keLhiw1UYkGHfbquf","_id":"c3566f20-e7c6-4b38-bf9f-7d52055698b1","url":"/compendium/cardiovascular","is_active":true,"_createdAt":"2024-05-24T05:30:54Z","name":"Cardiovascular","_updatedAt":"2024-05-24T05:30:54Z","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_type":"subNavigation"},{"is_active":true,"_createdAt":"2024-05-24T05:32:42Z","name":"Chronic Kidney Disease","_id":"f3a69e16-dc38-4135-886e-d70e18532bf4","_updatedAt":"2024-05-24T05:32:42Z","url":"/compendium/ckd","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbumO","_type":"subNavigation"},{"_createdAt":"2024-05-24T05:31:14Z","name":"Diabetes","_id":"79c02dc8-3c2d-451b-9797-008b25d61d4d","url":"/compendium/diabetes","is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_updatedAt":"2024-05-24T05:31:14Z","_rev":"Jz2W7keLhiw1UYkGHfbrEl","_type":"subNavigation"},{"name":"Heart Failure","_updatedAt":"2024-05-24T05:31:38Z","url":"/compendium/heart-failure","is_active":true,"navParent":{"_type":"reference","_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab"},"_createdAt":"2024-05-24T05:31:38Z","_rev":"Jz2W7keLhiw1UYkGHfbrQF","_type":"subNavigation","_id":"84c7dd54-fb21-4bc5-86bc-9bbf39a7f836"},{"_id":"aadd9bdc-4dd1-4ac1-be4f-2afb4315b6cb","url":"/compendium/type1diabetes","is_active":true,"_type":"subNavigation","_rev":"Jz2W7keLhiw1UYkGHfbsbS","name":"Type 1 Diabetes","_updatedAt":"2024-05-24T05:32:00Z","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:32:00Z"}]},{"_rev":"Jz2W7keLhiw1UYkGHfbSVf","_type":"subNavigation","is_active":true,"_createdAt":"2024-05-24T05:10:35Z","_id":"7599f50b-36ff-42a5-8d72-82814db9b988","name":"Dermatology","_updatedAt":"2024-05-24T05:10:35Z","url":"/compendium/dermatology","children":[{"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"url":"/compendium/alopecia","is_active":true,"_createdAt":"2024-05-23T21:42:49Z","_rev":"Jz2W7keLhiw1UYkGHfbTPe","_type":"subNavigation","name":"Alopecia","_id":"04523862-a8a1-4626-b288-95b3d4114267","_updatedAt":"2024-05-24T05:12:43Z"},{"_type":"subNavigation","name":"Atopic Dermatitis","_id":"637a0b1e-1b12-42bf-81a3-e6db5a997021","url":"/compendium/atopic-dermatitis","navParent":{"_type":"reference","_ref":"7599f50b-36ff-42a5-8d72-82814db9b988"},"_createdAt":"2024-05-24T05:12:02Z","_updatedAt":"2024-05-24T05:12:02Z","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbSvV"},{"_createdAt":"2024-05-24T05:12:30Z","_type":"subNavigation","_id":"a9dcce80-4f29-488e-b7ef-51f0fb562a5a","_updatedAt":"2024-05-24T05:12:36Z","is_active":true,"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"url":"/compendium/psoriasis","_rev":"Jz2W7keLhiw1UYkGHfbTJu","name":"Psoriasis"}],"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"}},{"url":"/compendium/hematology","children":[{"_type":"subNavigation","name":"ALL/AML","_id":"d79f2b30-e7f2-4915-bef8-1a73a9190a91","_updatedAt":"2024-05-29T15:28:26Z","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-29T15:28:26Z","_rev":"Iat2IZiT321TmGHwkF66wB","url":"/compendium/all"},{"_rev":"Iat2IZiT321TmGHwkF65Md","name":"CLL/SLL","_id":"664a6ece-64dd-41f8-87a0-7f5a47323c3b","_updatedAt":"2024-05-29T15:27:46Z","url":"/compendium/cll","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-29T15:26:57Z","_type":"subNavigation"},{"_type":"subNavigation","name":"GVHD","_id":"32cf626c-1ce6-4fb5-9dd7-088522dc46e6","url":"/compendium/gvhd","navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"},"_createdAt":"2024-05-29T15:28:51Z","_rev":"Iat2IZiT321TmGHwkF67tn","_updatedAt":"2024-05-29T15:28:51Z","is_active":true},{"_updatedAt":"2024-05-24T05:14:15Z","navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"},"name":"Hemophilia","_rev":"Jz2W7keLhiw1UYkGHfbUDt","_type":"subNavigation","_id":"4dd2ce64-8f4d-4285-bc1a-ec40ffc99b51","url":"/compendium/hemophilia","is_active":true,"_createdAt":"2024-05-24T05:14:15Z"},{"_createdAt":"2024-05-24T05:45:17Z","_rev":"Iat2IZiT321TmGHwkF6NtX","url":"/compendium/multiple-myeloma","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_type":"subNavigation","name":"Multiple Myeloma","_id":"84e2d674-0fe1-4bd1-9d97-2f8bc8589ba0","_updatedAt":"2024-05-29T15:35:07Z"},{"_rev":"Iat2IZiT321TmGHwkF6a5X","name":"Myelodysplastic Syndromes","url":"/compendium/myelodysplastic-syndromes","is_active":true,"_createdAt":"2024-05-24T05:45:36Z","_id":"3a327f90-a5fc-4d87-9a18-02f54cb40b8e","_updatedAt":"2024-05-29T15:35:22Z","navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"},"_type":"subNavigation"},{"_updatedAt":"2024-06-05T20:02:27Z","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-29T15:29:21Z","_rev":"Up1TL5YPo1fhI8V2tpNnMb","_id":"a6003c4f-e7f0-422a-8129-49a2d78eb113","is_active":true,"_type":"subNavigation","name":"Myeloproliferative Neoplasms","url":"/compendium/mpn"},{"url":"/compendium/nhl","_createdAt":"2024-05-24T05:43:54Z","_rev":"rmdpbbz4U7GL9ExaGp96DY","_id":"fc247a6b-0b33-4e18-ae78-56e677c6bb18","name":"Non-Hodgkin Lymphoma","_updatedAt":"2024-06-25T17:42:12Z","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_type":"subNavigation"},{"navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"},"name":"Rare Blood","is_active":true,"_createdAt":"2024-05-24T05:14:40Z","_rev":"Jz2W7keLhiw1UYkGHfbUPN","_type":"subNavigation","_id":"85e2fc3e-ac5c-4b47-8b14-411d730d20d9","_updatedAt":"2024-05-24T05:14:40Z","url":"/compendium/rareblood"}],"_rev":"Jz2W7keLhiw1UYkGHfbU3q","_updatedAt":"2024-05-24T05:13:48Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:13:48Z","_type":"subNavigation","name":"Hematology","_id":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","is_active":true},{"_updatedAt":"2024-06-11T20:17:54Z","is_active":true,"_rev":"N7mKycgLbGtEq6btkLqjkf","_type":"subNavigation","name":"Hepatology","children":[{"is_active":true,"navParent":{"_ref":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbwkP","_type":"subNavigation","_createdAt":"2024-05-24T05:34:54Z","name":"Liver","_id":"2aefee8c-db97-4e7d-b600-efb48e6bcb6c","_updatedAt":"2024-05-24T05:34:54Z","url":"/compendium/liver-cancer"}],"_id":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:34:29Z"},{"is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","name":"Immunology","children":[{"_type":"subNavigation","_id":"b3daefd0-0ac3-4be2-ad23-f9c3fa37cf37","_updatedAt":"2024-05-24T05:23:39Z","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"name":"Autoimmune","url":"/compendium/autoimmune","_createdAt":"2024-05-24T05:23:39Z","_rev":"Jz2W7keLhiw1UYkGHfbkp8"},{"_type":"subNavigation","name":"Inflammation","url":"/compendium/Inflammation","navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2024-05-24T05:23:59Z","_rev":"Jz2W7keLhiw1UYkGHfbkzB","_id":"6016d41d-9d43-49fa-99b6-7caca304f30d","_updatedAt":"2024-05-24T05:23:59Z","is_active":true},{"is_active":true,"_createdAt":"2024-05-24T05:24:47Z","_rev":"Jz2W7keLhiw1UYkGHfbmd6","url":"/compendium/lupus","navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_type":"subNavigation","name":"Lupus","_id":"b537fcea-aea3-40ca-83c1-0907fdc9ccb5","_updatedAt":"2024-05-24T05:24:47Z"},{"_type":"subNavigation","url":"/compendium/myasthenia-gravis","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2024-05-24T05:25:23Z","_rev":"Jz2W7keLhiw1UYkGHfbn7F","name":"Myasthenia Gravis","_id":"ef6c4efc-5932-4148-b626-cbf42e1c49c3","_updatedAt":"2024-05-24T05:25:23Z"}],"_updatedAt":"2024-05-24T05:23:19Z","url":"/compendium/immunology","_id":"1b1e3727-8b82-42da-9a62-b20472b9c797","_createdAt":"2024-05-24T05:23:19Z","_rev":"Jz2W7keLhiw1UYkGHfbkam"},{"is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcA9Y","_type":"subNavigation","url":"/compendium/infectious-disease","children":[{"_id":"ffcd30d0-169f-4a8f-9f01-616142f33712","_updatedAt":"2024-05-24T05:36:03Z","url":"/compendium/covid-19","navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_createdAt":"2024-05-24T05:36:03Z","_rev":"rcwwj6TiN2Q0ymhqDyeyP3","_type":"subNavigation","name":"COVID-19","is_active":true},{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfcAxn","_type":"subNavigation","name":"HIV","url":"/compendium/hiv","navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_createdAt":"2024-05-24T05:36:22Z","_id":"a53004c6-9fe2-4b9c-a86a-ad74f9204b3a","_updatedAt":"2024-05-24T05:36:29Z"},{"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_updatedAt":"2024-05-24T05:37:06Z","url":"/compendium/rsv","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyezNO","_type":"subNavigation","name":"RSV","_id":"ca70e9ab-a981-4629-a766-81f7890b3977","_createdAt":"2024-05-24T05:37:06Z"},{"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"is_active":true,"_createdAt":"2024-05-24T05:37:53Z","_rev":"Jz2W7keLhiw1UYkGHfcFFM","_type":"subNavigation","name":"Vaccines","_id":"a0ec0591-b4a1-4723-b984-b681c957523f","_updatedAt":"2024-05-24T05:37:53Z","url":"/compendium/vaccines"}],"_id":"b62af616-818b-4bda-b606-bd64287f9a85","_updatedAt":"2024-05-24T05:35:38Z","_createdAt":"2024-05-24T05:35:38Z","name":"Infectious Disease"},{"is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"url":"/compendium/mental-health","_type":"subNavigation","name":"Mental Health","children":[{"is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyf7Qk","name":"Major Depressive Disorder","navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_createdAt":"2024-05-24T05:38:58Z","_type":"subNavigation","_id":"efcab5a8-97d8-4f5a-ba99-0a0555531f5a","_updatedAt":"2024-05-24T05:38:58Z","url":"/compendium/mdd"},{"_type":"subNavigation","name":"Sleep","_id":"f52dbfa9-aefe-4d21-b432-7052a136ae98","url":"/compendium/sleep","navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_createdAt":"2024-05-24T05:39:18Z","_updatedAt":"2024-05-24T05:39:18Z","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyf96m"}],"_rev":"rcwwj6TiN2Q0ymhqDyf4PU","_createdAt":"2024-05-24T05:38:33Z","_id":"db67ff69-2c58-4931-ad3d-767a636e38b0","_updatedAt":"2024-05-24T05:38:33Z"},{"_rev":"G7uWgc8ggxb5zBvm8zNRmt","children":[{"name":"Duchenne Muscular Dystrophy","_updatedAt":"2024-05-24T05:40:18Z","navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfERb","_type":"subNavigation","_id":"3e24f5af-027e-4f0b-a7e2-a3ffaf756a35","url":"/compendium/dmd","is_active":true,"_createdAt":"2024-05-24T05:40:18Z"},{"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfIhq","_type":"subNavigation","_updatedAt":"2024-05-24T05:40:38Z","is_active":true,"_createdAt":"2024-05-24T05:40:30Z","name":"Epilepsy","_id":"d4e270df-2a59-4109-a7be-9c10f80722a7","url":"/compendium/epilepsy"},{"_updatedAt":"2024-05-24T05:41:07Z","url":"/compendium/multiple-sclerosis","is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfJRc","name":"Multiple Sclerosis","_id":"7539f9b5-8f2a-4e1b-a10f-8cc748cd1489","_createdAt":"2024-05-24T05:41:07Z","_type":"subNavigation"},{"name":"Parkinson Disease","_id":"90ebd8e7-e6d1-4128-8010-0b205fedb430","_updatedAt":"2024-05-24T05:41:29Z","navParent":{"_type":"reference","_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11"},"_createdAt":"2024-05-24T05:41:29Z","_rev":"rcwwj6TiN2Q0ymhqDyfJiG","_type":"subNavigation","is_active":true,"url":"/compendium/parkinson"}],"_updatedAt":"2024-06-11T20:18:36Z","name":"Neurology","_id":"bafe1c52-a8b5-4786-bcee-668409d14a11","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:39:38Z","_type":"subNavigation"},{"_updatedAt":"2024-09-04T14:25:34Z","url":"/compendium/obesity","_createdAt":"2024-09-04T14:25:34Z","is_active":true,"name":"Obesity","children":[],"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"B2kOGngERQtEUh1WG5WXvd","_type":"subNavigation","_id":"fe48de19-78d2-4ed0-83fa-8884fb340de2"},{"url":"/compendium/oncology","_updatedAt":"2024-05-24T05:41:55Z","_id":"90b398eb-3349-4b6a-b205-780a34cb4717","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfKov","_type":"subNavigation","is_active":true,"_createdAt":"2024-05-24T05:41:55Z","children":[{"_updatedAt":"2024-05-24T05:42:17Z","url":"/compendium/breast-cancer","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:42:17Z","_type":"subNavigation","name":"Breast Cancer","_rev":"rcwwj6TiN2Q0ymhqDyfMpl","_id":"03ea9371-55cd-42e2-b300-7078b94ff467"},{"_type":"subNavigation","_updatedAt":"2024-05-24T05:42:35Z","is_active":true,"_createdAt":"2024-05-24T05:42:35Z","_rev":"rcwwj6TiN2Q0ymhqDyfatY","name":"Cholangiocarcinoma","_id":"8b57fc91-4191-420c-a224-cb869f8fa0d7","url":"/compendium/cholangiocarcinoma","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"}},{"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcTh6","_type":"subNavigation","_id":"e45ff858-e1bc-4b4a-9398-e12877b61607","_updatedAt":"2024-05-24T05:43:23Z","url":"/compendium/colorectal-cancer","is_active":true,"_createdAt":"2024-05-24T05:43:23Z","name":"Colorectal Cancer"},{"_rev":"Jz2W7keLhiw1UYkGHfsKT5","_id":"289f747b-dffd-4006-a27d-4933a46fd7c1","_updatedAt":"2024-05-24T13:25:09Z","is_active":true,"_createdAt":"2024-05-24T05:44:17Z","_type":"subNavigation","name":"Immuno-Oncology","url":"/compendium/immuno-oncology","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"}},{"_updatedAt":"2024-05-29T15:32:02Z","_createdAt":"2024-05-29T15:32:02Z","_rev":"Iat2IZiT321TmGHwkF6F4B","_type":"subNavigation","name":"Liver Cancer","_id":"9d17bccc-3f33-4793-90e3-0adecfa71fa1","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"url":"/compendium/liver-cancer"},{"name":"Lung Cancer","_id":"89f99f56-72a9-4dcd-9d8c-3d717d66a5f0","url":"/compendium/lung-cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:44:58Z","_type":"subNavigation","_updatedAt":"2024-05-24T05:44:58Z","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyfff0"},{"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:45:56Z","_rev":"Jz2W7keLhiw1UYkGHfsIwL","_updatedAt":"2024-05-24T13:24:22Z","is_active":true,"name":"Non–Small Cell Lung Cancer","_id":"85d30c37-d6a1-4028-9c0f-ecdf36de220d","url":"/compendium/nsclc","_type":"subNavigation"},{"_id":"5a67adcb-11d8-48a6-8c39-b2956f5f3e86","_updatedAt":"2024-05-24T05:46:17Z","_createdAt":"2024-05-24T05:46:17Z","_rev":"Jz2W7keLhiw1UYkGHfcbF4","_type":"subNavigation","name":"Ovarian Cancer","url":"/compendium/ovarian-cancer","is_active":true,"navParent":{"_type":"reference","_ref":"90b398eb-3349-4b6a-b205-780a34cb4717"}},{"is_active":true,"_id":"bcfe0d88-7498-4268-95e6-875c94a2dab5","_updatedAt":"2024-05-24T05:47:42Z","url":"/compendium/prostate-cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:47:42Z","_rev":"rcwwj6TiN2Q0ymhqDyfmoB","_type":"subNavigation","name":"Prostate Cancer"},{"name":"Skin Cancer","_updatedAt":"2024-05-24T05:48:18Z","_createdAt":"2024-05-24T05:48:18Z","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfpKE","_type":"subNavigation","_id":"a3a04e72-c707-450d-b9d3-f9ebacc9f997","url":"/compendium/skincancer","is_active":true},{"is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-29T15:30:06Z","_rev":"Iat2IZiT321TmGHwkF69Qd","_id":"6d1dc4b4-1be8-41ee-9bba-90ad4ce546b3","_updatedAt":"2024-05-29T15:30:06Z","_type":"subNavigation","name":"Soft Tissue Sarcoma","url":"/compendium/soft-tissue-sarcoma"}],"name":"Oncology"},{"is_active":true,"_type":"subNavigation","_id":"eee19078-eb50-46e7-a97c-8f16d79eea97","_rev":"Jz2W7keLhiw1UYkGHfcePj","name":"Ophthalmology","url":"/compendium/ophthalmology","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:48:54Z","_updatedAt":"2024-05-24T05:48:54Z","children":[]},{"_updatedAt":"2024-06-03T20:54:07Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"5DUHcaiKRKj5c8wHOPlDws","name":"Pulmonology","is_active":true,"_createdAt":"2024-05-24T05:49:11Z","children":[{"is_active":true,"name":"COPD","_id":"3a19d535-d61e-43b1-bf6a-d6ced486a0b9","_updatedAt":"2024-05-24T05:49:28Z","url":"/compendium/copd","navParent":{"_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"reference"},"_createdAt":"2024-05-24T05:49:28Z","_rev":"rcwwj6TiN2Q0ymhqDyfrwW","_type":"subNavigation"},{"is_active":true,"name":"Pulmonary Arterial Hypertension","_id":"474080cd-4295-4a70-907d-e1fc93c435cc","url":"/compendium/pah","navParent":{"_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"reference"},"_createdAt":"2024-05-24T05:49:52Z","_rev":"rcwwj6TiN2Q0ymhqDyfuBv","_type":"subNavigation","_updatedAt":"2024-05-24T05:49:52Z"}],"_type":"subNavigation","_id":"e6c5e55f-7a5a-4f23-add2-fbf91df76400"},{"_createdAt":"2024-05-24T05:50:50Z","_type":"subNavigation","is_active":true,"children":[{"navParent":{"_type":"reference","_ref":"de690920-3cdc-4c43-a27e-ba4e38a62059"},"_createdAt":"2024-05-24T05:51:19Z","_type":"subNavigation","_id":"9e780f76-2008-441b-ab5f-00d3a6d1a5b0","url":"/compendium/sma","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyg1k4","name":"Spinal Muscular Atrophy","_updatedAt":"2024-05-24T05:51:19Z"}],"_updatedAt":"2024-05-24T05:50:50Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"url":"/compendium/raredisease","name":"Rare Disease","_id":"de690920-3cdc-4c43-a27e-ba4e38a62059","_rev":"rcwwj6TiN2Q0ymhqDyg1Ah"},{"is_active":true,"_createdAt":"2024-05-24T05:50:22Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","children":[{"name":"Asthma","url":"/compendium/asthma","is_active":true,"_createdAt":"2024-05-24T05:52:02Z","_rev":"rcwwj6TiN2Q0ymhqDyg2wy","_type":"subNavigation","navParent":{"_ref":"f2a34114-0396-44cb-b241-11ef7b175500","_type":"reference"},"_id":"b2b2802f-2918-4431-8f4f-3bc7e6e6042f","_updatedAt":"2024-05-24T05:52:02Z"},{"_updatedAt":"2024-06-03T18:31:07Z","url":"/compendium/ipf","is_active":true,"_createdAt":"2024-06-03T18:31:07Z","_rev":"5DUHcaiKRKj5c8wHOPKtuf","name":"Idiopathic Pulmonary Fibrosis","navParent":{"_type":"reference","_ref":"f2a34114-0396-44cb-b241-11ef7b175500"},"_type":"subNavigation","_id":"4dac47d5-8dd1-4e90-b4be-b6b5e605f6f5"}],"_rev":"Jz2W7keLhiw1UYkGHfcjSf","name":"Respiratory","_id":"f2a34114-0396-44cb-b241-11ef7b175500","url":"/compendium/respiratory","_updatedAt":"2024-05-24T05:50:22Z"},{"name":"Rheumatology","_updatedAt":"2024-05-24T05:52:28Z","children":[],"_rev":"Jz2W7keLhiw1UYkGHfcm6J","_createdAt":"2024-05-24T05:52:28Z","is_active":true,"_id":"3ecb2952-6710-46b1-ab05-36997bfb4a33","url":"/compendium/rheumatology","_type":"subNavigation","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"}},{"name":"Women's Health","_updatedAt":"2024-05-24T05:52:51Z","children":[],"url":"/compendium/womens-health","is_active":true,"_type":"subNavigation","_id":"ead467ba-7c17-4a1b-9deb-a7af56a7366e","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:52:51Z","_rev":"Jz2W7keLhiw1UYkGHfcmDU"}],"_id":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","url":"/compendium","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbRHa","navParent":null},{"_type":"subNavigation","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyHDJ3","navParent":null,"subQuery":[{"navParent":{"_ref":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","_type":"reference"},"name":"Free In-Person Regional Events Focused on Oncology and Population Health","_updatedAt":"2024-05-23T21:05:49Z","_createdAt":"2024-05-23T21:04:56Z","_type":"subNavigation","_id":"f5b2c97b-d6d4-468b-8a9a-4814364994c8","url":"/ivbmevents?display=home","is_active":true,"children":[],"_rev":"uJbbwQWkLESsncBrcJSd1N"}],"name":"Spotlight","_id":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","_updatedAt":"2024-05-23T21:04:52Z","_createdAt":"2024-05-23T20:47:34Z","sortOrder":2},{"_type":"subNavigation","name":"Topics","_updatedAt":"2020-08-21T22:11:57Z","is_active":true,"_createdAt":"2020-04-14T14:05:54Z","_id":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","url":"/topic","sortOrder":2,"_rev":"iEeBpgQLYwZXMeCflboLMu","navParent":null,"subQuery":[{"_rev":"Jz2W7keLhiw1UYkGHfbHQ4","_updatedAt":"2024-05-24T05:05:19Z","_createdAt":"2024-05-24T05:05:19Z","_type":"subNavigation","_id":"43207521-4e5f-42d2-b013-34763a4d964c","is_active":true,"sortOrder":1,"name":"Biosimilars","url":"/compendium/biosimilars","children":[],"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"}},{"url":"/topic/center-on-health-equity-and-access","is_active":true,"navParent":{"_type":"reference","_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2"},"_createdAt":"2022-12-23T21:04:41Z","_type":"subNavigation","name":"Center on Health Equity \u0026 Access","_id":"4161ff97-2901-4526-80ee-3749b6dc6345","children":[],"_updatedAt":"2024-06-12T13:58:35Z","_rev":"N7mKycgLbGtEq6btkPIW3d"},{"_id":"232e30a0-2f7d-4ce1-9e4d-cc0cee73b20a","url":"/compendium/digital-health","children":[],"is_active":true,"navParent":{"_type":"reference","_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2"},"_rev":"rcwwj6TiN2Q0ymhqDygl51","name":"Digital Health","_createdAt":"2024-05-24T05:56:42Z","_type":"subNavigation","_updatedAt":"2024-05-24T05:56:42Z"},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfdAmX","_type":"subNavigation","name":"Formulary","_id":"3887cee2-5461-4cb3-b54f-297fcceb11ee","url":"/formulary","is_active":true,"_createdAt":"2024-05-24T05:57:01Z","_updatedAt":"2024-05-24T05:57:01Z","children":[]},{"_updatedAt":"2024-05-24T05:57:41Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"children":[],"_rev":"rcwwj6TiN2Q0ymhqDygmDl","_createdAt":"2024-05-24T05:57:41Z","name":"Gene Therapy","_id":"56aff93b-4f24-48fc-9dda-2d394397f956","url":"/compendium/gene-therapy","is_active":true,"_type":"subNavigation"},{"_type":"subNavigation","children":[],"_updatedAt":"2024-05-24T06:00:55Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T06:00:55Z","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDygv9D","name":"Guidelines","url":"/guidelines","_id":"69723346-76b2-4896-b2d9-2db53ed5da96"},{"is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"url":"/","_rev":"rcwwj6TiN2Q0ymhqDz7eaC","children":[{"navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_createdAt":"2024-05-24T05:58:26Z","_type":"subNavigation","name":"Employers","_id":"83fca4ec-4ff0-4766-9e49-0376d44179e8","_updatedAt":"2024-05-24T13:53:42Z","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDz6EMB","url":"/compendium/employers"},{"_rev":"rcwwj6TiN2Q0ymhqDz6F3s","name":"Medicare","_id":"5647b438-aca9-4b57-9d4d-2df660b5a6ce","_updatedAt":"2024-05-24T13:53:53Z","url":"/compendium/medicare","is_active":true,"navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_createdAt":"2024-05-24T05:58:44Z","_type":"subNavigation"},{"_createdAt":"2024-05-24T05:59:16Z","_id":"2c8ff713-9c43-4afc-aaca-e33ceb98f00c","_updatedAt":"2024-05-24T13:54:23Z","_type":"subNavigation","name":"Reimbursement","url":"/compendium/reimbursement","is_active":true,"navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDz6G8S"}],"_type":"subNavigation","name":"Health Care Administration","_updatedAt":"2024-05-24T14:10:39Z","_createdAt":"2024-05-24T13:53:24Z","_id":"cd6edcff-faa3-4bee-9071-042f8186052d"},{"_updatedAt":"2021-02-25T17:30:59Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2020-04-14T14:06:29Z","_id":"c9a8f6fd-0ad0-4a82-a385-13c03fe688d0","_type":"subNavigation","url":"/topic/healthcare-cost","name":"Health Care Cost","is_active":true,"_rev":"wx7I38TXtYeZdHCfn60Syn","children":[]},{"_createdAt":"2020-04-14T14:06:43Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"url":"/topic/healthcare-delivery","children":[],"_type":"subNavigation","name":"Health Care Delivery","_id":"d01b9875-6e51-42d1-bdf5-93fd8771855c","_updatedAt":"2021-02-25T17:29:58Z","_rev":"YN5IiYQkhJ3hq0R7jM8DQW","is_active":true},{"_updatedAt":"2022-12-21T19:05:52Z","url":"/topic/insurance","_type":"subNavigation","children":[],"name":"Insurance","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2020-04-14T14:07:01Z","_rev":"lslStCipHxtG437RQOGJ7p","_id":"d8eab058-f5ec-4c42-a95a-941c0a506543"},{"url":"/topic/policy","children":[],"name":"Policy","_updatedAt":"2020-04-14T14:07:15Z","_createdAt":"2020-04-14T14:07:15Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_id":"fd066f36-78ee-4112-a121-4e02f8e45b0b","is_active":true,"_rev":"T035zdq5xruIFPyK3OzgdQ","_type":"subNavigation"},{"name":"Population Health","children":[],"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_type":"subNavigation","_id":"d7893fef-5eb0-4b2d-b13d-a0bec73b2c14","_createdAt":"2024-05-24T05:59:24Z","_rev":"rcwwj6TiN2Q0ymhqDygvgV","is_active":true,"_updatedAt":"2024-05-24T06:01:29Z","url":"/compendium/population"},{"_id":"6188ac2f-7ec8-4cbb-a154-5822f606f3fa","_rev":"Jz2W7keLhiw1UYkGHfsKLu","_type":"subNavigation","name":"Product Approvals and Launches","children":[],"_createdAt":"2024-05-24T06:01:51Z","_updatedAt":"2024-05-24T13:24:58Z","url":"/approvals-launches","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"}},{"_rev":"QxOJBWa4XErmibN6Cb5bN0","children":[],"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"is_active":true,"url":"/topic/technology","_id":"4e2fe99b-3ac4-4b48-89ed-774dd51675df","_updatedAt":"2020-04-14T14:07:28Z","_createdAt":"2020-04-14T14:07:28Z","_type":"subNavigation","name":"Technology"},{"_type":"subNavigation","url":"/topic/value-based-care","_rev":"T035zdq5xruIFPyK3OzhkC","_createdAt":"2020-04-14T14:07:42Z","_updatedAt":"2020-04-14T14:07:42Z","children":[],"_id":"22bd1bd6-88a6-4278-a846-e086cf30b141","is_active":true,"navParent":{"_type":"reference","_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2"},"name":"Value-Based Care"}]},{"_id":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","navParent":null,"_updatedAt":"2020-04-27T18:48:23Z","is_active":true,"sortOrder":3,"_type":"subNavigation","name":"Institute for Value-Based Medicine","_createdAt":"2020-04-27T18:48:09Z","_rev":"N0LuVAjtHhQSyVgQyS0Kyv","url":"/ivbm","subQuery":[{"_rev":"cyKVTGb2fpu5E4X0UMrv4p","url":"/ivbm","_type":"subNavigation","_createdAt":"2020-05-06T13:11:16Z","children":[],"name":"All Coverage","_id":"f7379c68-40be-45e4-9747-484dcec584d3","_updatedAt":"2020-05-06T13:11:16Z","is_active":true,"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"}},{"is_active":true,"children":[],"_rev":"k2D4PisPM2pBS5NIl95QbN","_type":"subNavigation","_createdAt":"2020-04-27T18:49:41Z","_id":"cc8a827f-3e94-413a-aa0c-0d8b40eb5f18","url":"/ivbm/event-coverage","name":"Event Coverage","_updatedAt":"2020-04-27T18:49:41Z","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"}},{"_rev":"k2D4PisPM2pBS5NIl95RlO","_id":"aa3f3bb8-9e8c-457d-aeb6-7b94b968395a","is_active":true,"url":"/ivbm/interviews","children":[],"_createdAt":"2020-04-27T18:50:03Z","_type":"subNavigation","name":"Interviews","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_updatedAt":"2020-04-27T18:50:03Z"},{"_type":"subNavigation","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"children":[],"name":"News","_createdAt":"2020-04-27T18:50:34Z","_id":"1be7e99c-8d37-4d70-a009-67eb03fae5ba","_updatedAt":"2020-04-27T18:50:34Z","is_active":true,"url":"/ivbm/news","_rev":"XtnP0djhkej33kSTbdUgmN"}]},{"_createdAt":"2020-04-14T14:09:11Z","_rev":"lsW1cEPdRFwwIdupAS8Stb","_type":"subNavigation","subQuery":[{"name":"AJMC Journals","_updatedAt":"2020-05-07T17:05:52Z","_rev":"NGYpFwzJghlKjBIAt48VzS","_type":"subNavigation","_id":"4e10ead3-6a42-43df-b251-b93b912a24cb","children":[],"is_active":true,"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"url":"/about","_createdAt":"2020-05-07T17:05:52Z"},{"_id":"4451f4fa-a919-45b4-b6e5-282668cd792e","_type":"subNavigation","name":"Anniversary","navParent":{"_type":"reference","_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1"},"_createdAt":"2020-04-14T14:09:38Z","is_active":true,"_rev":"rHX8vIEJKWyjgUO02y82fe","_updatedAt":"2020-04-14T14:09:38Z","url":"/anniversary","children":[]},{"name":"Author Forms","_updatedAt":"2020-06-09T11:44:06Z","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2020-04-14T14:10:37Z","_type":"subNavigation","_id":"99bccc8e-9329-496f-b588-ec3d080f0859","is_active":true,"url":"/authorshipforms","_rev":"VmKMEDy0rHs5jzhO3eZVVM","children":[]},{"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_rev":"0JTsteyxJPdyCvciQ9yBPv","_type":"subNavigation","_updatedAt":"2020-05-06T12:53:11Z","is_active":true,"children":[],"_createdAt":"2020-04-14T14:10:19Z","name":"Authors","_id":"518317a5-297f-4c4f-9d2a-6da7b8c98d9c","url":"/authors"},{"is_active":true,"url":"/seema-sonnad-nomination","_type":"subNavigation","children":[],"_createdAt":"2020-06-15T17:13:51Z","_rev":"m6BzyPIGe9IGx2bV3pSCbq","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"name":"Nominate a Rising Leader","_id":"a96a44c9-4d51-47c6-8f81-4263bd2f58b4","_updatedAt":"2020-06-15T17:13:51Z"},{"url":"/submit-a-manuscript","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2023-03-14T13:29:28Z","_rev":"TctAtfg0qER1kILh39bPC4","name":"Submit a Manuscript","_id":"4420e458-acb4-4edb-9f33-c4fc4504ff41","children":[],"is_active":true,"_updatedAt":"2023-03-14T13:29:28Z","_type":"subNavigation"}],"navParent":null,"sortOrder":4,"name":"About AJMC","_id":"9a07b754-3383-43ac-9d2d-a370d44406d1","_updatedAt":"2020-04-27T18:48:27Z","is_active":true}],"site_setting":{"gaID":"UA-155582410-5,UA-11140057-3","footerLinks":[{"url":"/about-us","_type":"urlArray","_key":"6170fdefc8129a5a7ef9dfdd78a2573e","title":"About"},{"_type":"urlArray","_key":"281c240875d5","title":"Contact","url":"/contactus"},{"url":"/editorial-boards","_type":"urlArray","_key":"25e9e6fb7b4422cd0ac20e1a1d993228","title":"Editorial Boards"},{"_type":"urlArray","_key":"20a44c137e8d","title":"Advertise","url":"/advertise"},{"blank":true,"_type":"urlArray","_key":"21b84fcc9b6e","title":"Do Not Sell My Information","url":"https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com"},{"_type":"urlArray","_key":"2f35307aab1f","title":"Terms \u0026 Conditions","url":"/terms"},{"url":"/privacy","_type":"urlArray","_key":"50ecd8627d01","title":"Privacy Policy"}],"_createdAt":"2020-04-14T14:14:32Z","creativeLayoutLatestNews":null,"socialLinks":[{"url":"https://www.facebook.com/TheAmericanJournalOfManagedCare","blank":true,"_type":"urlArray","_key":"5a09ae68c48c","title":"Facebook"},{"_key":"ad6b3d250e0b","title":"Twitter","url":"https://twitter.com/AJMC_Journal","blank":true,"_type":"urlArray"},{"_type":"urlArray","_key":"7d1e53fa7d09","title":"LinkedIn","url":"https://www.linkedin.com/company/american-journal-of-managed-care/","blank":true},{"title":"Instagram","url":"https://www.instagram.com/ajmcjournal/","blank":true,"_type":"urlArray","_key":"2478204aa05c"},{"title":"RSS","url":"/rss","blank":true,"_type":"urlArray","_key":"0ba4cf990c2f"}],"name":"AJMC - Managed Care News, Research, and Expert Insights","enableSanity2":true,"salesforceDMPId":"tr3xsudox","creativeLayout":null,"_updatedAt":"2024-06-04T19:08:40Z","_rev":"4ivhMQjTvj4eF8IoNFokPn","copyRightText":"AJMC®","_id":"siteSettings","keywords":["American Journal of Managed Care","AJMC"],"_type":"siteSettings","description":"The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.","siteURL":"www.ajmc.com"},"clinicalData":[{"_id":"4ee49086-e720-4a65-883e-4efc24de53bb","name":"Center on Health Equity \u0026 Access","identifier":"center-on-health-equity-and-access","sortOrder":null,"children":[]},{"name":"Clinical","identifier":"clinical","sortOrder":null,"children":[],"_id":"topic_clinical"},{"_id":"topic_healthcare-cost","name":"Health Care Cost","identifier":"healthcare-cost","sortOrder":null,"children":[]},{"_id":"topic_healthcare-delivery","name":"Health Care Delivery","identifier":"healthcare-delivery","sortOrder":null,"children":[]},{"identifier":"insurance","sortOrder":null,"children":[],"_id":"topic_insurance","name":"Insurance"},{"_id":"topic_policy","name":"Policy","identifier":"policy","sortOrder":null,"children":[]},{"name":"Technology","identifier":"technology","sortOrder":null,"children":[],"_id":"topic_technology"},{"sortOrder":null,"children":[],"_id":"topic_value-based-care","name":"Value-Based Care","identifier":"value-based-care"}],"seo_data":[],"recent_news":[{"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"summary":"Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).","thumbnail":{"_type":"mainImage","alt":"Boy with DMD using walker | Image credit: Svitlana – stock.adobe.com","asset":{"_ref":"image-7e20ff65b7abea493e84dace957fb80991ce7bb1-6048x4024-jpg","_type":"reference"}},"url":{"current":"viltolarsen-slows-dmd-progression-in-small-study","_type":"slug"},"factCheckAuthorMapping":null,"_id":"86d3362c-b948-469e-80be-ca1af7693cbe","title":"Viltolarsen Slows DMD Progression in Small Study","published":"2024-11-23T18:00:00.000Z","authorMapping":{"firstName":"Hayden","lastName":"Klein","_createdAt":"2021-07-07T19:05:23Z","url":{"current":"hayden-e-klein","_type":"slug"},"displayName":"Hayden E. Klein","_rev":"sgy4yN0CjmArmRDnE2KbUN","_type":"author","_id":"d4608bc5-b145-4495-9c67-41163578c9f2","biography":[{"style":"normal","_key":"038a30bd95f3","markDefs":[{"_key":"b0bea7fd1873","_type":"link","href":"https://www.linkedin.com/in/hayden-e-klein-40b8b1173/"}],"children":[{"_type":"span","marks":[],"text":"Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.","_key":"607fdc2dfcbb0"}],"_type":"block"},{"_key":"0c154c4abedd","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/hayden-e-klein-40b8b1173/","_key":"b0bea7fd1873","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies from Rutgers University. You can connect with Hayden on ","_key":"3c55bddd8456"},{"marks":["b0bea7fd1873"],"text":"LinkedIn","_key":"607fdc2dfcbb1","_type":"span"},{"_key":"607fdc2dfcbb2","_type":"span","marks":[],"text":"."}],"_type":"block","style":"normal"}],"profileImage":{"alt":"Hayden E. Klein","asset":{"_ref":"image-9a2a017c03e16e188b88d86afed2b268b4b00214-430x430-png","_type":"reference"},"_type":"mainImage"},"_updatedAt":"2024-05-20T19:26:45Z"}},{"_id":"9de436c7-b93c-4acd-82fc-20d1f27bec02","thumbnail":{"_type":"mainImage","alt":"Young woman receiving breast screening | Image Credit: My Ocean studio - stock.adobe.com","caption":"Younger women with HR-positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women. | Image Credit: My Ocean studio - stock.adobe.com","asset":{"_ref":"image-f6dde86a347fe1814dcaa933db7ea64e27db3add-8995x5997-jpg","_type":"reference"}},"url":{"current":"age-related-disparities-in-long-term-outcomes-for-er-her2-breast-cancer","_type":"slug"},"published":"2024-11-23T17:30:00.000Z","factCheckAuthorMapping":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"title":"Age-Related Disparities in Long-Term Outcomes for ER+, HER2– Breast Cancer","summary":"Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women. ","authorMapping":{"_createdAt":"2023-11-22T18:35:06Z","_rev":"sgy4yN0CjmArmRDnE2KiNm","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}},"_updatedAt":"2024-05-20T19:28:22Z","url":{"current":"cameron-santoro","_type":"slug"},"firstName":"Cameron","lastName":"Santoro","displayName":"Cameron Santoro","_type":"author","biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"text":"The American Journal of Managed Care","_key":"213c257c1eca","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"marks":[],"text":" (","_key":"acd931edd707","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"_type":"span","marks":["superscript"],"text":"®","_key":"8ddca200bc46"},{"marks":[],"text":".","_key":"ba3cca6122e3","_type":"span"}],"_type":"block","style":"normal","_key":"3da8fced8696"}]}},{"_id":"809dec58-4f3c-49a1-8c2b-53878dc5e0c3","title":"Edentulism May Heighten Sleep Apnea Risk","url":{"current":"edentulism-may-heighten-sleep-apnea-risk","_type":"slug"},"authorMapping":{"url":{"_type":"slug","current":"jared-kaltwasser"},"displayName":"Jared Kaltwasser","_createdAt":"2020-05-05T10:50:04Z","_rev":"0TowddpnSMVYA5OKF42uAM","_type":"author","_id":"author_18c68a1fd690db471eba0e0da3b8e979","biography":[{"style":"normal","_key":"75ff381b2d42","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/jaredkalt/","_key":"30c8f5445624"}],"children":[{"_type":"span","marks":[],"text":"Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.","_key":"e9f80bd7687c0"}],"_type":"block"},{"_type":"block","style":"normal","_key":"a90d9599d615","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/jaredkalt/","_key":"30c8f5445624","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"He has an MA from University of Sioux Falls. You can connect with Jared on ","_key":"95b8dd3e29db"},{"_type":"span","marks":["30c8f5445624"],"text":"LinkedIn","_key":"e9f80bd7687c1"},{"_type":"span","marks":[],"text":".","_key":"e9f80bd7687c2"}]}],"_updatedAt":"2022-08-30T13:26:44Z"},"factCheckAuthorMapping":null,"summary":"A systematic review has found a potential link between edentulism and sleep apnea risk, although the authors said differences in study designs prohibited a meta-analysis.","thumbnail":{"_type":"mainImage","alt":"Tooth loss | Image Credit: © valiantsin-stock.adobe.com","asset":{"_ref":"image-d8405a2a194a2c5f871d2c521ca31d0ec29d29bc-1200x738-jpg","_type":"reference"}},"published":"2024-11-23T15:00:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"}},{"_id":"1fdd2f09-9d9d-4679-8c5c-64fee40e632c","published":"2024-11-23T13:16:00.000Z","authorMapping":{"_id":"author_18c68a1fd690db471eba0e0da3b8e979","biography":[{"style":"normal","_key":"75ff381b2d42","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/jaredkalt/","_key":"30c8f5445624"}],"children":[{"_type":"span","marks":[],"text":"Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.","_key":"e9f80bd7687c0"}],"_type":"block"},{"_type":"block","style":"normal","_key":"a90d9599d615","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/jaredkalt/","_key":"30c8f5445624"}],"children":[{"_type":"span","marks":[],"text":"He has an MA from University of Sioux Falls. You can connect with Jared on ","_key":"95b8dd3e29db"},{"_type":"span","marks":["30c8f5445624"],"text":"LinkedIn","_key":"e9f80bd7687c1"},{"_type":"span","marks":[],"text":".","_key":"e9f80bd7687c2"}]}],"_updatedAt":"2022-08-30T13:26:44Z","url":{"_type":"slug","current":"jared-kaltwasser"},"displayName":"Jared Kaltwasser","_createdAt":"2020-05-05T10:50:04Z","_rev":"0TowddpnSMVYA5OKF42uAM","_type":"author"},"factCheckAuthorMapping":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"title":"Novel Relapsed/Refractory CLL Therapies Have Similar Safety Profiles","summary":"The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or refractory chronic lymphocytic leukemia (CLL).","thumbnail":{"_type":"mainImage","alt":"Older woman taking out dose of pills from glass bottle | Image Credit: © fizkes - stock.adobe.com","asset":{"_ref":"image-b276506cb9fe42e52165074a6e038a4b99789dcb-5622x3622-jpg","_type":"reference"}},"url":{"current":"novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles","_type":"slug"}}],"latest_publications":[{"factCheckBy":[{"profileImage":null,"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_key":"b8dda18bb0dc","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"marks":["em"],"text":"AJMC","_key":"953d8c643cce","_type":"span"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412"},{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1","_type":"span"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block","style":"normal","_key":"a03d32973d6e"}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"}}],"thumbnail":{"_type":"mainImage","asset":{"metadata":{"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAFABQDASIAAhEBAxEB/8QAFwABAAMAAAAAAAAAAAAAAAAAAAIFCP/EAB0QAAICAwADAAAAAAAAAAAAAAECAAMEERITITP/xAAVAQEBAAAAAAAAAAAAAAAAAAABAv/EABcRAQEBAQAAAAAAAAAAAAAAAAAxAQL/2gAMAwEAAhEDEQA/ANFmtqktPkY7IEjis1mQlfRHXvYiI7U8xcLjtr7OYiIKf//Z","dimensions":{"_type":"sanity.imageDimensions","width":437,"aspectRatio":3.8,"height":115},"isOpaque":true,"blurHash":"DARW3j9v?vR.IV~qWXM{ayof","_type":"sanity.imageMetadata","palette":{"vibrant":{"population":0.07,"background":"#678db6","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"foreground":"#000","title":"#000","population":1.36,"background":"#c5cdd0","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.41,"background":"#383838","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"background":"#60829c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.66},"lightVibrant":{"foreground":"#000","title":"#000","population":0.02,"background":"#a4daec","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.5,"background":"#15445f","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"title":"#000","population":1.36,"background":"#c5cdd0","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":false},"_rev":"qMZkEXqBAV3IRERLM7zYaX","path":"images/0vv8moc6/ajmc/3e665a0c15a17fc3c7ade987a36f77617f865715-437x115.jpg","size":8393,"assetId":"3e665a0c15a17fc3c7ade987a36f77617f865715","_type":"sanity.imageAsset","mimeType":"image/jpeg","sha1hash":"3e665a0c15a17fc3c7ade987a36f77617f865715","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/3e665a0c15a17fc3c7ade987a36f77617f865715-437x115.jpg","uploadId":"S6qsHDgdYFzzPaJkPMiq04qdRlFigqm8","_createdAt":"2024-11-22T12:47:16Z","_updatedAt":"2024-11-22T12:47:16Z","extension":"jpg","_id":"image-3e665a0c15a17fc3c7ade987a36f77617f865715-437x115-jpg","originalFilename":"CHEA LOGO.jpg"}},"published":"2024-11-22T12:37:00.000Z","title":"To Improve Clinical Trial Equity in Multiple Myeloma, Just Ask","summary":null,"url":"to-improve-clinical-trial-equity-in-multiple-myeloma-just-ask","authorDetails":[{"firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"children":[{"_key":"9737335da1ed0","_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® ("},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"style":"normal","_key":"a03d32973d6e","markDefs":[{"_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"text":".","_key":"9737335da1ed2","_type":"span","marks":[]}],"_type":"block"}],"showSocialShare":null,"displayName":"Mary Caffrey"}],"_id":"5877a6f2-9fdc-47af-8a5c-89e09960f92a","issueGroup":{"_ref":"477f9888-ea5b-4621-bb40-41487563b322","_type":"reference"}},{"_id":"e122e007-e3bd-49b9-982a-29e287e95906","title":"Collaborating for Cancer Care Equity: Community and Academic Insights","thumbnail":{"_type":"mainImage","asset":{"_rev":"EbkpNMUbiIwDU1ASliP5Sw","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/54f2a4431fd4ea73ec6c2ec625fd0d107129c22d-285x121.png","path":"images/0vv8moc6/ajmc/54f2a4431fd4ea73ec6c2ec625fd0d107129c22d-285x121.png","assetId":"54f2a4431fd4ea73ec6c2ec625fd0d107129c22d","extension":"png","uploadId":"TBdykeEPkoVIc4yGVg1aMDXZqoY4mmnp","_type":"sanity.imageAsset","mimeType":"image/png","sha1hash":"54f2a4431fd4ea73ec6c2ec625fd0d107129c22d","size":3589,"metadata":{"isOpaque":true,"blurHash":"MQQ9ycah-:Rkx[~pM|D*%Lt7_2IVt6a{ay","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.1,"background":"#663881"},"muted":{"background":"#7a5f8f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.66},"lightVibrant":{"population":1.44,"background":"#deb7ee","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":5.11,"background":"#510684","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#b6aac4","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.23},"vibrant":{"background":"#5a0696","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.6},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.11,"background":"#510684"}},"hasAlpha":false,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":2.355371900826446,"height":121,"_type":"sanity.imageDimensions","width":285}},"_updatedAt":"2024-11-21T18:37:58Z","originalFilename":"NYU Lang Health.png","_createdAt":"2024-11-21T18:37:58Z","_id":"image-54f2a4431fd4ea73ec6c2ec625fd0d107129c22d-285x121-png"}},"url":"collaborating-for-cancer-care-equity-community-and-academic-insights","factCheckBy":[{"displayName":"Maggie L. Shaw","firstName":null,"lastName":null,"url":{"current":"maggie-l-shaw","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}},"biography":[{"children":[{"marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.","_key":"abc0e18a29ce0","_type":"span"}],"_type":"block","style":"normal","_key":"643be033259e","markDefs":[]},{"style":"normal","_key":"f4070c315fab","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/","_key":"159c764717fb","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_key":"abc0e18a29ce1","_type":"span","marks":["159c764717fb"],"text":"LinkedIn"},{"marks":[],"text":".","_key":"abc0e18a29ce2","_type":"span"}],"_type":"block"}],"showSocialShare":null}],"issueGroup":{"_ref":"477f9888-ea5b-4621-bb40-41487563b322","_type":"reference"},"summary":"Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.","published":"2024-11-21T18:30:00.000Z","authorDetails":[{"showSocialShare":null,"displayName":"Maggie L. Shaw","firstName":null,"lastName":null,"url":{"_type":"slug","current":"maggie-l-shaw"},"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}},"biography":[{"_type":"block","style":"normal","_key":"643be033259e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.","_key":"abc0e18a29ce0"}]},{"children":[{"marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2","_type":"span"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_type":"span","marks":[],"text":".","_key":"abc0e18a29ce2"}],"_type":"block","style":"normal","_key":"f4070c315fab","markDefs":[{"_key":"159c764717fb","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/"}]}]}]},{"_id":"3ab0a249-35da-4929-895b-bc3bc50fe93c","summary":"Coverage from the IVBM Regional event in Denver, Colorado.","url":"elevating-value-in-cancer-care-with-innovations-accessibility-equity","published":"2024-11-21T17:23:00.000Z","factCheckBy":[{"displayName":"Cameron Santoro","firstName":"Cameron","lastName":"Santoro","url":{"current":"cameron-santoro","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}},"biography":[{"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"8ddca200bc46"},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}],"_type":"block","style":"normal","_key":"3da8fced8696","markDefs":[]}],"showSocialShare":null}],"issueGroup":{"_ref":"477f9888-ea5b-4621-bb40-41487563b322","_type":"reference"},"title":"Elevating Value in Cancer Care With Innovations, Accessibility, Equity","thumbnail":{"_type":"mainImage","asset":{"_rev":"AGf4LvcO2r7q1La1cjaXrz","_type":"sanity.imageAsset","size":266092,"_createdAt":"2024-07-23T15:37:52Z","originalFilename":"AJMC_Denver_Final 1.png","mimeType":"image/png","sha1hash":"c93bf646d31467af3bf1146ded1ddb1b32755d08","metadata":{"_type":"sanity.imageMetadata","palette":{"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.07,"background":"#18a3d3"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.24,"background":"#28374c"},"muted":{"background":"#61739a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.19},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.01,"background":"#5ce4fc"},"darkVibrant":{"population":0.04,"background":"#064487","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#d5bec1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.04},"vibrant":{"title":"#fff","population":1.07,"background":"#18a3d3","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":2022,"aspectRatio":3.1348837209302327,"height":645},"isOpaque":false,"blurHash":"D85Zzn4T?^H;oI.ADg%MM_j="},"uploadId":"gJzaHcTHR9p1SOaC0U8krFjLzNeOH32L","path":"images/0vv8moc6/ajmc/c93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png","_id":"image-c93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645-png","extension":"png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png","assetId":"c93bf646d31467af3bf1146ded1ddb1b32755d08","_updatedAt":"2024-07-23T15:37:52Z"}},"authorDetails":[{"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"text":" (","_key":"acd931edd707","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"text":"®","_key":"7c809e803edb","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"_type":"span","marks":["superscript"],"text":"®","_key":"8ddca200bc46"},{"_key":"ba3cca6122e3","_type":"span","marks":[],"text":"."}],"_type":"block","style":"normal","_key":"3da8fced8696"}],"showSocialShare":null,"displayName":"Cameron Santoro","firstName":"Cameron","lastName":"Santoro","url":{"_type":"slug","current":"cameron-santoro"},"profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}}}]},{"issueGroup":{"_ref":"3b0140fe-ebe5-450c-b4e4-9f7b3e0f41d3","_type":"reference"},"summary":"Adults currently aging into Medicare utilized counseling and psychotherapy services at higher rates than those in prior cohorts at the same age.","authorDetails":[{"biography":null,"showSocialShare":null,"displayName":"Grace McCormack, PhD","firstName":"Grace","lastName":"McCormack","url":{"current":"grace-mccormack-phd","_type":"slug"},"profileImage":null},{"displayName":"Erin L. Duffy, PhD, MPH","firstName":"Erin","lastName":"Duffy","url":{"_type":"slug","current":"erin-l-duffy-phd-mph"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Adam Biener, PhD","firstName":"Adam","lastName":"Biener","url":{"current":"adam-biener-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"firstName":"Grace","lastName":"McCormack","url":{"current":"grace-mccormack-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Grace McCormack, PhD"},{"biography":null,"showSocialShare":null,"displayName":"Erin L. Duffy, PhD, MPH","firstName":"Erin","lastName":"Duffy","url":{"current":"erin-l-duffy-phd-mph","_type":"slug"},"profileImage":null},{"lastName":"Biener","url":{"current":"adam-biener-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Adam Biener, PhD","firstName":"Adam"}],"_id":"f5657fbb-1a24-4a40-b7dd-55b0c5bd2234","title":"Recent Cohorts Aging Into Medicare Use More Counseling and Psychotherapy Than Past Cohorts","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"metadata":{"dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38,"background":"#628cad"}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","mimeType":"image/png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","extension":"png","_type":"sanity.imageAsset","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png"}},"url":"recent-cohorts-aging-into-medicare-use-more-counseling-and-psychotherapy-than-past-cohorts","published":"2024-11-14T14:00:00.000Z"},{"summary":"Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"extension":"png","_type":"sanity.imageAsset","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","metadata":{"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true},"_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","mimeType":"image/png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png"}},"_id":"d99dde01-66cf-4191-8bad-05d431132d9f","title":"How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care ","published":"2024-11-13T14:00:00.000Z","authorDetails":[{"displayName":"Arthur S. Hong, MD, MPH","firstName":"Arthur","lastName":"Hong","url":{"current":"arthur-s-hong-md-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Beverly Kyalwazi, MD","firstName":"Beverly","lastName":"Kyalwazi","url":{"current":"beverly-kyalwazi-md","_type":"slug"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"Ethan A. Halm, MD, MPH, MBA","firstName":"Ethan","lastName":"Halm","url":{"_type":"slug","current":"ethan-a-halm-md-mph-mba"},"profileImage":null},{"url":{"current":"d-mark-courtney-md-msci","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"D. Mark Courtney, MD, MSCI","firstName":"D.","lastName":"Courtney"},{"firstName":"John","lastName":"Sweetenham","url":{"current":"john-w-sweetenham-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John W. Sweetenham, MD"},{"displayName":"Navid Sadeghi, MD, MSPH","firstName":"Navid","lastName":"Sadeghi","url":{"current":"navid-sadeghi-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"John V. Cox, DO, MBA","firstName":"John","lastName":"Cox","url":{"current":"john-v-cox-do-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Simon","lastName":"Craddock Lee","url":{"current":"simon-j-craddock-lee-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Simon J. Craddock Lee, PhD, MPH"}],"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Arthur S. Hong, MD, MPH","firstName":"Arthur","lastName":"Hong","url":{"current":"arthur-s-hong-md-mph","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Beverly Kyalwazi, MD","firstName":"Beverly","lastName":"Kyalwazi","url":{"current":"beverly-kyalwazi-md","_type":"slug"},"profileImage":null,"biography":null},{"lastName":"Halm","url":{"current":"ethan-a-halm-md-mph-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Ethan A. Halm, MD, MPH, MBA","firstName":"Ethan"},{"url":{"current":"d-mark-courtney-md-msci","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"D. Mark Courtney, MD, MSCI","firstName":"D.","lastName":"Courtney"},{"url":{"_type":"slug","current":"john-w-sweetenham-md"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John W. Sweetenham, MD","firstName":"John","lastName":"Sweetenham"},{"firstName":"Navid","lastName":"Sadeghi","url":{"current":"navid-sadeghi-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Navid Sadeghi, MD, MSPH"},{"biography":null,"showSocialShare":null,"displayName":"John V. Cox, DO, MBA","firstName":"John","lastName":"Cox","url":{"current":"john-v-cox-do-mba","_type":"slug"},"profileImage":null},{"biography":null,"showSocialShare":null,"displayName":"Simon J. Craddock Lee, PhD, MPH","firstName":"Simon","lastName":"Craddock Lee","url":{"current":"simon-j-craddock-lee-phd-mph","_type":"slug"},"profileImage":null}],"issueGroup":{"_ref":"3b0140fe-ebe5-450c-b4e4-9f7b3e0f41d3","_type":"reference"},"url":"how-english--and-spanish-preferring-patients-with-cancer-decide-on-emergency-care"},{"summary":"Emergency department (ED) visits and hospitalizations for ambulatory care–sensitive conditions (ACSCs) among Medicaid patients constitute almost 40% of all ED visits and hospitalizations, with lower rates observed in areas with greater proximity to urgent care facilities and density of rural health clinics.","thumbnail":{"asset":{"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","metadata":{"dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","mimeType":"image/png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","_type":"sanity.imageAsset","_updatedAt":"2023-07-11T20:45:56Z"},"_type":"mainImage","alt":"AJMC"},"url":"geographic-variations-and-facility-determinants-of-acute-care-utilization-and-spending-for-acscs","published":"2024-11-12T14:00:00.000Z","authorDetails":[{"firstName":"Sadiq","lastName":"Patel","url":{"current":"sadiq-y-patel-phd-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Sadiq Y. Patel, PhD, MS"},{"lastName":"Baum","url":{"current":"aaron-baum-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Aaron Baum, PhD","firstName":"Aaron"},{"lastName":"Basu","url":{"current":"sanjay-basu-md-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Sanjay Basu, MD, PhD","firstName":"Sanjay"}],"issueGroup":{"_ref":"3b0140fe-ebe5-450c-b4e4-9f7b3e0f41d3","_type":"reference"},"title":"Geographic Variations and Facility Determinants of Acute Care Utilization and Spending for ACSCs","factCheckBy":[{"displayName":"Sadiq Y. Patel, PhD, MS","firstName":"Sadiq","lastName":"Patel","url":{"_type":"slug","current":"sadiq-y-patel-phd-ms"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Baum","url":{"_type":"slug","current":"aaron-baum-phd"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Aaron Baum, PhD","firstName":"Aaron"},{"showSocialShare":null,"displayName":"Sanjay Basu, MD, PhD","firstName":"Sanjay","lastName":"Basu","url":{"current":"sanjay-basu-md-phd","_type":"slug"},"profileImage":null,"biography":null}],"_id":"404b320c-f480-4fc3-b080-8fa1dd562551"},{"published":"2024-10-25T13:04:00.000Z","authorDetails":[{"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"_key":"80606b0b2412","markDefs":[],"children":[{"_key":"9737335da1ed0","_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® ("},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal"},{"style":"normal","_key":"a03d32973d6e","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"text":".","_key":"9737335da1ed2","_type":"span","marks":[]}],"_type":"block"}],"showSocialShare":null}],"title":"Beyond McKesson and Florida Cancer Specialists, Deals Are Reshaping Community Oncology ","thumbnail":{"_type":"mainImage","alt":"Orange City ribbon-cutting | Image credit: FCS press release","caption":"Ribbon-cutting at new facility in Orange City for Florida Cancer Specialists \u0026 Research Institute in February 2024. | Image credit: FCS press release","asset":{"extension":"jpg","_id":"image-4cc5fe49422965d25cd9df088a7f56d3a2de40b1-1200x628-jpg","originalFilename":"Orange-City-Ribbon-Cutting-022724.jpg","path":"images/0vv8moc6/ajmc/4cc5fe49422965d25cd9df088a7f56d3a2de40b1-1200x628.jpg","size":206688,"_updatedAt":"2024-10-25T13:47:39Z","_createdAt":"2024-10-25T13:47:39Z","metadata":{"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.910828025477707,"height":628},"isOpaque":true,"blurHash":"MkL:AbR5tQRPo}~AV@kDi^ozx^oet7WBW=","_type":"sanity.imageMetadata","palette":{"darkMuted":{"title":"#fff","population":2.59,"background":"#4c3827","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"title":"#fff","population":7.44,"background":"#8e7b63","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":0.36,"background":"#f58d57","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.28,"background":"#714918"},"lightMuted":{"foreground":"#000","title":"#fff","population":7.27,"background":"#c1a394","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#e48c53","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":5.37},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.44,"background":"#8e7b63"},"_type":"sanity.imagePalette"},"hasAlpha":false},"_type":"sanity.imageAsset","sha1hash":"4cc5fe49422965d25cd9df088a7f56d3a2de40b1","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/4cc5fe49422965d25cd9df088a7f56d3a2de40b1-1200x628.jpg","assetId":"4cc5fe49422965d25cd9df088a7f56d3a2de40b1","uploadId":"i9vAHOJP6REIOEUWNlG2EiJ2k2uzm3nO","_rev":"l8hWsBDY1XE7uXNKgKoAse","mimeType":"image/jpeg"}},"summary":null,"url":"beyond-mckesson-and-florida-cancer-specialists-deals-are-reshaping-community-oncology","factCheckBy":[{"profileImage":null,"biography":[{"style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_key":"b8dda18bb0dc","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"marks":["em"],"text":"AJMC","_key":"953d8c643cce","_type":"span"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1","_type":"span"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block","style":"normal","_key":"a03d32973d6e"}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"}}],"_id":"f46ba78f-9e25-4566-a21d-7f2d8013f43b","issueGroup":{"_ref":"f3dd603a-37be-46c5-a0ed-79c2e9f9a55d","_type":"reference"}},{"summary":"The authors evaluated whether adolescents receiving care at accountable care organizations (ACOs) vs non-ACOs were more likely to initiate and complete the human papillomavirus (HPV) vaccination series.","thumbnail":{"_type":"mainImage","asset":{"mimeType":"image/png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","_type":"sanity.imageAsset","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","metadata":{"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778}},"_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"url":"accountable-care-organizations-and-hpv-vaccine-uptake-a-multilevel-analysis","factCheckBy":[{"showSocialShare":null,"displayName":"Eileen J. Carter, PhD, RN","firstName":"Eileen","lastName":"Carter","url":{"current":"eileen-j-carter-phd-rn","_type":"slug"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"Yuen Tsz Abby Lau, PhD","firstName":"Yuen Tsz","lastName":"Lau","url":{"current":"yuen-tsz-abby-lau-phd","_type":"slug"},"profileImage":null},{"url":{"current":"laurel-buchanan-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Laurel Buchanan, MA","firstName":"Laurel","lastName":"Buchanan"},{"displayName":"David M. Krol, MD, MPH","firstName":"David","lastName":"Krol","url":{"current":"david-m-krol-md-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Jun Yan, PhD","firstName":"Jun","lastName":"Yan","url":{"current":"jun-yan-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Robert","lastName":"Aseltine","url":{"current":"robert-h-aseltine-jr-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Robert H. Aseltine Jr, PhD"}],"_id":"444a4315-6531-40e0-845b-418d00ed04bb","issueGroup":{"_ref":"f9450ef8-d89e-4aaa-9fac-2b11c3a068fb","_type":"reference"},"title":"Accountable Care Organizations and HPV Vaccine Uptake: A Multilevel Analysis","published":"2024-10-24T18:00:00.000Z","authorDetails":[{"biography":null,"showSocialShare":null,"displayName":"Eileen J. Carter, PhD, RN","firstName":"Eileen","lastName":"Carter","url":{"current":"eileen-j-carter-phd-rn","_type":"slug"},"profileImage":null},{"displayName":"Yuen Tsz Abby Lau, PhD","firstName":"Yuen Tsz","lastName":"Lau","url":{"current":"yuen-tsz-abby-lau-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Laurel","lastName":"Buchanan","url":{"current":"laurel-buchanan-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Laurel Buchanan, MA"},{"lastName":"Krol","url":{"current":"david-m-krol-md-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"David M. Krol, MD, MPH","firstName":"David"},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jun Yan, PhD","firstName":"Jun","lastName":"Yan","url":{"current":"jun-yan-phd","_type":"slug"}},{"biography":null,"showSocialShare":null,"displayName":"Robert H. Aseltine Jr, PhD","firstName":"Robert","lastName":"Aseltine","url":{"current":"robert-h-aseltine-jr-phd","_type":"slug"},"profileImage":null}]},{"_id":"c797bf68-6f9e-4d02-9336-14c1800b8a24","issueGroup":{"_type":"reference","_ref":"f9450ef8-d89e-4aaa-9fac-2b11c3a068fb"},"thumbnail":{"alt":"AJMC","asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","metadata":{"dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#044679"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","mimeType":"image/png","_type":"sanity.imageAsset","_updatedAt":"2023-07-11T20:45:56Z","extension":"png"},"_type":"mainImage"},"authorDetails":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Alexandra G. Hames, PhD","firstName":"Alexandra","lastName":"Hames","url":{"current":"alexandra-g-hames-phd","_type":"slug"}},{"biography":null,"showSocialShare":null,"displayName":"Renuka Tipirneni, MD, MSc","firstName":"Renuka","lastName":"Tipirneni","url":{"current":"renuka-tipirneni-md-msc","_type":"slug"},"profileImage":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Galen E. Switzer, PhD","firstName":"Galen","lastName":"Switzer","url":{"_type":"slug","current":"galen-e-switzer-phd"}},{"firstName":"John","lastName":"Ayanian","url":{"current":"john-z-ayanian-md-mpp","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John Z. Ayanian, MD, MPP"},{"showSocialShare":null,"displayName":"Jeffrey T. Kullgren, MD, MS, MPH","firstName":"Jeffrey","lastName":"Kullgren","url":{"current":"jeffrey-t-kullgren-md-ms-mph","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Erica Solway, PhD, MPH, MSW","firstName":"Erica","lastName":"Solway","url":{"current":"erica-solway-phd-mph-msw","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Eric T. Roberts, PhD","firstName":"Eric","lastName":"Roberts","url":{"current":"eric-t-roberts-phd","_type":"slug"}}],"factCheckBy":[{"displayName":"Alexandra G. Hames, PhD","firstName":"Alexandra","lastName":"Hames","url":{"_type":"slug","current":"alexandra-g-hames-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"_type":"slug","current":"renuka-tipirneni-md-msc"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Renuka Tipirneni, MD, MSc","firstName":"Renuka","lastName":"Tipirneni"},{"firstName":"Galen","lastName":"Switzer","url":{"current":"galen-e-switzer-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Galen E. Switzer, PhD"},{"biography":null,"showSocialShare":null,"displayName":"John Z. Ayanian, MD, MPP","firstName":"John","lastName":"Ayanian","url":{"current":"john-z-ayanian-md-mpp","_type":"slug"},"profileImage":null},{"biography":null,"showSocialShare":null,"displayName":"Jeffrey T. Kullgren, MD, MS, MPH","firstName":"Jeffrey","lastName":"Kullgren","url":{"current":"jeffrey-t-kullgren-md-ms-mph","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Erica Solway, PhD, MPH, MSW","firstName":"Erica","lastName":"Solway","url":{"current":"erica-solway-phd-mph-msw","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Eric T. Roberts, PhD","firstName":"Eric","lastName":"Roberts","url":{"current":"eric-t-roberts-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"title":"Racial/Ethnic Disparities in Cost-Related Barriers to Care Among Near-Poor Beneficiaries in Medicare Advantage vs Traditional Medicare","summary":"Among near-poor Black and Hispanic individuals, Medicare Advantage was associated with increased vision care and some, although not uniform, reductions in access disparities vs traditional Medicare.","url":"racial-ethnic-disparities-in-cost-related-barriers-to-care-among-near-poor-beneficiaries-in-medicare-advantage-vs-traditional-medicare","published":"2024-10-23T14:00:11.540Z"},{"_id":"0f3eca76-cd72-4e5c-b4bc-cdc6fe1cea34","issueGroup":{"_ref":"f9450ef8-d89e-4aaa-9fac-2b11c3a068fb","_type":"reference"},"summary":"This article explores late-life relocations in patients with dementia, hospital stays, and their implications for health care policy, geriatric care, and future research priorities.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","metadata":{"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778}},"_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","mimeType":"image/png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","_type":"sanity.imageAsset","_updatedAt":"2023-07-11T20:45:56Z"}},"factCheckBy":[{"showSocialShare":null,"displayName":"Reza Amini, PhD, MD, MPH","firstName":"Reza","lastName":"Amini","url":{"current":"reza-amini-phd-md-mph","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Azmat Sidhu, MPH","firstName":"Azmat","lastName":"Sidhu","url":{"current":"azmat-sidhu-mph","_type":"slug"},"profileImage":null,"biography":null}],"title":"Hospital Stays and Probable Dementia as Predictors of Relocation to Long-Term Care Facilities","url":"hospital-stays-and-probable-dementia-as-predictors-of-relocation-to-long-term-care-facilities","published":"2024-10-22T13:00:00.000Z","authorDetails":[{"showSocialShare":null,"displayName":"Reza Amini, PhD, MD, MPH","firstName":"Reza","lastName":"Amini","url":{"current":"reza-amini-phd-md-mph","_type":"slug"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"Azmat Sidhu, MPH","firstName":"Azmat","lastName":"Sidhu","url":{"current":"azmat-sidhu-mph","_type":"slug"},"profileImage":null}]},{"_id":"2fe4c86e-9756-4ef8-ab38-411834bb1a83","issueGroup":{"_ref":"f3dd603a-37be-46c5-a0ed-79c2e9f9a55d","_type":"reference"},"thumbnail":{"alt":"MinnOncology logo | Image: Minnesota Oncology","caption":"MinnOncology logo | Image: Minnesota Oncology","asset":{"uploadId":"KFZplqb0QKaISRQVulrrZEj0ohzt8bwt","_type":"sanity.imageAsset","mimeType":"image/jpeg","size":11001,"_createdAt":"2024-10-14T16:43:33Z","_id":"image-7d70f8513adc70c28ce0e147ba594bb572d73064-540x235-jpg","originalFilename":"minnesota-oncology.jpg","extension":"jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/7d70f8513adc70c28ce0e147ba594bb572d73064-540x235.jpg","path":"images/0vv8moc6/ajmc/7d70f8513adc70c28ce0e147ba594bb572d73064-540x235.jpg","_updatedAt":"2024-10-14T16:43:33Z","_rev":"KLVqzQL7KTVccOrMxma2pU","assetId":"7d70f8513adc70c28ce0e147ba594bb572d73064","metadata":{"isOpaque":true,"blurHash":"MFS6V%t8~Vxu9G^+j[x]j[D*%gofsooft6","_type":"sanity.imageMetadata","palette":{"muted":{"background":"#8e9559","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.11},"lightVibrant":{"foreground":"#000","title":"#000","population":0.38,"background":"#9be8ee","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#24475d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.21},"lightMuted":{"background":"#ccd3a1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.1},"vibrant":{"foreground":"#fff","title":"#fff","population":0.2,"background":"#0bb6ce","_type":"sanity.imagePaletteSwatch"},"dominant":{"title":"#fff","population":0.47,"background":"#3f483a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#3f483a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.47}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAJABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAQFAwj/xAAhEAABBAEEAwEAAAAAAAAAAAACAAEDBBEFITFxFDNDkf/EABUBAQEAAAAAAAAAAAAAAAAAAAID/8QAFxEAAwEAAAAAAAAAAAAAAAAAAAIRAf/aAAwDAQACEQMRAD8A6ee3kXzFILvtuym6MFmnJY8qUpmkLIYbhlR1H1D2lR5DtPFuEmeNB9rGfmf4hbIQKn//2Q==","dimensions":{"height":235,"_type":"sanity.imageDimensions","width":540,"aspectRatio":2.297872340425532}},"sha1hash":"7d70f8513adc70c28ce0e147ba594bb572d73064"},"_type":"mainImage"},"url":"the-daily-balancing-act-of-value-based-cancer-care","published":"2024-10-14T20:00:00.000Z","title":"The Daily Balancing Act of Value-Based Cancer Care","summary":null,"authorDetails":[{"firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}],"_type":"block","style":"normal"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d","nofollow":true},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_key":"48d199d8ecd5","_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on "},{"marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01","_type":"span"},{"marks":[],"text":" or ","_key":"67a67d3764f02","_type":"span"},{"_key":"67a67d3764f03","_type":"span","marks":["c419f18a7ffe"],"text":"Twitter"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}],"showSocialShare":true,"displayName":"Laura Joszt, MA"}],"factCheckBy":[{"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":[{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}],"children":[{"_key":"67a67d3764f00","_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011."}],"_type":"block","style":"normal","_key":"4a950aea97b3"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}],"showSocialShare":true}]},{"authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Rose is an associate editorial director at ","_key":"123612bd9b2b0"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"2cd28f20d2b9"},{"_key":"032c8e723210","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" (","_key":"e2d5625eae03"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_type":"span","marks":[],"text":").","_key":"688f269c2ad0"}],"_type":"block","style":"normal","_key":"3a2b873558e3"},{"style":"normal","_key":"3a18842aed2b","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/","_key":"a1a427c7e90e","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805"},{"_type":"span","marks":["a1a427c7e90e"],"text":"LinkedIn","_key":"123612bd9b2b1"},{"_type":"span","marks":[],"text":".","_key":"123612bd9b2b2"}],"_type":"block"}],"showSocialShare":null,"displayName":"Rose McNulty","firstName":"Rose","lastName":"McNulty","url":{"_type":"slug","current":"rose-mcnulty"}}],"factCheckBy":[{"firstName":"Rose","lastName":"McNulty","url":{"current":"rose-mcnulty","_type":"slug"},"profileImage":{"alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"},"_type":"mainImage"},"biography":[{"_type":"block","style":"normal","_key":"3a2b873558e3","markDefs":[],"children":[{"text":"Rose is an associate editorial director at ","_key":"123612bd9b2b0","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"2cd28f20d2b9"},{"text":"®","_key":"032c8e723210","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":" (","_key":"e2d5625eae03"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_type":"span","marks":[],"text":").","_key":"688f269c2ad0"}]},{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/","_key":"a1a427c7e90e","nofollow":true,"blank":true}],"children":[{"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805","_type":"span","marks":[]},{"text":"LinkedIn","_key":"123612bd9b2b1","_type":"span","marks":["a1a427c7e90e"]},{"_type":"span","marks":[],"text":".","_key":"123612bd9b2b2"}],"_type":"block","style":"normal","_key":"3a18842aed2b"}],"showSocialShare":null,"displayName":"Rose McNulty"}],"issueGroup":{"_ref":"f3dd603a-37be-46c5-a0ed-79c2e9f9a55d","_type":"reference"},"title":"Transforming Value-Based Oncology Care in an Evolving Therapeutic Landscape","summary":null,"thumbnail":{"_type":"mainImage","asset":{"metadata":{"_type":"sanity.imageMetadata","palette":{"dominant":{"title":"#fff","population":0.2,"background":"#32424f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#32424f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.2},"muted":{"title":"#fff","population":0.16,"background":"#886d76","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#96e0f1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.1},"darkVibrant":{"background":"#045ca4","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightMuted":{"foreground":"#000","title":"#fff","population":0.17,"background":"#caa7ae","_type":"sanity.imagePaletteSwatch"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.03,"background":"#db1b41"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAALABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAMGBQj/xAAhEAACAgICAQUAAAAAAAAAAAABAgADBREEEhRBUVNhkf/EABUBAQEAAAAAAAAAAAAAAAAAAAAB/8QAFxEBAQEBAAAAAAAAAAAAAAAAABEhQf/aAAwDAQACEQMRAD8A6FoyOUbirYlIcuOwDKQR9GNGSyCjVlNQfW9bm/oRVlFTv2etS3uRLib1OXZjKK+q6aCuvUwlB4nH+FPyEUj/2Q==","dimensions":{"_type":"sanity.imageDimensions","width":310,"aspectRatio":1.901840490797546,"height":163},"isOpaque":true,"blurHash":"MTRfnKxuWCkCWCt7RjjZoejZ~poJoJjsoK"},"uploadId":"Cn0HwxWFv0Ec8KIymIMyyzBtesHXyLzB","sha1hash":"b3c196af748f73352b08b68beb6bd7d1b1becb97","path":"images/0vv8moc6/ajmc/b3c196af748f73352b08b68beb6bd7d1b1becb97-310x163.jpg","assetId":"b3c196af748f73352b08b68beb6bd7d1b1becb97","_createdAt":"2024-10-14T12:53:32Z","originalFilename":"fcs logo.jpg","extension":"jpg","_type":"sanity.imageAsset","mimeType":"image/jpeg","size":7531,"_rev":"tCpUdDwaYfiJObLAq3Mq1j","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/b3c196af748f73352b08b68beb6bd7d1b1becb97-310x163.jpg","_id":"image-b3c196af748f73352b08b68beb6bd7d1b1becb97-310x163-jpg","_updatedAt":"2024-10-14T12:53:32Z"}},"published":"2024-10-14T18:00:00.000Z","_id":"ac700a43-4c32-49dd-81d3-c17f7eb1b5c2","url":"transforming-value-based-oncology-care-in-an-evolving-therapeutic-landscape"},{"summary":"The authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.","published":"2024-09-20T13:00:00.000Z","authorDetails":[{"displayName":"Deborah R. Kaye, MD, MS","firstName":"Deborah","lastName":"Kaye","url":{"current":"deborah-r-kaye-md-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Hui-Jie Lee, PhD","firstName":"Hui-Jie","lastName":"Lee","url":{"_type":"slug","current":"hui-jie-lee-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Alexander Gordee, MA","firstName":"Alexander","lastName":"Gordee","url":{"current":"alexander-gordee-ma","_type":"slug"}},{"lastName":"George","url":{"current":"daniel-j-george-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Daniel J. George, MD","firstName":"Daniel"},{"lastName":"Scales","url":{"current":"charles-d-scales-jr-md-mshs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Charles D. Scales Jr, MD, MSHS","firstName":"Charles"},{"lastName":"Ubel","url":{"current":"peter-a-ubel-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Peter A. Ubel, MD","firstName":"Peter"},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"M. Kate Bundorf, PhD, MBA, MPH","firstName":"M.","lastName":"Bundorf","url":{"current":"m-kate-bundorf-phd-mba-mph","_type":"slug"}}],"factCheckBy":[{"showSocialShare":null,"displayName":"Deborah R. Kaye, MD, MS","firstName":"Deborah","lastName":"Kaye","url":{"current":"deborah-r-kaye-md-ms","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Hui-Jie Lee, PhD","firstName":"Hui-Jie","lastName":"Lee","url":{"_type":"slug","current":"hui-jie-lee-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Gordee","url":{"current":"alexander-gordee-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Alexander Gordee, MA","firstName":"Alexander"},{"firstName":"Daniel","lastName":"George","url":{"current":"daniel-j-george-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Daniel J. George, MD"},{"displayName":"Charles D. Scales Jr, MD, MSHS","firstName":"Charles","lastName":"Scales","url":{"_type":"slug","current":"charles-d-scales-jr-md-mshs"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Peter A. Ubel, MD","firstName":"Peter","lastName":"Ubel","url":{"current":"peter-a-ubel-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"M. Kate Bundorf, PhD, MBA, MPH","firstName":"M.","lastName":"Bundorf","url":{"current":"m-kate-bundorf-phd-mba-mph","_type":"slug"},"profileImage":null}],"_id":"d8777579-53e5-4e4f-a977-0e8f0c366418","issueGroup":{"_ref":"b8e3b82c-0452-4c4b-8ec4-c441a3a5bfb8","_type":"reference"},"title":"Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"extension":"png","_type":"sanity.imageAsset","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","metadata":{"palette":{"muted":{"foreground":"#fff","title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata"},"_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","mimeType":"image/png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png"}},"url":"systemic-treatments-for-advanced-prostate-cancer-relationship-between-health-insurance-plan-and-treatment-costs"},{"factCheckBy":[{"lastName":"Ouayogodé","url":{"current":"marietou-h-ouayogode-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Mariétou H. Ouayogodé, PhD","firstName":"Mariétou"},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Brianna Hardy, BS","firstName":"Brianna","lastName":"Hardy","url":{"current":"brianna-hardy-bs","_type":"slug"}},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John Mullahy, PhD","firstName":"John","lastName":"Mullahy","url":{"current":"john-mullahy-phd","_type":"slug"}},{"showSocialShare":null,"displayName":"Maureen A. Smith, MD, PhD, MPH","firstName":"Maureen","lastName":"Smith","url":{"current":"maureen-a-smith-md-phd-mph","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"Ellen","lastName":"Meara","url":{"current":"ellen-meara-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Ellen Meara, PhD"}],"_id":"caac8d8b-f8a3-4614-8abe-abe358cfa806","published":"2024-09-19T13:00:00.000Z","authorDetails":[{"url":{"current":"marietou-h-ouayogode-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Mariétou H. Ouayogodé, PhD","firstName":"Mariétou","lastName":"Ouayogodé"},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Brianna Hardy, BS","firstName":"Brianna","lastName":"Hardy","url":{"current":"brianna-hardy-bs","_type":"slug"}},{"firstName":"John","lastName":"Mullahy","url":{"current":"john-mullahy-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John Mullahy, PhD"},{"displayName":"Maureen A. Smith, MD, PhD, MPH","firstName":"Maureen","lastName":"Smith","url":{"current":"maureen-a-smith-md-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Ellen Meara, PhD","firstName":"Ellen","lastName":"Meara","url":{"current":"ellen-meara-phd","_type":"slug"}}],"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","metadata":{"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2"},"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAKCAYAAAC0VX7mAAAACXBIWXMAABYlAAAWJQFJUiTwAAABxklEQVQoka2STW/aQBCG+f/qLZdeqkrpoQqpWiIlCk2BhKCEErAxRXGMnQ8wJoAxGMyX7fX6rWbSpqXnWlrN7M7sszPvOAMAaZrif32Z3zCySSKRSIlYJFhtQgTrLVbbCNsohpQSUqYIY8ErigU2YYxNGPGe7hHjFUiHjutj6C0w8ZfQLAeK0UPTtKF2bEwXK8yCNZ+3LAd6d4iOPcbjYIKB63MBO0BvvkSxYaDctHDvuCg0DJzd3OHsRsd+voaG0UP7YYAP+Rren1RxVGnxfjDxMZousN5GL0CCiSRhSLakIFtU0DT7DL9QTVy1HxiQLan4WtPxNlfBm48FHBQVPHtzloIkIvsLmMIP1tzWafUWh+cqCnUD+e+3KCkd1PQnfC5reHd8zRCye58u+IHucMoaU7ukP7EyJHR/PENd76J173CrhyUVuUsN52oH1fYjyk2TK6b1pazhqPKDH9OsPkx7zPfDKH6ZMpVK+tnjGVw/YGjusoVv9TsYvRG6Q48vTOZL1srqu1wZ+aQfDZKGRbJxhdS3SCSESFiL0TRgsZ+ePRaaziiZ8qgbyqP2yCdLMfIpvjPl139RSkRCcPK/sT/7v/3d+E98j+pE3hWucAAAAABJRU5ErkJggg==","dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778}},"_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","mimeType":"image/png","size":203185,"_updatedAt":"2023-07-11T20:45:56Z","extension":"png","_type":"sanity.imageAsset","originalFilename":"AJMC_logo_NEW.png","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"url":"care-transition-management-and-patient-outcomes-in-hospitalized-medicare-beneficiaries","issueGroup":{"_ref":"b8e3b82c-0452-4c4b-8ec4-c441a3a5bfb8","_type":"reference"},"title":"Care Transition Management and Patient Outcomes in Hospitalized Medicare Beneficiaries","summary":"Hospital care transition activity facilitates uptake of Medicare-reimbursed transitional care management, which is associated with lower spending and better patient outcomes."},{"_id":"53f2a80a-ab08-4863-9f67-14a3c7903a0d","issueGroup":{"_ref":"b8e3b82c-0452-4c4b-8ec4-c441a3a5bfb8","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"metadata":{"_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions","width":778},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj"},"_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","mimeType":"image/png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","_type":"sanity.imageAsset","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png"}},"url":"copd-treatment-ratio-a-measure-for-improving-copd-population-health","title":"COPD Treatment Ratio: A Measure for Improving COPD Population Health","summary":"This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes.","published":"2024-09-18T16:00:00.000Z","authorDetails":[{"url":{"current":"megha-a-parikh-phd-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Megha A. Parikh, PhD, MS","firstName":"Megha","lastName":"Parikh"},{"biography":null,"showSocialShare":null,"displayName":"Sabree C. Burbage, PharmD, MPH","firstName":"Sabree","lastName":"Burbage","url":{"current":"sabree-c-burbage-pharmd-mph","_type":"slug"},"profileImage":null},{"displayName":"Meghan H. Gabriel, PhD","firstName":"Meghan","lastName":"Gabriel","url":{"current":"meghan-h-gabriel-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Ben E. Shirley, BSPH","firstName":"Ben","lastName":"Shirley","url":{"current":"ben-e-shirley-bsph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Campbell","url":{"current":"patrick-j-campbell-pharmd-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Patrick J. Campbell, PharmD, PhD","firstName":"Patrick"}],"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Megha A. Parikh, PhD, MS","firstName":"Megha","lastName":"Parikh","url":{"current":"megha-a-parikh-phd-ms","_type":"slug"},"profileImage":null},{"biography":null,"showSocialShare":null,"displayName":"Sabree C. Burbage, PharmD, MPH","firstName":"Sabree","lastName":"Burbage","url":{"current":"sabree-c-burbage-pharmd-mph","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Meghan H. Gabriel, PhD","firstName":"Meghan","lastName":"Gabriel","url":{"current":"meghan-h-gabriel-phd","_type":"slug"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"Ben E. Shirley, BSPH","firstName":"Ben","lastName":"Shirley","url":{"current":"ben-e-shirley-bsph","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Patrick J. Campbell, PharmD, PhD","firstName":"Patrick","lastName":"Campbell","url":{"current":"patrick-j-campbell-pharmd-phd","_type":"slug"},"profileImage":null,"biography":null}]},{"url":"healthy-state-practicing-what-they-preach-in-louisiana","authorDetails":[{"showSocialShare":null,"displayName":"Mary K. Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"},"profileImage":{"alt":"Mary K. Caffrey","asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"},"default":false,"_type":"mainImage"},"biography":null}],"factCheckBy":[{"profileImage":{"default":false,"_type":"mainImage","alt":"Mary K. Caffrey","asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Mary K. Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"}}],"summary":"An IVBM event cohosted by The American Journal of Managed Care focused on Healthy State, a multiyear, multistakeholder commitment to moving Louisiana ahead in America’s Health Rankings.","thumbnail":{"alt":"New Orleans Bourbon Street | Image Credit: © f11photo - stock.adobe.com","asset":{"sha1hash":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","_createdAt":"2024-08-28T16:07:24Z","_updatedAt":"2024-08-28T16:07:46Z","extension":"jpg","title":null,"size":4265557,"_rev":"LtkInV1jlQdtEIFjVqjDMg","_type":"sanity.imageAsset","description":null,"mimeType":"image/jpeg","path":"images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","metadata":{"_type":"sanity.imageMetadata","palette":{"lightVibrant":{"population":6.13,"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.13,"background":"#935917"},"lightMuted":{"background":"#b6a9cd","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.06},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":5.95,"background":"#efa11f"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":6.13,"background":"#f6d770"},"_type":"sanity.imagePalette","darkMuted":{"background":"#2e3d58","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.99},"muted":{"population":5.22,"background":"#976e64","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":2800,"aspectRatio":1.4997321906802357,"height":1867},"exif":{"FocalLength":28,"PixelYDimension":1867,"Sharpness":0,"DateTimeDigitized":null,"SensitivityType":2,"FNumber":5.6,"SceneCaptureType":0,"FocalPlaneYResolution":2164.4328018223237,"MaxApertureValue":4,"ExposureTime":2,"_type":"sanity.imageExifMetadata","ColorSpace":1,"RecommendedExposureIndex":100,"Contrast":0,"DateTimeOriginal":"2016-11-15T06:32:19.000Z","FocalPlaneXResolution":2164.4328018223237,"ShutterSpeedValue":-1,"FocalPlaneResolutionUnit":3,"DigitalZoomRatio":1,"ApertureValue":4.970853658536585,"ExposureBiasValue":0,"LensModel":"16-35mm F4 G SSM OSS","PixelXDimension":2800,"LensSpecification":[16,35,4,4],"CustomRendered":0,"WhiteBalance":0,"FocalLengthIn35mmFormat":42,"MeteringMode":5,"ExposureMode":1,"ISO":100,"LightSource":0,"BrightnessValue":-0.89296875,"Saturation":2,"ExposureProgram":1},"isOpaque":true,"blurHash":"VLKJoRB?^vPDoi765Ev|$*$x~W-poztRR-%#x]SxNyt7"},"altText":null,"uploadId":"kH1bS8OTS7iWFNmOt3qixxFUDmuSmj11","opt":{"media":{"tags":null}},"assetId":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","_id":"image-29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867-jpg","originalFilename":"New Orleans Bourbon Street - f11photo - AdobeStock_169182961.jpeg"},"_type":"mainImage"},"title":"Healthy State: Practicing What They Preach in Louisiana","published":"2024-09-16T16:31:55.211Z","_id":"04159ba8-44f9-40b5-b25f-0ae627881e39","issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"}},{"_id":"2a95bae0-0c9f-4bc1-8e7d-3602ac803646","summary":"Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.","thumbnail":{"_type":"mainImage","alt":"Denver Colorado | Image Credit: © f11photo - stock.adobe.com","asset":{"mimeType":"image/jpeg","_id":"image-c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700-jpg","originalFilename":"Denver Colorado - f11photo - stock.adobe.com.jpeg","_rev":"WVB52uR738qojYGNKmrerb","_createdAt":"2024-09-13T18:14:54Z","_type":"sanity.imageAsset","_updatedAt":"2024-09-13T18:14:54Z","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAMABQDASIAAhEBAxEB/8QAGAAAAgMAAAAAAAAAAAAAAAAAAAcCBAX/xAAfEAACAgICAwEAAAAAAAAAAAABAgADBBEGEiExYQX/xAAWAQEBAQAAAAAAAAAAAAAAAAACAwT/xAAdEQABBAIDAAAAAAAAAAAAAAADAAECEQQxBRJB/9oADAMBAAIRAxEAPwCeBhfnUkd7arNe+reptUZ/HVcV2voiKx8m2mtTWQCfgly3NtZEdhWWHgHqJI3InaVstA4C6aTkqyOIJWvfKRSRvREImxc7gMx8n5CBs83qLxhel//Z","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.7142857142857142,"height":700},"exif":{"ColorSpace":1,"PixelXDimension":1200,"PixelYDimension":700,"_type":"sanity.imageExifMetadata","DateTimeDigitized":"2014-09-12T07:37:33.000Z"},"isOpaque":true,"blurHash":"MjHx1~IoS$S4oL%QRijZWrbH9vocWAoffP","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":6.64,"background":"#4f4e2c","_type":"sanity.imagePaletteSwatch"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.67,"background":"#50659b"},"lightVibrant":{"background":"#e9cf8d","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.31},"darkVibrant":{"background":"#544d07","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.56},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.17,"background":"#a2a7c8"},"vibrant":{"title":"#fff","population":1.42,"background":"#ca762d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"background":"#4f4e2c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.64}}},"uploadId":"H7WTao1JKvhWv1JBicLCJENbGPV6jpQH","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","path":"images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","size":584915,"assetId":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","extension":"jpg","sha1hash":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b"}},"url":"multifaceted-approach-can-help-patients-benefit-from-the-expanded-lipid-lowering-toolbox","factCheckBy":[{"biography":[{"_type":"block","style":"normal","_key":"9271b97a8f45","markDefs":[],"children":[{"marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934","_type":"span"},{"text":"The American Journal of Managed Care","_key":"4eac35f29678","_type":"span","marks":["em"]},{"marks":["superscript"],"text":"®","_key":"b16316585120","_type":"span"},{"text":" (","_key":"ed200dc9139a","_type":"span","marks":[]},{"_key":"b773bee92455","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"marks":[],"text":") and ","_key":"b9461d308bc8","_type":"span"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"text":"®","_key":"14118ee858d3","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_type":"span","marks":["em"],"text":"AJAC","_key":"6353c3a02e0f"},{"_type":"span","marks":[],"text":"), and joined ","_key":"7f777b20be12"},{"_key":"682a0f2ea0d4","_type":"span","marks":["em"],"text":"AJMC"},{"_key":"8b1f00d70d7f","_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals."}]},{"markDefs":[{"href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc"},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block","style":"normal","_key":"a90d7ab4c801"}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"},"_type":"mainImage","alt":"Christina Mattina"}}],"issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"title":"Institute for Value-Based Medicine®: Multifaceted Approach Can Help Patients Benefit From the Expanded Lipid-Lowering Toolbox","published":"2024-09-16T16:31:18.436Z","authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"text":"AJMC","_key":"b773bee92455","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_type":"span","marks":[],"text":") and ","_key":"b9461d308bc8"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_type":"span","marks":["superscript"],"text":"®","_key":"14118ee858d3"},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"marks":["em"],"text":"AJAC","_key":"6353c3a02e0f","_type":"span"},{"_type":"span","marks":[],"text":"), and joined ","_key":"7f777b20be12"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block","style":"normal","_key":"9271b97a8f45"},{"_type":"block","style":"normal","_key":"a90d7ab4c801","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true,"blank":true}],"children":[{"marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc","_type":"span"},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"marks":[],"text":".","_key":"83d100c64d0e","_type":"span"}]}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"}}]},{"issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"telemedicine | Image Credit: © rh2010 - stock.adobe.com","asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","assetId":"aa55cba013e542363db5e3021a7d049b005c0d44","size":10640408,"uploadId":"ueKegQc9OLg07IP1riXXhgBAywYfiVMU","_rev":"yLkPQ1Yunv4gUqVh5QBQaa","_type":"sanity.imageAsset","mimeType":"image/jpeg","sha1hash":"aa55cba013e542363db5e3021a7d049b005c0d44","extension":"jpg","metadata":{"_type":"sanity.imageMetadata","palette":{"lightMuted":{"population":6.95,"background":"#bbbcbe","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#ba825c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"dominant":{"population":6.95,"background":"#bbbcbe","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#61553c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.82},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0,"background":"#b4745c"},"lightVibrant":{"background":"#e7d1c6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.05},"darkVibrant":{"title":"#fff","population":6.07,"background":"#493a1a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":7360,"aspectRatio":1.498371335504886,"height":4912},"isOpaque":true,"blurHash":"VEDl=,D%4n?c-;_N%M-pD%xvM{-;_3DiWBt7xax]t7M{"},"path":"images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","_id":"image-aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912-jpg","_updatedAt":"2023-12-05T16:28:07Z","_createdAt":"2023-12-05T16:28:07Z","originalFilename":"telemedicine - rh2010.jpeg"}},"url":"telehealth-insights-from-an-integrated-care-system","authorDetails":[{"biography":null,"showSocialShare":null,"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca","lastName":"Flournoy","url":{"_type":"slug","current":"rebecca-flournoy-mph"},"profileImage":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah","url":{"current":"reema-shah-mph","_type":"slug"}},{"lastName":"Moisan","url":{"current":"elizabeth-moisan-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth"},{"firstName":"Cecilia","lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH"}],"factCheckBy":[{"url":{"current":"rebecca-flournoy-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca","lastName":"Flournoy"},{"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah","url":{"current":"reema-shah-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth","lastName":"Moisan","url":{"current":"elizabeth-moisan-ms","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH","firstName":"Cecilia","lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null}],"_id":"336a74f6-937d-40c6-a94c-b14c26f025f6","summary":"Experiences from a large, integrated, value-based health system suggest that telehealth can be an effective care delivery approach. Public policies can improve telehealth access and care.","published":"2024-09-16T16:29:41.215Z","title":"Telehealth Insights From an Integrated Care System"},{"factCheckBy":[{"firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_key":"b8dda18bb0dc","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"marks":["em"],"text":"AJMC","_key":"953d8c643cce","_type":"span"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block"},{"style":"normal","_key":"a03d32973d6e","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1","_type":"span"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block"}],"showSocialShare":null,"displayName":"Mary Caffrey"}],"published":"2024-08-19T16:19:00.000Z","authorDetails":[{"biography":[{"children":[{"_key":"9737335da1ed0","_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® ("},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"_key":"a03d32973d6e","markDefs":[{"_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"text":".","_key":"9737335da1ed2","_type":"span","marks":[]}],"_type":"block","style":"normal"}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null}],"title":"Building a Virtual Model for Care After Cancer","summary":null,"thumbnail":{"_type":"mainImage","alt":"Nurse offering virtual visit | Image credit: Pexels/ Tima Miroshnichenko","caption":"Nurse offering virtual visit | Image credit: Pexels/ Tima Miroshnichenko","asset":{"_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88-5928x3952.jpg","size":1146957,"_rev":"wjCpg6dpTOIsmpmsT5C0z0","_id":"image-ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88-5928x3952-jpg","metadata":{"palette":{"lightMuted":{"title":"#fff","population":2.7,"background":"#c4b7a8","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"population":0.01,"background":"#bc8e62","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"dominant":{"background":"#3e321f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.7},"_type":"sanity.imagePalette","darkMuted":{"population":7.7,"background":"#3e321f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"foreground":"#fff","title":"#fff","population":0.01,"background":"#945c5c","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"foreground":"#000","title":"#fff","population":0,"background":"#d7bca2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.19,"background":"#6e5434"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":5928,"aspectRatio":1.5,"height":3952},"isOpaque":true,"blurHash":"VLLXb^Dh.9?bD%_4%gIUM_jZD%NG%MR*bb?cR*flo#t8","_type":"sanity.imageMetadata"},"sha1hash":"ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88","_createdAt":"2024-08-19T18:07:41Z","_updatedAt":"2024-08-19T18:07:41Z","extension":"jpg","uploadId":"2MwogAhJjfoY4HPFZ5xFzgjlENqac6KT","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88-5928x3952.jpg","assetId":"ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88","originalFilename":"telemedicine.jpeg"}},"url":"building-a-virtual-model-for-care-after-cancer","_id":"f8b60efe-f6db-4fc2-a830-b561053d4e91","issueGroup":{"_ref":"8f469cb0-5c36-4eaf-ab0e-2a34a0c7bf53","_type":"reference"}},{"_id":"eaa4797e-cc0e-4b10-b3c5-169ea3739552","title":"Revised EOM Offers More Favorable Opportunities for Community Practices, Experts Say","thumbnail":{"_type":"mainImage","alt":"COA seal | Image : COA","asset":{"extension":"png","path":"images/0vv8moc6/ajmc/17ee076fc9d3da91dfa9c86f1e4048fa882b29eb-602x602.png","originalFilename":"COA_seal_2019-4C.png","_updatedAt":"2024-05-21T20:44:39Z","uploadId":"55Ghe83hpIc18afc6jZj9tvxmCfNsnZ7","_rev":"sgy4yN0CjmArmRDnE4d79D","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/17ee076fc9d3da91dfa9c86f1e4048fa882b29eb-602x602.png","size":89027,"_id":"image-17ee076fc9d3da91dfa9c86f1e4048fa882b29eb-602x602-png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":602,"aspectRatio":1,"height":602},"isOpaque":false,"blurHash":"eBK9_:sp2@XSI8jGkWWUMdjb1HWV_#VsQmR+rrRPt,t7ptj@HXbF6-","_type":"sanity.imageMetadata","palette":{"dominant":{"title":"#fff","population":19.23,"background":"#143c8c","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":1.07,"background":"#293653","_type":"sanity.imagePaletteSwatch"},"muted":{"foreground":"#fff","title":"#fff","population":0.42,"background":"#54719f","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"background":"#fa84a0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.07},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":19.23,"background":"#143c8c"},"lightMuted":{"background":"#a0acc0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":3.12},"vibrant":{"title":"#fff","population":19.15,"background":"#e31934","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true},"sha1hash":"17ee076fc9d3da91dfa9c86f1e4048fa882b29eb","assetId":"17ee076fc9d3da91dfa9c86f1e4048fa882b29eb","_createdAt":"2024-05-21T20:44:39Z","mimeType":"image/png"}},"factCheckBy":[{"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_key":"b8dda18bb0dc","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"marks":["em"],"text":"AJMC","_key":"953d8c643cce","_type":"span"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1","_type":"span"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}]}]}],"issueGroup":{"_type":"reference","_ref":"8f469cb0-5c36-4eaf-ab0e-2a34a0c7bf53"},"summary":null,"url":"revised-eom-offers-more-favorable-opportunities-for-community-practices-experts-say","published":"2024-08-16T17:21:00.000Z","authorDetails":[{"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"children":[{"_key":"9737335da1ed0","_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® ("},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"style":"normal","_key":"a03d32973d6e","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"text":".","_key":"9737335da1ed2","_type":"span","marks":[]}],"_type":"block"}]}]},{"issueGroup":{"_ref":"8f469cb0-5c36-4eaf-ab0e-2a34a0c7bf53","_type":"reference"},"title":"Collaborative Innovation: Flatiron Health and Canopy Partner to Streamline Continuous Care for Oncology Practices","thumbnail":{"_type":"mainImage","alt":"Flatiron + Canopy logo | Image: Canopy","caption":"Flatiron + Canopy logo | Image: Canopy","asset":{"originalFilename":"flatiron canopy.png","extension":"png","sha1hash":"48b05b74a043a14725208c64dc5511c83f873960","assetId":"48b05b74a043a14725208c64dc5511c83f873960","_createdAt":"2024-08-16T11:54:45Z","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/48b05b74a043a14725208c64dc5511c83f873960-2048x738.png","_id":"image-48b05b74a043a14725208c64dc5511c83f873960-2048x738-png","_updatedAt":"2024-08-16T11:54:45Z","metadata":{"isOpaque":true,"blurHash":"D47nu1xU%Lx^4n?dxtt7ofM{","_type":"sanity.imageMetadata","palette":{"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.58,"background":"#a4afd8"},"vibrant":{"population":42.73,"background":"#1c2c84","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"foreground":"#fff","title":"#fff","population":42.73,"background":"#1c2c84","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"background":"#465281","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.44},"muted":{"title":"#fff","population":0.1,"background":"#5e599d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#d5d4fc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.03},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01,"background":"#041c71"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":2048,"aspectRatio":2.7750677506775068,"height":738}},"uploadId":"3ct5wI5akdtTDeBzgjxMzDWJAYaAnmYK","path":"images/0vv8moc6/ajmc/48b05b74a043a14725208c64dc5511c83f873960-2048x738.png","_rev":"EDJmlW7GHoHEwq10zl3D3G","mimeType":"image/png","size":930539}},"published":"2024-08-16T11:30:00.000Z","_id":"77701ccb-39e1-4b49-ac6b-b5aa65801a00","summary":null,"url":"collaborative-innovation-flatiron-health-and-canopy-partner-to-streamline-continuous-care-for-oncology-practices","authorDetails":[{"url":{"_type":"slug","current":"lavi-kwiatkowsky"},"profileImage":null,"biography":[{"style":"normal","_key":"4839ffeb2829","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Lavi Kwiatkowsky is the founder and CEO of Canopy.","_key":"33c855f42e2b0"}],"_type":"block"}],"showSocialShare":null,"displayName":"Lavi Kwiatkowsky","firstName":"lavi","lastName":"Kwiatkowsky"},{"displayName":"Geoff Calkins","firstName":"Geoff","lastName":"Calkins","url":{"_type":"slug","current":"geoff-calkins"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"firstName":"lavi","lastName":"Kwiatkowsky","url":{"current":"lavi-kwiatkowsky","_type":"slug"},"profileImage":null,"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Lavi Kwiatkowsky is the founder and CEO of Canopy.","_key":"33c855f42e2b0"}],"_type":"block","style":"normal","_key":"4839ffeb2829"}],"showSocialShare":null,"displayName":"Lavi Kwiatkowsky"},{"showSocialShare":null,"displayName":"Geoff Calkins","firstName":"Geoff","lastName":"Calkins","url":{"current":"geoff-calkins","_type":"slug"},"profileImage":null,"biography":null}]},{"summary":"At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care® and Sutter Health, experts illuminated the current state of cardiometabolic health care and offered a glimpse into the future.","url":"cardiometabolic-interventions-focus-on-accessibility-evidence-based-medicine","published":"2024-06-14T13:00:00.000Z","authorDetails":[{"lastName":null,"url":{"current":"giuliana-grossi","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Giuliana Grossi","asset":{"_ref":"image-5dc1da24786c43a7f87e4ea0a7ae3880e6cee39f-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Giuliana Grossi","firstName":null}],"factCheckBy":[{"profileImage":{"_type":"mainImage","alt":"Giuliana Grossi","asset":{"_ref":"image-5dc1da24786c43a7f87e4ea0a7ae3880e6cee39f-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Giuliana Grossi","firstName":null,"lastName":null,"url":{"current":"giuliana-grossi","_type":"slug"}}],"_id":"1472df1f-ab77-4b68-8ced-12ff81256022","issueGroup":{"_type":"reference","_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0"},"title":"Cardiometabolic Interventions Focus on Accessibility, Evidence-Based Medicine","thumbnail":{"_type":"mainImage","alt":"San Francisco's Golden Gate Bridge | Image Credit: © phitha - stock.adobe.com","asset":{"metadata":{"_type":"sanity.imageMetadata","palette":{"lightVibrant":{"background":"#fbe182","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":4.62},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.69,"background":"#6f2c2a"},"lightMuted":{"population":8.5,"background":"#9099c0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"title":"#fff","population":7.2,"background":"#f2a973","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":8.5,"background":"#9099c0"},"_type":"sanity.imagePalette","darkMuted":{"population":7.93,"background":"#2e3250","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"foreground":"#fff","title":"#fff","population":0.47,"background":"#9c5c58","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"aspectRatio":1.5,"height":800,"_type":"sanity.imageDimensions","width":1200},"exif":{"FocalPlaneResolutionUnit":3,"Saturation":0,"ISO":200,"ColorSpace":1,"LensSpecification":[70,300,4.5,5.6],"_type":"sanity.imageExifMetadata","FocalLengthIn35mmFormat":220,"ExposureMode":0,"MaxApertureValue":4.970853658536585,"DateTimeDigitized":"2016-06-04T04:25:41.000Z","ApertureValue":6.9188632619439865,"ExposureBiasValue":0,"WhiteBalance":1,"Sharpness":0,"CustomRendered":0,"PixelXDimension":1200,"ShutterSpeedValue":-1.6780719083366258,"Contrast":0,"FocalLength":220,"SensitivityType":2,"LightSource":14,"RecommendedExposureIndex":200,"FocalPlaneYResolution":2164.4328018223237,"DateTimeOriginal":"2016-06-04T04:25:41.000Z","FNumber":11,"MeteringMode":5,"SceneCaptureType":0,"PixelYDimension":800,"ExposureTime":3.2,"FocalPlaneXResolution":2164.4328018223237,"BrightnessValue":-0.44765625,"LensModel":"FE 70-300mm F4.5-5.6 G OSS","ExposureProgram":3,"DigitalZoomRatio":1},"isOpaque":true,"blurHash":"VuJ@2qs:WCjYbb}%soahbIjs-:R*WBoJW:I.W=WEoLj["},"_rev":"SWZtARO2mf3vRstToueLld","_id":"image-1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800-jpg","_updatedAt":"2024-06-07T15:30:01Z","size":416089,"assetId":"1f3095024fd984fa3a60b43c4cf33663635bcaf7","_type":"sanity.imageAsset","mimeType":"image/jpeg","sha1hash":"1f3095024fd984fa3a60b43c4cf33663635bcaf7","_createdAt":"2024-06-07T15:30:01Z","originalFilename":"San Francisco Golden Gate Bridge - phitha - stock.adobe.com.jpeg","extension":"jpg","uploadId":"O5nnIZFuz4knEBd9QmteN8nCCmR8xh2K","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800.jpg","path":"images/0vv8moc6/ajmc/1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800.jpg"}}},{"title":"Experts Highlight How GLP-1s Have Revolutionized Management of T2D and Obesity ","url":"experts-highlight-how-glp-1s-have-revolutionized-management-of-t2d-and-obesity","authorDetails":[{"biography":[{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}],"_type":"block","style":"normal","_key":"4a950aea97b3"},{"style":"normal","_key":"b28d8058b3d8","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe","nofollow":true}],"children":[{"_key":"48d199d8ecd5","_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on "},{"marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01","_type":"span"},{"marks":[],"text":" or ","_key":"67a67d3764f02","_type":"span"},{"_key":"67a67d3764f03","_type":"span","marks":["c419f18a7ffe"],"text":"Twitter"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block"}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}}}],"factCheckBy":[{"url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":[{"_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}],"children":[{"_key":"67a67d3764f00","_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011."}],"_type":"block","style":"normal"},{"style":"normal","_key":"b28d8058b3d8","markDefs":[{"href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d","nofollow":true,"blank":true,"_type":"link"},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block"}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt"}],"_id":"4d553701-915f-4873-8b9f-4f53893d6561","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"},"summary":"The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists has been revolutionary.","thumbnail":{"asset":{"metadata":{"exif":{"LensSpecification":[18,55,2.8,4],"SensingMethod":2,"CustomRendered":0,"ISO":500,"LensSerialNumber":"48A03748","BrightnessValue":5.84,"LensModel":"XF18-55mmF2.8-4 R LM OIS","FocalPlaneYResolution":2083.4231274638632,"ExposureProgram":3,"LensMake":"FUJIFILM","MaxApertureValue":2.9708536585365852,"ColorSpace":1,"Saturation":1,"SubjectDistanceRange":0,"ExposureMode":0,"FocalPlaneResolutionUnit":3,"ShutterSpeedValue":3.584962502403692,"ExposureTime":0.08333333333333333,"DateTimeDigitized":"2016-07-24T00:00:00.000Z","FocalLength":18,"ApertureValue":8.643856143856144,"ExposureBiasValue":0.33,"FocalLengthIn35mmFormat":27,"PixelXDimension":1200,"LightSource":11,"DateTimeOriginal":"2016-07-24T18:28:07.000Z","WhiteBalance":1,"_type":"sanity.imageExifMetadata","Sharpness":0,"SensitivityType":1,"FNumber":20,"SceneCaptureType":0,"MeteringMode":5,"PixelYDimension":800,"FocalPlaneXResolution":2083.4231274638632},"isOpaque":true,"blurHash":"VwHx:8$xRit5WA_4$~jEaej[T1oMWEa}axENR-f6bIWC","_type":"sanity.imageMetadata","palette":{"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.56,"background":"#8897be"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.13,"background":"#0d90d3"},"dominant":{"population":6.22,"background":"#677397","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":2.79,"background":"#30384f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#677397","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.22},"lightVibrant":{"foreground":"#000","title":"#000","population":2.52,"background":"#efc989","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"title":"#fff","population":0,"background":"#043484","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"height":800,"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5}},"_type":"sanity.imageAsset","sha1hash":"264df279db594adda69bc3737a08c6773f27a6ef","_createdAt":"2024-06-07T15:42:37Z","uploadId":"gcL2RcGUNOwVnVWGsh0ao9mQiEvDHrKK","_rev":"FTf7O3KU2GxuMy4tElpSB4","mimeType":"image/jpeg","path":"images/0vv8moc6/ajmc/264df279db594adda69bc3737a08c6773f27a6ef-1200x800.jpg","size":501001,"assetId":"264df279db594adda69bc3737a08c6773f27a6ef","_id":"image-264df279db594adda69bc3737a08c6773f27a6ef-1200x800-jpg","_updatedAt":"2024-06-07T15:42:37Z","originalFilename":"Cleveland Ohio - Ai - stock.adobe.com.jpeg","extension":"jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/264df279db594adda69bc3737a08c6773f27a6ef-1200x800.jpg"},"_type":"mainImage","alt":"Cleveland Ohio | Image Credit: © Ai - stock.adobe.com.jpeg"},"published":"2024-06-13T19:00:00.000Z"},{"_id":"e881417a-9e64-48ca-9b72-7daafa2dd9c4","title":"Reducing Delays in Breast Cancer Care Using an Innovative Digital Health Platform","summary":"The use of a novel digital health platform achieved a 55% reduction in time to treatment among women with a new diagnosis of breast cancer.","published":"2024-06-13T13:00:00.000Z","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"Medical technology and digital health network concept | Image Credit: © ipopba - stock.adobe.com","asset":{"uploadId":"hTRTLrPbL2uAPSQkjvmAG41W4tGru8UX","sha1hash":"1e602bba35858bd62230432132517d1d42061e3d","_createdAt":"2023-09-25T20:33:46Z","originalFilename":"Medicine doctor hold icon health and electronic medical record on interface. Digital healthcare and network connection on hologram virtual screen, insurance. medical technology and network concept - ipopba - stock.adobe.com.jpeg","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg","assetId":"1e602bba35858bd62230432132517d1d42061e3d","_id":"image-1e602bba35858bd62230432132517d1d42061e3d-1280x800-jpg","_updatedAt":"2023-09-25T20:33:46Z","_type":"sanity.imageAsset","extension":"jpg","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1280,"aspectRatio":1.6,"height":800},"isOpaque":true,"blurHash":"VKJ01o~pIBTJo#K6MxxuRjs:R6xuNGxuRORi-;IUSexb","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"population":8.47,"background":"#205a7b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":4.58,"background":"#a4c2d3","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#2bc4d6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.22},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.47,"background":"#205a7b"},"_type":"sanity.imagePalette","darkMuted":{"background":"#655176","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.14},"muted":{"title":"#fff","population":7.54,"background":"#629eb9","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"foreground":"#000","title":"#000","population":3.38,"background":"#badff5","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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"},"_rev":"pEhoUqandJkxjPidorVwRV","path":"images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg","size":323017}},"url":"reducing-delays-in-breast-cancer-care-using-an-innovative-digital-health-platform","authorDetails":[{"displayName":"Dennis R. Holmes, MD","firstName":"Dennis","lastName":"Holmes","url":{"current":"dennis-r-holmes-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"_type":"slug","current":"steven-d-evans-md"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Steven D. Evans, MD","firstName":"Steven","lastName":"Evans"},{"firstName":"Warren","lastName":"Fisher","url":{"current":"warren-fisher-do","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Warren Fisher, DO"},{"firstName":"Darren","lastName":"Wheeler","url":{"current":"darren-wheeler-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Darren Wheeler, MD"},{"url":{"current":"riya-pulicharam-md-cpi","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Riya Pulicharam, MD, CPI","firstName":"Riya","lastName":"Pulicharam"}],"factCheckBy":[{"displayName":"Dennis R. Holmes, MD","firstName":"Dennis","lastName":"Holmes","url":{"current":"dennis-r-holmes-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Steven D. Evans, MD","firstName":"Steven","lastName":"Evans","url":{"current":"steven-d-evans-md","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Warren Fisher, DO","firstName":"Warren","lastName":"Fisher","url":{"current":"warren-fisher-do","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Darren Wheeler, MD","firstName":"Darren","lastName":"Wheeler","url":{"current":"darren-wheeler-md","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Riya Pulicharam, MD, CPI","firstName":"Riya","lastName":"Pulicharam","url":{"current":"riya-pulicharam-md-cpi","_type":"slug"},"profileImage":null,"biography":null}]}],"isLiveSite":true,"host":"www.ajmc.com","settings":{"title":"AJMC","networkID":"4688","adUnit":"ajmc.com","liveDomain":"www.ajmc.com","publicationName":"AJMC","logo":"/ajmc_logo_inverted.png","white_logo":"/ajmc_logo_inverted.png","logoHeight":"50px","enableEdgeCache":true,"sMaxAge":300,"staleWhileRevalidate":359,"clinicalTopicTopLatestNews":true,"megaMenuTaxName":"topic","megaMenuChildren":true,"sharingImageUrl":"https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png","twitterHandle":"@AJMC_Journal","publicationMapping":"publications","useNewSubNavMegaMenu":true,"redesignDetail":true,"redesignSAP":true,"useNewFooter":true,"newFooterLogos":[{"img":"/CHA_Logo.png","alt":"CH Logo","mobileWidth":"158px","mobileHeight":"42px","link":"/topic/center-on-health-equity-and-access","target":"_self"},{"img":"/CB.png","alt":"Center for Biosimilars Logo","mobileWidth":"170px","mobileHeight":"42px","link":"https://www.centerforbiosimilars.com/","target":"_blank"}],"useV3Components":true,"useAuthorRedesign":true,"navigationOptions":{"version":"2","variant":"4","customSpecialtyText":"Speciality Area"},"gateEnabled":"modal"},"homepage_creative_layout":{"creativeLayout":null}},"targeting":{"content_placement":["compendium/multiple-myeloma"],"document_url":["compendium/multiple-myeloma"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"statusCode":200,"data":{"page":{"taxonomy":{"_createdAt":"2020-03-30T18:16:46Z","_rev":"oruil6rlosjyltJbhrNMGF","name":"Compendium","_updatedAt":"2024-04-09T09:14:18Z","identifier":"compendium","pixelTrackingCode":null,"_type":"taxonomy","_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","isMainTopic":true},"label":null,"pageSliders":null,"orderDesc":null,"creativeLayoutLatestNews":null,"url":{"current":"/compendium","_type":"slug"},"filterRequired":false,"filters":null,"articleDetailConfig":{"enableSegmentRecommend":true,"brightcoveAccountID":"10203567001","disqusShortName":"www-ajmc-com","downloadCitation":true,"shareOptions":{"hideFacebook":false,"SocialIconSize":32,"twitterSiteName":"@AJMC_Journal","hidePinterest":false,"shareSubject":"Check out this article!","twitterHandle":"AJMC","siteName":"ajmc"},"brightcovePlayerID":"pbDmfQhRw","drupalleadBaseURL":"https://drupalleads.mjh.group/injectablewebform/output/","issueMapping":"/publications"},"featureContent":null,"videoPlayerConfig":null,"identifier":null,"creativeLayout":null,"styling":{"imageControl":{"_type":"imageControl","showImage":true,"thumbnailRadius":{"bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem","topRight":"0rem"}},"divider":{"_type":"divider","dividerSize":1},"titleOptions":{"_type":"titleOptions","titleSize":"1rem"},"useDefaultLayout":true,"border":{"borderType":"lines","borderRadius":{"topLeft":"0rem","topRight":"0rem","bottomLeft":"0rem","bottomRight":"0rem"},"_type":"border","borderSize":0},"contentControl":{"showSummary":true,"_type":"contentControl","showPublished":true,"readMore":true,"showAuthor":true}},"fixIdentifier":null,"archived":false,"externalLinks":null,"useV3":true,"excludeFromSitemap":false,"title":"Compendium","parent":null,"theme":"default","relatedMegaMenu":null,"content":null,"hasSubCategory":false,"linkedPage":null,"labelRequired":false,"cmeConfig":null,"searchConfig":{"baseUrl":"/view/"},"disableEpisode":null,"docGroup":null,"contentCategories":null,"gateCode":null,"pageType":"Clinical Topic","creativeLayoutDetail":null,"franchise":null,"isDsoGated":null,"pages":null,"intro":null,"contentCategory":null},"pageData":{"totalCount":276,"pageSize":30,"pageNumber":1,"data":[{"url":"making-cancer-care-easier-with-community-bispecific-antibody-programs","summary":"Allowing patients to stay in their homes to receive bispecific antibodies can make the whole cancer journey easier, explained Courtney VanHouzen, PharmD, of Cowell Family Cancer Center, Munson Healthcare.","contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"authors":[{"displayName":"Alexandra Gerlach","url":"alexandra-gerlach"},{"displayName":"Laura Joszt, MA","url":"laura-joszt"}],"_id":"4592b889-11bd-463c-b4d6-6457d62790f5","title":"Making Cancer Care Easier With Community Bispecific Antibody Programs","thumbnail":{"asset":{"_type":"reference","_ref":"image-4edd101225fd12036d64c1d3622149d3bddcd243-1280x719-png"},"_type":"mainImage","alt":"Screenshot of an interview with Courtney VanHouzen, PharmD"},"published":"2024-10-15T21:00:00.000Z","updatedOn":null,"factCheckAuthors":null},{"updatedOn":null,"_id":"7c70804f-67ec-43f7-b394-2e297286b18e","title":"Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy","url":"miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy","thumbnail":{"alt":"Thomas Jefferson | Image: Thomas Jefferson University ","caption":"Thomas Jefferson | Image: Thomas Jefferson University ","asset":{"_ref":"image-3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600-jpg","_type":"reference"},"_type":"mainImage"},"factCheckAuthors":null,"summary":null,"published":"2024-10-13T15:15:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Ryan Flinn","url":"ryan-flinn"}]},{"_id":"1e600b18-6cba-4183-8bba-71f348cea85e","url":"delays-in-myeloma-oral-therapy-linked-to-race-age","thumbnail":{"_type":"mainImage","alt":"Health disparities word cloud | Image Credit: Colored Lights-stock.adobe.com","asset":{"_ref":"image-75a045d91321b8483c43f41bf052203a0cb3f568-4397x3412-jpg","_type":"reference"}},"summary":"Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.","updatedOn":null,"factCheckAuthors":null,"title":"Delays in Myeloma Oral Therapy Linked to Race, Age","published":"2024-10-11T18:41:17.126Z","contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}]},{"published":"2024-10-02T18:39:44.613Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null,"_id":"7d2a30bf-7a33-4d6b-830e-71129f8747eb","title":"Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care","url":"isatuximab-approval-highlights-role-of-anti-cd38-antibody-in-myeloma-care","thumbnail":{"_type":"mainImage","alt":"Surbhi Sidana, MD, MBBS, Stanford University","asset":{"_ref":"image-d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675-jpg","_type":"reference"}},"summary":"On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant. "},{"url":"varied-types-levels-of-support-needed-for-patients-with-multiple-myeloma","thumbnail":{"caption":"Multiple myeloma | Image credit: freshidea - stock.adobe.com","asset":{"_ref":"image-7f842239e3b3b2e06a220dac987c201761de64b3-7073x3500-jpg","_type":"reference"},"_type":"mainImage","alt":"Multiple myeloma | Image credit: freshidea - stock.adobe.com"},"summary":"Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"factCheckAuthors":null,"_id":"52688b90-4ed6-4b0b-824f-357ca7689c13","title":"Varied Types, Levels of Support Needed for Patients With Multiple Myeloma","published":"2024-09-20T15:21:00.000Z","updatedOn":null,"authors":[{"displayName":"Julia Bonavitacola","url":"julia-bonavitacola"}]},{"url":"bridging-global-treatment-gaps-in-relapsed-multiple-myeloma","thumbnail":{"_type":"mainImage","alt":"Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center","caption":"Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center","asset":{"_ref":"image-cda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675-jpg","_type":"reference"}},"summary":"The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the world, explains Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center.","published":"2024-09-17T13:30:00.000Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null,"title":"Bridging Global Treatment Gaps in Relapsed Multiple Myeloma","authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"_id":"52cc03c6-0300-4ad4-bcd0-3aaa313ef023"},{"thumbnail":{"_type":"mainImage","alt":"Clinical trial results | Image Credit: Egor-stock.adobe.com","asset":{"_ref":"image-e8b89f6523b42f0e4eac2c396f686ac915160fbf-1200x738-jpg","_type":"reference"}},"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null,"_id":"5236e1fc-e3b2-4fe9-9258-c399a3acce54","title":"D-VRd Boosts MRD Negativity in Transplant-Eligible Multiple Myeloma","url":"d-vrd-boosts-mrd-negativity-in-transplant-eligible-multiple-myeloma","summary":"The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant. ","published":"2024-09-12T21:34:00.043Z","updatedOn":null,"authors":[{"displayName":"Chris Ryan","url":"chris-ryan"}]},{"url":"triple-target-car-t-cells-benefits-and-challenges","summary":"In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.","published":"2024-08-30T12:00:00.000Z","updatedOn":null,"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"_id":"d62a2b61-38c6-4929-b14c-96e9a72634df","title":"Triple-Target CAR T Cells: Benefits and Challenges","thumbnail":{"_type":"mainImage","alt":"Leland Metheny, MD, University Hospitals Seidman Cancer Center","asset":{"_ref":"image-cda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675-jpg","_type":"reference"}},"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"factCheckAuthors":null},{"_id":"27b5f113-12db-4337-a9dd-a1b3672b1dff","published":"2024-08-21T20:01:35.111Z","updatedOn":null,"authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}],"factCheckAuthors":null,"title":"FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma","url":"fda-issues-crl-for-linvoseltamab-in-r-r-multiple-myeloma","thumbnail":{"asset":{"_ref":"image-cdc10674fe8a1ccf14048f3b60b2e86e3ffe8bb1-5000x3337-jpg","_type":"reference"},"_type":"mainImage","alt":"Regeneron logo | Image credit: Casimiro – stock.adobe.com"},"summary":"The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.","contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"}},{"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null,"thumbnail":{"_type":"mainImage","alt":"stem cells | Image Credit: jarun011-stock.adobe.com","asset":{"_ref":"image-8caf2ee1f420c7185048fb92441c1b5b881d218a-1200x738-jpg","_type":"reference"}},"updatedOn":null,"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"summary":"To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.\n","published":"2024-08-20T16:38:22.765Z","_id":"d7a6119f-2aa8-4f84-a694-ea8ee71a550a","title":"Second ASCT Extends Survival in Relapsed Multiple Myeloma","url":"second-asct-extends-survival-in-relapsed-multiple-myeloma"},{"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"_id":"53ea5726-2750-4a2c-b347-3726470681b3","title":"Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD","thumbnail":{"_type":"mainImage","alt":"MM treatment | Image Credit: Dzmitry-stock.adobe.com","asset":{"_ref":"image-568bbc1591d5d6400d39c9416b6235ce6dfcf018-1200x738-jpg","_type":"reference"}},"published":"2024-08-14T18:47:01.225Z","updatedOn":null,"url":"challenges-with-pomalidomide-for-patients-with-comorbid-rrmm-ckd","summary":"Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.\n","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null},{"published":"2024-08-06T22:09:40.053Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"url":"novel-therapies-needed-for-older-patients-with-rrmm","thumbnail":{"_type":"mainImage","alt":"MM blood test | Image Credit: luchschenF-stock.adobe.com","asset":{"_ref":"image-0636f60ec186da460f794acfef0878325c54f9ec-1200x738-jpg","_type":"reference"}},"summary":"Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.","updatedOn":null,"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null,"_id":"107aff69-b0ed-485e-9ec2-ed2eb8ca9ee2","title":"Novel Therapies Needed for Older Patients With RRMM"},{"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null,"_id":"58e1ff15-c2d2-4e40-9f8f-7eac700da4ca","title":"Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM","url":"daratumumab-and-hyaluronidase-fihj-based-quadruplet-approved-in-mm","summary":"Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.\n","published":"2024-07-31T17:22:08.229Z","updatedOn":null,"thumbnail":{"_type":"mainImage","alt":"FDA | Image Credit: ra2studio-stock.adobe.com","asset":{"_ref":"image-f2d1812ac576b862153d30d4fe7e135bec6ddffc-1200x738-jpg","_type":"reference"}},"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"}},{"factCheckAuthors":null,"_id":"e40bcd34-736f-40bb-b137-15f51f6fdc8c","title":"Dual-Target CAR T Cells Achieve 100% Response Rate in MM","url":"dual-target-car-t-cells-achieve-100-response-rate-in-mm","summary":"This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).","published":"2024-07-25T15:00:00.000Z","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"thumbnail":{"_type":"mainImage","alt":"CAR T in MM | Image Credit: LASZLO-stock.adobe.com","asset":{"_ref":"image-a8ce964403b3f6531ee8a6c5d1ff46969a56666b-1200x728-jpg","_type":"reference"}},"updatedOn":null},{"thumbnail":{"_type":"mainImage","alt":"Joseph Mikhael, MD, an expert on multiple myeloma","asset":{"_ref":"image-f6b179d9974841eb0d393e097d87babad52e750c-1920x1080-png","_type":"reference"}},"summary":"Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.","published":"2024-07-19T19:38:00.000Z","contentCategory":{"_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z"},"authors":[{"displayName":"Joseph Mikhael, MD","url":"joseph-mikhael-md"}],"_id":"1a4247a9-ab9c-449f-8e89-545874a25983","title":"EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma","url":"eha-2024-teclistimab-in-high-risk-relapsed-refractory-multiple-myeloma","factCheckAuthors":null,"updatedOn":null},{"factCheckAuthors":null,"url":"use-of-prophylactic-tocilizumab-with-teclistamab-takeaways-from-asco-2024","published":"2024-07-17T19:50:40.638Z","updatedOn":null,"summary":"Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.","contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"authors":[{"displayName":"Alfred L. Garfall, MD","url":"alfred-l-garfall-md"}],"_id":"8f6bfda0-f3e3-464c-84d8-30ba1234910c","title":"Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024","thumbnail":{"_type":"mainImage","alt":"Alfred L. Garfall, MD, an expert on multiple myeloma","asset":{"_ref":"image-3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080-png","_type":"reference"}}},{"updatedOn":null,"authors":[{"displayName":"Joseph Mikhael, MD","url":"joseph-mikhael-md"}],"factCheckAuthors":null,"_id":"25145d5f-d9c4-4252-8900-8a3ee628ed13","title":"Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024","url":"treatment-in-early-relapse-multiple-myeloma-takeaways-from-eha-2024","thumbnail":{"_type":"mainImage","alt":"Joseph Mikhael, MD, an expert on multiple myeloma","asset":{"_ref":"image-f6b179d9974841eb0d393e097d87babad52e750c-1920x1080-png","_type":"reference"}},"summary":"Dr. Mikhael discusses treatment in early relapse of multiple myeloma.","published":"2024-07-17T19:38:26.004Z","contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"}},{"title":"Myeloma Survivorship Program: Findings and Future Steps","url":"myeloma-survivorship-program-findings-and-future-steps","published":"2024-07-17T18:18:44.032Z","updatedOn":null,"factCheckAuthors":null,"_id":"f658dbb9-8338-4a50-9eab-c895dfb7cfda","thumbnail":{"_type":"mainImage","alt":"Support group image | Image Credit: Tom Merton/KOTO-stock.adobe.com","asset":{"_ref":"image-266dba9b57f0c1e1669791ffd8130eef47282a33-1200x728-jpg","_type":"reference"}},"summary":"Peer and survivorship support are lacking for patients living with multiple myeloma, leading investigators to evaluate a group-focused multidisciplinary intervention that encompassed physical and mental activities.\n","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}]},{"_id":"c5873007-9a63-4b75-adbb-cb5f9e254ae6","title":"Final GRIFFIN Trial Data Confirm Daratumumab Benefit Against MM","url":"final-griffin-trial-data-confirm-daratumumab-benefit-against-mm","thumbnail":{"_type":"mainImage","alt":"Multiple myeloma | Image Credit: Felipe Caparrós-stock.adobe.com","asset":{"_type":"reference","_ref":"image-5cba2040fb990cdd20d42e332cc21083c9a38581-1200x728-jpg"}},"summary":"Patient outcomes in this trial were compared between the regimens of lenalidomide, bortezomib, and dexamethasone and daratumumab, lenalidomide, bortezomib, and dexamethasone for use against multiple myeloma (MM).\n","published":"2024-07-10T20:02:29.544Z","updatedOn":null,"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null},{"thumbnail":{"_type":"mainImage","alt":"Interview with Joseph Mikhael, MD, MEd, FRCPC, FACP","asset":{"_ref":"image-23b8d7cf863336087bed8bb220c2d6e7aaf9050e-1200x675-jpg","_type":"reference"}},"summary":"In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.","published":"2024-07-07T13:30:00.000Z","authors":[{"displayName":"Brooke McCormick","url":"brooke-mccormick"},{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null,"_id":"eec92739-0be1-4b51-842e-b4d56d69c442","url":"game-changing-strategies-for-early-relapsed-myeloma","contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"},"title":"Game-Changing Strategies for Early-Relapsed Myeloma","updatedOn":null},{"summary":"In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma.","published":"2024-07-02T12:33:25.011Z","authors":[{"displayName":"Brooke McCormick","url":"brooke-mccormick"},{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"thumbnail":{"_type":"mainImage","alt":"AJMC with Dr Suzane Lentzsch | Background image credit: ipopba - stock.adobe.com","asset":{"_ref":"image-366bb84a36b5bbb43be763745d5d1de6601b8e61-3750x2000-png","_type":"reference"}},"updatedOn":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"factCheckAuthors":null,"_id":"04130fa9-a52a-407c-8890-aa462f729e8a","title":"Advancements and Challenges in Treating Relapsed/Refractory Multiple Myeloma","url":"advancements-and-challenges-in-treating-relapsed-refractory-multiple-myeloma"},{"published":"2024-06-28T13:58:35.411Z","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Ariana Pelosci","url":"ariana-pelosci"}],"title":"Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma","url":"ide-cel-generates-durable-responses-in-functionally-high-risk-myeloma","summary":"In April, the FDA approved decabtagene vicleucel (ide-cel) for earlier treatment of relapsed/refractory multiple myleoma.","updatedOn":null,"factCheckAuthors":null,"_id":"29243bcc-6ccb-4c93-a14a-d1a9a55dbf86","thumbnail":{"_type":"mainImage","alt":"multiple myeloma | Image Credit: ibreakstock-stock.adobe.com","asset":{"_ref":"image-b3dd27f5b3c839de0cc4b205d4e44336b925b677-1200x728-jpg","_type":"reference"}}},{"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Brooke McCormick","url":"brooke-mccormick"},{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"_id":"2c12c09e-083a-4144-baf7-037040db4705","summary":"In this interview from our coverage of the European Hematology Association 2024 Congress, Joseph Mikhael, MD, MEd, FRCPC, FACP, International Myeloma Foundation, discusses the complex principles that underlie treating multiple myeloma (MM) in the US.","published":"2024-06-27T21:53:00.000Z","updatedOn":null,"title":"The Tremendous Complexity of Treating RRMM","url":"the-tremendous-complexity-of-treating-rrmm","thumbnail":{"_type":"mainImage","alt":"Joseph Mikhael, MD, MEd, FRCPC, FACP","asset":{"_ref":"image-23b8d7cf863336087bed8bb220c2d6e7aaf9050e-1200x675-jpg","_type":"reference"}},"factCheckAuthors":null},{"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"title":"Dr Suzanne Lentzsch Highlights Promising Linvoseltamab Results in Treating RRMM","url":"dr-suzanne-lentzsch-highlights-promising-linvoseltamab-results-in-treating-rrmm","thumbnail":{"_type":"mainImage","alt":"AJMC with Dr Suzane Lentzsch | Background image credit: ipopba - stock.adobe.com","asset":{"_type":"reference","_ref":"image-366bb84a36b5bbb43be763745d5d1de6601b8e61-3750x2000-png"}},"summary":"Suzanne Lentzsch, MD, PhD, of Columbia University, presented promising results of linvoseltamab for treating relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association 2024 Congress.","published":"2024-06-21T13:00:00.000Z","updatedOn":null,"authors":[{"displayName":"Brooke McCormick","url":"brooke-mccormick"}],"_id":"fdb9b0fa-5b15-4906-a465-891bed235279","factCheckAuthors":null},{"_id":"b9a308e3-570b-480d-b411-3e8cf293f8f7","thumbnail":{"_type":"mainImage","alt":"multiple myeloma diagnosis | Image Credit: shidlovski-stock.adobe.com","asset":{"_ref":"image-0b344275aab19e5e3756affd170b28a5f881845f-1200x628-jpg","_type":"reference"}},"published":"2024-06-13T14:30:21.579Z","contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"title":"MRD2STOP: Promise in Halting Myeloma Maintenance Therapy","url":"mrd2stop-promise-in-halting-myeloma-maintenance-therapy","summary":"One patient died during this study, which used PET/CT, flow cytometry, and next-generation sequencing to define measurable residual disease negativity.","updatedOn":null,"factCheckAuthors":null},{"published":"2024-06-04T00:15:00.000Z","contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"factCheckAuthors":null,"_id":"7ed5ac6c-f51b-400a-8001-0cdf4a0e1642","title":"IMROZ: Adding Isatuximab to SOC in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Cut Risk of Disease Progression or Death 40%","url":"imroz-adding-isatuximab-to-soc-in-transplant-ineligible-newly-diagnosed-multiple-myeloma-cut-risk-of-disease-progression-or-death-40-","thumbnail":{"_type":"mainImage","alt":"Sarclisa packaging | Image credit: Sanofi","caption":"Sarclisa packaging | Image credit: Sanofi","asset":{"_ref":"image-6f74eb3d8d988ca4cbf715879d1b287fdd803e01-968x508-jpg","_type":"reference"}},"summary":"Combining the anti-CD38 monoclonal antibody with a standard backbone triplet should be the new standard of care for newly diagnosed patients not eligible for transplant, said lead investigator Thierry Facon, MD.","updatedOn":null,"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"}]},{"contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"title":"Future Indications and Frontline Potential of Cilta-Cel in Multiple Myeloma: Insights From Dr Binod Dhakal","url":"future-indications-and-frontline-potential-of-cilta-cel-in-multiple-myeloma-insights-from-dr-binod-dhakal","thumbnail":{"_type":"mainImage","alt":"Binod Dhakal, MD","asset":{"_ref":"image-4287639dedc490b040e69194f9d38464eb6444a1-1200x724-jpg","_type":"reference"}},"summary":"In the final part of our interview with Binod Dhakal, MD, lead investigator of the CARTITUDE-4 study, he looks to the future of earlier treatment for relapsed/refractory multiple myeloma. ","published":"2024-05-24T19:48:00.000Z","updatedOn":null,"factCheckAuthors":null,"_id":"a67efa00-77c9-4484-bb75-ed029e493f51"},{"title":"Raymond Thertulien, MD, PhD, on How Abnormalities Drive Treatment Choices in Multiple Myeloma","summary":null,"updatedOn":null,"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"_id":"77a49b9a-4695-41a7-8fb9-e7077503fd7d","url":"raymond-thertulien-md-phd-on-how-abnormalities-drive-treatment-choices-in-multiple-myeloma","thumbnail":{"_type":"mainImage","alt":"Raymond Thertulien, MD, PhD | Image credit: LinkedIn","caption":"Raymond Thertulien, MD, PhD | Image credit: LinkedIn","asset":{"_ref":"image-41eb5a69edf2fc2a89c1ae52b03d0593bfb6d266-230x284-jpg","_type":"reference"}},"published":"2024-05-20T08:21:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null},{"title":"CAR T Proves Effective and Safe for Refractory Multiple Myeloma","url":"car-t-proves-effective-and-safe-for-refractory-multiple-myeloma","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"85bee011-6708-4a51-b265-4959a760e64e","summary":"Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.","published":"2024-05-15T17:15:40.624Z","authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null,"thumbnail":{"_type":"mainImage","alt":"MM image | Image Credit: Svetlana-stock.adobe.com","asset":{"_ref":"image-489f3675b313076477343c9a9201cf95dd28fc06-1200x800-jpg","_type":"reference"}}},{"factCheckAuthors":null,"thumbnail":{"_type":"mainImage","alt":"Binod Dhakal, MD","asset":{"_type":"reference","_ref":"image-4287639dedc490b040e69194f9d38464eb6444a1-1200x724-jpg"}},"summary":"In part 2 of our interview with Binod Dhakal, MD, he addresses how CARTITUDE-4 study findings help to advance the clinical understanding of ciltacabtagene autoleucel (cilta-cel) and the importance of vigilance and education on the treatment’s adverse effects.\n","published":"2024-05-06T15:57:50.369Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"_id":"fc1f8456-b0b7-40df-8f0e-6c16f67b6b18","title":"Dr Binod Dhakal: The Importance of Patient Monitoring With Cilta-Cel Treatment","url":"dr-binod-dhakal-the-importance-of-patient-monitoring-with-cilta-cel-treatment"}],"targeting":{"content_placement":["compendium/multiple-myeloma"],"document_url":["compendium/multiple-myeloma"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"currentTopic":{"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"ptceKeywordMapping":null,"pixelTrackingCode":null,"thumbnail":null,"name":"Multiple Myeloma","summary":[{"style":"normal","_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"text":"AJMC","_key":"3a355a7e133a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block"}],"url":"multiple-myeloma","cmeType":"per","parent":{"_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","name":"Compendium","url":"compendium","parent":null},"_id":"26bcac93-deb1-4f11-9290-5efec6d9e357"},"filterData":[],"relatedTopics":null,"podcastsData":[],"videoSeriesData":[],"videoNonSeriesData":[{"_updatedAt":"2024-10-24T17:16:26Z","ExcludeFromPubMedXML":false,"_type":"article","seoTag":["multiple myeloma","isatuximab","surrogate end point"],"thumbnail":{"asset":{"extension":"jpg","mimeType":"image/jpeg","uploadId":"KmeVYjwEdoE53rfAVfEednO41NJQUR2N","_type":"sanity.imageAsset","size":134400,"metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.7777777777777777,"height":675},"isOpaque":true,"blurHash":"MeLqa}lA_MWDV@_2ozM{xuV[M{n%Rjofxu","_type":"sanity.imageMetadata","palette":{"vibrant":{"population":0,"background":"#4073be","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"foreground":"#000","title":"#fff","population":4.38,"background":"#cebdad","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.74,"background":"#343f59"},"muted":{"title":"#fff","population":0.01,"background":"#647a9c","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":1.53,"background":"#e5d4bc"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.69,"background":"#1c3252","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#cebdad","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":4.38}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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"},"_rev":"2oSzY2xHyUGh6118HqAcjB","sha1hash":"d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac","path":"images/0vv8moc6/ajmc/d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg","_id":"image-d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675-jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg","assetId":"d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac","_createdAt":"2024-10-02T16:08:51Z","_updatedAt":"2024-10-02T16:08:51Z","originalFilename":"Sidana Thumbnail.jpg"}},"source":null,"published":"2024-10-24T16:59:06.697Z","url":{"current":"mrd-a-game-changer-in-multiple-myeloma","_type":"slug"},"contentCategory":{"_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z"},"link":"/view/mrd-a-game-changer-in-multiple-myeloma","updatedOn":null,"taxonomyMapping":[{"_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews"},{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z","name":"Multiple Myeloma","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","summary":[{"style":"normal","_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}],"_type":"block"}],"identifier":"multiple-myeloma","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy"},{"identifier":"clinical","_createdAt":"2020-05-04T23:46:13Z","name":"Clinical","_id":"topic_clinical","_updatedAt":"2022-02-18T12:13:55Z","summary":[{"children":[{"marks":[],"text":"The ","_key":"e80c79954e08","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a","_type":"span","marks":[]},{"_key":"cc409f2da7da","_type":"span","marks":["em"],"text":"The American Journal of Managed Care"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17"},{"_type":"span","marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf"}],"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[]}],"_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"}},{"_createdAt":"2020-04-14T15:02:13Z","_rev":"GeM6ny2T6Y1Qp0cm9jBxeg","_type":"taxonomy","name":"Hematology","_id":"compendium_hematology","_updatedAt":"2020-07-30T14:48:10Z","identifier":"hematology","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"}}],"factCheckAuthorMapping":null,"is_visible":true,"_createdAt":"2024-10-24T16:14:55Z","authorMapping":[{"displayName":"Maggie L. Shaw","_id":"author_51b2956e2bd42e0d6e35a66971fd60bc","biography":[{"style":"normal","_key":"643be033259e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.","_key":"abc0e18a29ce0"}],"_type":"block"},{"style":"normal","_key":"f4070c315fab","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/","_key":"159c764717fb","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_type":"span","marks":[],"text":".","_key":"abc0e18a29ce2"}],"_type":"block"}],"_updatedAt":"2024-08-07T15:47:36Z","url":{"current":"maggie-l-shaw","_type":"slug"},"_createdAt":"2020-05-05T10:50:09Z","_rev":"4vyIlJfwMwqB8NbLEufdwW","_type":"author","profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}}}],"_rev":"Nphhc06GU7PslEeOdbRtob","body":[{"source":"brightcove","_key":"f4b14cd49936","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675-jpg","_type":"reference"}},"videoDuration":"PT2M17S","videoDescription":"Interview with Surbhi Sidana, MD, MBBS","_type":"videoDetails","videoTitle":"MRD: A Game Changer in multiple myeloma"},"_type":"video","caption":"Surbhi Sidana, MD, MBBS","videoID":"6363688938112","disableAutoPlayVideo":false},{"style":"normal","_key":"001a5aba3648","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"bd8a0bbc0d55"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"In part 2 of our interview with Surbhi Sidana, MD, MBBS, vice chair of the American Society of Hematology’s Committee on Communications and associate professor of medicine and director of the Myeloma Disease Focused Group at Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: minimal residual disease status.","_key":"2999cc26c4f60"}],"_type":"block","style":"normal","_key":"27b9cd91ebb2"},{"_key":"d5dfea1bc93f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"57a82be0d7bd0"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Here she explains just what are these remnants of cancer that remain after completion of treatment and their significance to future treatment decisions and outcomes.","_key":"065a56b787ac0"}],"_type":"block","style":"normal","_key":"bc4a0fe69eed"},{"style":"normal","_key":"53e48d35b7f6","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"d6240b2a7d170"}],"_type":"block"},{"_type":"block","style":"normal","_key":"42505e0bddbf","markDefs":[{"_type":"link","href":"https://www.ajmc.com/view/isatuximab-approval-highlights-role-of-anti-cd38-antibody-in-myeloma-care","_key":"33ff064e5a57","blank":true},{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/fda-approves-isatuximab-with-vrd-as-first-line-option-for-transplant-ineligible-multiple-myeloma","_key":"45288976db66"},{"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"b8fbc6cb991c","nofollow":false}],"children":[{"_type":"span","marks":[],"text":"Also make sure to check our ","_key":"233a7b9cfdfd0"},{"text":"part 1","_key":"233a7b9cfdfd1","_type":"span","marks":["33ff064e5a57"]},{"_key":"233a7b9cfdfd2","_type":"span","marks":[],"text":" of our exclusive interview with her regarding the recent "},{"_type":"span","marks":["45288976db66"],"text":"FDA approval of isatuximab","_key":"233a7b9cfdfd3"},{"_type":"span","marks":[],"text":" (Sarclisa; Sanofi-Aventis) plus bortezomib (Velcade; Takeda), lenalidomide (Revlimid; Celgene), and dexamethasone (VRd) in the first line for patients with ","_key":"233a7b9cfdfd4"},{"_key":"759af42b30ba","_type":"span","marks":["b8fbc6cb991c"],"text":"multiple myeloma"},{"_type":"span","marks":[],"text":" (MM) ineligible for transplant.","_key":"88a1e14a5bbb"}]},{"style":"normal","_key":"83e09869ba92","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"ad2f18b425d00"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"This transcript has been lightly edited","_key":"0a5abaffc4620"},{"marks":[],"text":".","_key":"0a5abaffc4621","_type":"span"}],"_type":"block","style":"normal","_key":"6edfca3655e4"},{"children":[{"_type":"span","marks":[],"text":"","_key":"acfe1769097a0"}],"_type":"block","style":"normal","_key":"ec9e40d38cc3","markDefs":[]},{"_type":"block","style":"normal","_key":"3fe4ac0dbacd","markDefs":[],"children":[{"text":"Transcript","_key":"25b494b65bd70","_type":"span","marks":["strong","underline"]}]},{"_type":"block","style":"normal","_key":"91547337254a","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e817b690afd20"}]},{"_type":"block","style":"normal","_key":"033033bf6c86","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"What is the role of MRD status in multiple myeloma and how does it direct treatment decisions and outcomes?","_key":"779ec60978e30"}]},{"style":"normal","_key":"5938bc942673","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"6e442d7034d40"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"Minimal residual disease is a sensitive way to measure disease that our current criteria cannot measure through blood-based testing or bone marrow–based testing.","_key":"00d2568842c00"}],"_type":"block","style":"normal","_key":"aad2e34a659e","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"","_key":"17912850dabd0"}],"_type":"block","style":"normal","_key":"8c0d279326bc","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"Historically, we evaluated myeloma through monoclonal proteins or free light chains in the blood and urine and percentage of plasma cells in the bone marrow. But this is like the iceberg: you can detect something on the surface, then you do a bone marrow [test and] you can detect something under the surface. But we know that even with those techniques, a lot of disease was left behind that they were just not sensitive enough to detect. So, MRD, or minimal residual disease, testing is just a more sensitive technique to detect disease that cannot be detected by conventional technologies.","_key":"4b3feb5ff4ea0"}],"_type":"block","style":"normal","_key":"42663d1d89af","markDefs":[]},{"style":"normal","_key":"d5c4a53f535f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"963bac9bb6f30"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"There's a couple of ways to do it by our current methodologies. Both of them right now rely on bone marrow testing: next-generation flow cytometry, which is an advanced flow cytometry to [provide a] more sensitive way of detection, or next-generation sequencing that detects the clone in myeloma at the time of diagnosis or relapse and tracks that clone through sequencing of the VDJ region in the plasma cell and just tracks that one clone to detect it at a very low level.","_key":"8f9de165a7cc0"}],"_type":"block","style":"normal","_key":"9cd8bd26c74c","markDefs":[]},{"_type":"block","style":"normal","_key":"10f739c2a94b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"bcb4ac9e5d860"}]},{"_type":"block","style":"normal","_key":"005a8ef2b630","markDefs":[],"children":[{"text":"It's just a sensitive way to detect disease that we couldn't previously detect. And what this tells us is that if you have low-level disease that we cannot detect by MRD—it doesn't mean there's no disease, just that these techniques cannot detect—those patients do better. We've seen that historically.","_key":"38d06ac96fe20","_type":"span","marks":[]}]},{"_key":"cf90ac37678c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e40841cfd7a60"}],"_type":"block","style":"normal"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/after-odac-what-s-next-for-mrd-testing-in-multiple-myeloma-","_key":"17839c83ace1"}],"children":[{"_type":"span","marks":[],"text":"Now, the FDA ODAC [Oncologic Drugs Advisory Committee] came out ","_key":"54b2dae43cf80"},{"marks":["17839c83ace1"],"text":"with a decision","_key":"54b2dae43cf81","_type":"span"},{"_type":"span","marks":[],"text":" that MRD will be used as a surrogate end point. They're open to that as a surrogate end point for drug approval. So, I think the field is moving in that direction. So, yes, MRD negativity rates were actually higher in this clinical trial [IMROZ, NCT03319667] with a quadruplet induction.","_key":"54b2dae43cf82"}],"_type":"block","style":"normal","_key":"1759ec02d35c"},{"_key":"042a745eb7bc","markDefs":[],"children":[{"_key":"d5e4a676c1f00","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"_key":"d888804a3c5d","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/cepheus-sub-q-daratumumab-with-vrd-improves-mrd-negativity-pfs-in-myeloma-if-transplant-deferred","_key":"379fada9485e"}],"children":[{"_type":"span","marks":[],"text":"We just had the IMS 2024 meeting in Brazil, and there they presented another clinical trial, which was very similar, just used a different anti-CD38, ","_key":"b4c7a478db150"},{"text":"the CEPHEUS trial","_key":"b4c7a478db151","_type":"span","marks":["379fada9485e"]},{"_type":"span","marks":[],"text":", where the primary end point was actually MRD negativity. So, in the IMROZ trial, the primary end point was PFS [progression-free survival], but there the primary end point was MRD negativity. So, our field is changing rapidly.","_key":"b4c7a478db152"}],"_type":"block","style":"normal"}],"title":"MRD: A Game Changer in Multiple Myeloma","_id":"51b5be8a-83c6-4679-83e9-28c65886cfc3","articleType":"Commentary","summary":"In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: minimal residual disease (MRD) status."},{"body":[{"videoID":"6362724980112","disableAutoPlayVideo":false,"source":"brightcove","_key":"2f25a6efa2c8","videoObject":{"videoDescription":"IMS Recap","_type":"videoDetails","videoTitle":"IMS Recap","thumbnail":{"asset":{"_type":"reference","_ref":"image-2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250-png"},"_type":"image"},"videoDuration":"PT3M35S"},"_type":"video","caption":"IMS Recap"},{"_type":"block","style":"normal","_key":"1df999cbcef5","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/conference/ims","_key":"49ff5da8a62e"}],"children":[{"_type":"span","marks":[],"text":"We spoke with the following global experts who attended the ","_key":"a74b3d3afe900"},{"_type":"span","marks":["49ff5da8a62e"],"text":"2024 International Myeloma Society ","_key":"a74b3d3afe901"},{"_type":"span","marks":[],"text":"meeting regarding what they believe was the most interesting update in the myeloma space this year:","_key":"a74b3d3afe902"}]},{"children":[{"_key":"973599256d640","_type":"span","marks":[],"text":"Pieter Sonneveld, MD, PhD, professor of hematology at the Erasmus University Medical Center, chairman of the Multiple Myeloma Working Group and European Myeloma Network"}],"level":1,"_type":"block","style":"normal","_key":"bba4eee10a79","listItem":"bullet","markDefs":[]},{"_key":"7822449cbc1c","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Saad Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center","_key":"2142d338fb010"}],"level":1,"_type":"block","style":"normal"},{"_key":"b27f651e080a","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin","_key":"c6d5a73b502d0"}],"level":1,"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c4cab8f17bde"}],"_type":"block","style":"normal","_key":"90a6708ef6de"},{"markDefs":[],"children":[{"text":"This transcript has been lightly edited for clarity.","_key":"1cc15d0f07b80","_type":"span","marks":["em"]}],"_type":"block","style":"normal","_key":"ba76b9cbc224"},{"markDefs":[],"children":[{"text":"","_key":"e2abfa9ade9e","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"ea9e45f011e7"},{"_key":"72824939b46f","markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"f23aae87ea070"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"b0599dd59c96"}],"_type":"block","style":"normal","_key":"a06af72e3eda"},{"_key":"d916fb3f46b0","markDefs":[],"children":[{"marks":["strong"],"text":"What update in the myeloma space this year has been the most interesting to you?","_key":"91c40933d98e0","_type":"span"}],"_type":"block","style":"normal"},{"_key":"c214d90ea3c2","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"ea23e1476f7b"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":["strong"],"text":"Sonneveld:","_key":"40aa8e33d1930"},{"_type":"span","marks":[],"text":" The most interesting update to me is the ","_key":"a5df4fb4ab66"},{"_type":"span","marks":["90babe82269a"],"text":"PERSEUS study","_key":"4d89f3738a50"},{"text":", a study using traditional drugs like VRd [bortezomib, lenalidomide, and dexamethasone] and adding the monoclonal antibody daratumumab. This results in a great effect in the frontline setting of treatment for multiple myeloma.","_key":"702b7894016e","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"6337904d02fc","markDefs":[{"_key":"90babe82269a","nofollow":true,"blank":true,"_type":"link","href":"https://www.ajmc.com/view/daratumumab-quadruplets-show-durable-outcomes-in-transplant-eligible-multiple-myeloma"}]},{"children":[{"_type":"span","marks":[],"text":"","_key":"45e024e269ba0"}],"_type":"block","style":"normal","_key":"00472c80195a","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"At the same time, we are also aware of new developments like CAR [chimeric antigen receptor] T-cell treatments and treatments with bispecific antibodies.","_key":"542a2e47377b0"}],"_type":"block","style":"normal","_key":"4f659b993f62"},{"_type":"block","style":"normal","_key":"6659f5c3e0a4","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"f456171e3d8c0"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The organization for which I'm working, The European Myeloma Network [EMN], also coordinates 2 important trials in the frontline setting. One trial is comparing CAR T-cell treatment with standard autologous stem cell transplantation. This trial is ongoing in many countries around the world, coordinated by EMN.","_key":"6c8862d0afd30"}],"_type":"block","style":"normal","_key":"b53aaf0fb805"},{"markDefs":[],"children":[{"_key":"ce37f7ff812d0","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"306dac0fb23e"},{"style":"normal","_key":"25f3bbc12420","markDefs":[],"children":[{"_key":"4703da37a2820","_type":"span","marks":[],"text":"The other trial is about the use of bispecifics in the maintenance setting—in this case, teclistamab, also for a frontline treatment for patients with multiple myeloma. Trials have been done in the relapse setting and we know they are very effective, have very high response rates, and lasting responses of good quality."}],"_type":"block"},{"markDefs":[],"children":[{"_key":"3da478fac5c10","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"d58d43cba6ea"},{"style":"normal","_key":"48e5ff43a8c4","markDefs":[],"children":[{"_type":"span","marks":[],"text":"We expect that when moving these novel agents from the relapse setting to the frontline setting, the impact on the treatment in terms of response rate, but especially duration of response, will be huge.","_key":"feccf4e2f14d0"}],"_type":"block"},{"style":"normal","_key":"6ba987eb24c5","markDefs":[],"children":[{"marks":[],"text":"","_key":"5ac4d28ffae00","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"We expect that this will be the next step in myeloma treatment that will set the new standard of care and we expect a lot from that. Over the next 5 to 10 years, we will see the developments with these new agents. I think the whole world of myeloma treatment will change with the results of these new trials.","_key":"2fb0ffc23d630"}],"_type":"block","style":"normal","_key":"623e2a2f8348"},{"_key":"0dfb971ca3eb","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"918bea17fc430"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":["strong"],"text":"Usmani:","_key":"22b115cf62df0"},{"_type":"span","marks":[],"text":" The movement from 3-drug combinations to anti-CD38–based quadruplet induction approaches for patients has been a very important step forward for patients. The next important avenue that we have to figure out is what kind of maintenance strategies would suffice for standard-risk patients, what do we need for high-risk patients? We need to look at the duration of therapy. These will be important things to consider for the future research directions.","_key":"2eee7ce32be0"}],"_type":"block","style":"normal","_key":"3b93783ed2a3","markDefs":[]},{"style":"normal","_key":"dced72f92372","markDefs":[],"children":[{"marks":[],"text":"","_key":"93613732e47f0","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Dhakal:","_key":"6a3a154730bb0"},{"marks":[],"text":" There are a lot of new CAR T [therapies] being developed, both against BCMA [B-cell maturation antigen] and non-BCMA, like GPRC5D. Under this, it has been pretty encouraging and shows some very good results. In addition, there are small molecules that are being developed, particularly for the protein integrators, BCL-2 inhibitors, and a lot of developments in the bispecific antibodies, but not only for BCMA, but also GPRC5D/FcRH5. More importantly, things are moving earlier in the early-line setting and are showing very impressive efficacy and safety, and this really kind of sets this platform for us to have a very deep, durable response in majority of the patients in the future.","_key":"85f0c1b89c03","_type":"span"}],"_type":"block","style":"normal","_key":"e5dce6eeacc5"}],"seoTag":["PERSEUS","daratumumab","CAR T-cell treatment","BCMA","GPRC5D"],"updatedOn":null,"factCheckAuthorMapping":null,"_updatedAt":"2024-10-01T17:30:07Z","ExcludeFromPubMedXML":false,"articleType":"Commentary","_id":"58b86721-21c2-4ef0-a879-e426c525a59a","documentGroupMapping":[{"_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference","_key":"fe376d98d56e"}],"link":"/view/ims-2024-speakers-look-back-on-exciting-myeloma-updates","source":null,"_type":"article","contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"},"_createdAt":"2024-10-01T16:38:43Z","thumbnail":{"asset":{"extension":"png","uploadId":"WiWdoMEnQ8H8mhrjsn3sbaaLHWnGfMjO","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png","assetId":"2fa4d6766aabad75eb6f160b7ecb099788f2be9d","_createdAt":"2024-10-01T17:08:45Z","_type":"sanity.imageAsset","size":4039572,"mimeType":"image/png","_id":"image-2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250-png","_updatedAt":"2024-10-01T17:08:45Z","originalFilename":"IMS - 2024 Recap.png","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":3750,"aspectRatio":1.6666666666666667,"height":2250},"isOpaque":true,"blurHash":"MCEy[U_4rvVDr_-@R6n4$%s?H=IVnixZM}","_type":"sanity.imageMetadata","palette":{"dominant":{"foreground":"#fff","title":"#fff","population":7.95,"background":"#667ba1","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.24,"background":"#304a5b"},"muted":{"background":"#667ba1","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.95},"lightVibrant":{"foreground":"#000","title":"#fff","population":3.7,"background":"#e8a39d","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0,"background":"#26535e"},"lightMuted":{"background":"#a3b4c7","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":4.73},"vibrant":{"foreground":"#000","title":"#fff","population":0.02,"background":"#6cb2c3","_type":"sanity.imagePaletteSwatch"}}},"_rev":"YVH2fYgeJpexFIow4LOQC6","sha1hash":"2fa4d6766aabad75eb6f160b7ecb099788f2be9d","path":"images/0vv8moc6/ajmc/2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png"}},"is_visible":true,"_rev":"LKAfGsMVtGrsTVLa3APUAH","authorMapping":[{"displayName":"Cameron Santoro","_createdAt":"2023-11-22T18:35:06Z","_type":"author","_updatedAt":"2024-05-20T19:28:22Z","url":{"current":"cameron-santoro","_type":"slug"},"profileImage":{"alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"},"_type":"mainImage"},"firstName":"Cameron","lastName":"Santoro","_rev":"sgy4yN0CjmArmRDnE2KiNm","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","biography":[{"_key":"3da8fced8696","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"marks":["superscript"],"text":"®","_key":"f546acb0aa91","_type":"span"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"text":"AJMC","_key":"843f7d4e787d","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe","_type":"span","marks":[]},{"marks":["superscript"],"text":"®","_key":"8ddca200bc46","_type":"span"},{"text":".","_key":"ba3cca6122e3","_type":"span","marks":[]}],"_type":"block","style":"normal"}]},{"_updatedAt":"2022-11-23T19:49:06Z","firstName":"Ashley","lastName":"Gallagher","displayName":"Ashley Gallagher","_createdAt":"2022-11-23T19:49:06Z","_type":"author","_rev":"52vAUxG62nnEnK65YmG5ja","_id":"930acce9-21e2-4ba4-bd26-97bdfa82bdd7","url":{"current":"ashley-gallagher","_type":"slug"}},{"_rev":"cejbFjqp0SNu6k7v9JvYJx","url":{"_type":"slug","current":"aislinn-antrim"},"firstName":"Aislinn","lastName":"Antrim","displayName":"Aislinn Antrim","_createdAt":"2023-03-16T17:42:50Z","_type":"author","_id":"401d7aa2-c737-425a-8a3e-6a8587b363ef","_updatedAt":"2023-03-16T17:42:50Z"}],"published":"2024-10-01T18:23:24.621Z","documentGroup":{"_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference"},"title":"IMS 2024 Speakers Look Back on Exciting Myeloma Updates","summary":"Speakers at the 2024 International Myeloma Society (IMS) conference share the updates from the myeloma space that they were most excited about this year.","taxonomyMapping":[{"_createdAt":"2020-03-30T19:06:53Z","_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference","_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z","identifier":"conference"},{"_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh"},{"_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_updatedAt":"2022-01-19T10:20:16Z","identifier":"news","_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso","_type":"taxonomy","name":"News"},{"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma"}],"url":{"current":"ims-2024-speakers-look-back-on-exciting-myeloma-updates","_type":"slug"}},{"documentGroupMapping":[{"_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference","_key":"31bdf80a59e5"}],"published":"2024-09-26T21:06:15.917Z","ExcludeFromPubMedXML":false,"_rev":"hNQIYgKOTVo7tcUOb3Te2y","source":null,"factCheckAuthorMapping":null,"link":"/view/evaluating-t-cell-therapies-in-first-line-multiple-myeloma-treatment","updatedOn":null,"taxonomyMapping":[{"_createdAt":"2020-03-30T19:06:53Z","_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference","_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z","identifier":"conference"},{"identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z"},{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z","summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357"}],"url":{"current":"evaluating-t-cell-therapies-in-first-line-multiple-myeloma-treatment","_type":"slug"},"thumbnail":{"asset":{"assetId":"790660959e556ef9c9d3b479bb627446ee9ecc80","originalFilename":"Screenshot 2024-09-23 at 2.24.02 PM.png","extension":"png","uploadId":"Sx7CAsCvpN5rOfk8tPbySDnAMfCtZAXP","_type":"sanity.imageAsset","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png","_rev":"dB2TH3ETy51FRPfE8a93kc","sha1hash":"790660959e556ef9c9d3b479bb627446ee9ecc80","metadata":{"_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#553e2f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.29},"_type":"sanity.imagePalette","darkMuted":{"background":"#553e2f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.29},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.74,"background":"#91817b"},"lightVibrant":{"background":"#dce3f4","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.09},"darkVibrant":{"title":"#fff","population":2.26,"background":"#040514","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":5.27,"background":"#b8c5ce","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"population":0.05,"background":"#3b6a84","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":2864,"aspectRatio":1.7527539779681762,"height":1634},"isOpaque":true,"blurHash":"MtH2ZjNGoIRjMx~qM|ayWBRjofWBafoLkC"},"path":"images/0vv8moc6/ajmc/790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png","_createdAt":"2024-09-25T15:37:16Z","_updatedAt":"2024-09-25T15:37:16Z","size":4623212,"_id":"image-790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634-png"}},"_createdAt":"2024-09-26T15:03:54Z","title":"Evaluating T-Cell Therapies in First-Line Multiple Myeloma Treatment","_id":"85749e24-afc5-4611-b062-69f03d911ded","_updatedAt":"2024-09-26T21:06:26Z","articleType":"Commentary","seoTag":["T-cell therapy","multiple myeloma","IMS"],"is_visible":true,"documentGroup":{"_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference"},"body":[{"_type":"video","caption":"Rahul Banerjee, MD, FACP","videoID":"6362509035112","disableAutoPlayVideo":false,"source":"brightcove","_key":"b3d640f01a05","videoObject":{"videoDescription":"Rahul Banerjee, MD, FACP","_type":"videoDetails","videoTitle":"Rahul Banerjee, MD, FACP.","thumbnail":{"_type":"image","asset":{"_ref":"image-790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634-png","_type":"reference"}},"videoDuration":"PT4M57S"}},{"style":"normal","_key":"23b179bc4e8c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"There are limited randomized data on studies that focus on T-cell–directed therapies in the first-line setting for multiple myeloma. However, the ongoing CARTITUDE-5 and CARTITUDE-6 studies are comparing chimeric antigen receptor (CAR) T-cell therapies with traditional treatments, said Rahul Banerjee, MD, FACP, assistant professor for the Division of Hematology and Oncology at the University of Washington.","_key":"edfcbaf8cf060"}],"_type":"block"},{"children":[{"text":"","_key":"a28672cf3d900","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"2358f285af15","markDefs":[]},{"style":"normal","_key":"504e33b94215","markDefs":[{"_key":"6e454f708090","blank":true,"_type":"link","href":"https://www.ajmc.com/conference/ims"}],"children":[{"_type":"span","marks":[],"text":"Banerjee attended the annual ","_key":"eab5f55bf6680"},{"_type":"span","marks":["6e454f708090"],"text":"International Myeloma Society","_key":"eab5f55bf6681"},{"_type":"span","marks":[],"text":" conference to discuss how to determine the type of T-cell–directed therapies to use for patient populations. Although newer CAR T-cell therapies are expected to be more effective based on less T-cell exhaustion, he expressed concerns regarding infectious complications and the unmet need for specialized centers that are equipped to treat CAR T-cell therapies.","_key":"eab5f55bf6682"}],"_type":"block"},{"_type":"block","style":"normal","_key":"e88b91739c27","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"02e2f039893e"}]},{"children":[{"_type":"span","marks":[],"text":"The ","_key":"83574bfa980b0"},{"_key":"83574bfa980b1","_type":"span","marks":["51836a73e689"],"text":"CARTITUDE-5 study"},{"marks":[],"text":" is comparing the efficacy of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) vs VRd induction followed by lenalidomide and dexamethasone maintenance in newly diagnosed patients with multiple myeloma.","_key":"83574bfa980b2","_type":"span"}],"_type":"block","style":"normal","_key":"cac7b08d0157","markDefs":[{"href":"https://clinicaltrials.gov/study/NCT04923893","_key":"51836a73e689","nofollow":true,"blank":true,"_type":"link"}]},{"markDefs":[],"children":[{"text":"","_key":"c9918a1be4e80","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"dddaf339b189"},{"style":"normal","_key":"3c533929ed22","markDefs":[{"_type":"link","href":"https://clinicaltrials.gov/study/NCT05257083","_key":"6a267c6d9669","nofollow":true,"blank":true}],"children":[{"marks":[],"text":"Banerjee also addressed the ","_key":"774674be57ef0","_type":"span"},{"marks":["6a267c6d9669"],"text":"CARTITUDE-6 study","_key":"774674be57ef1","_type":"span"},{"_key":"774674be57ef2","_type":"span","marks":[],"text":" that is comparing the efficacy of daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) followed by cilta-cel vs DVRd followed by autologous stem cell transplant in newly diagnosed patients with multiple myeloma."}],"_type":"block"},{"style":"normal","_key":"3f74f5cb7312","markDefs":[],"children":[{"_key":"7404ddff69d20","_type":"span","marks":[],"text":""}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"\"Bispecifics are also being explored in the front-line setting. There are several studies that have been looking at this; ","_key":"87a59d2302ff0"},{"_type":"span","marks":["5f0064ee00eb"],"text":"MajesTEC-7","_key":"87a59d2302ff1"},{"_type":"span","marks":[],"text":" comes to mind.\"","_key":"87a59d2302ff2"}],"_type":"block","style":"normal","_key":"b2e64e806882","markDefs":[{"_key":"5f0064ee00eb","nofollow":true,"blank":true,"_type":"link","href":"https://clinicaltrials.gov/study/NCT05552222"}]},{"_type":"block","style":"normal","_key":"0864143ad372","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"39a33d70bbec0"}]},{"_key":"8124e4de41e8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Banerjee explains the purpose of MajesTEC-7 was to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide and talquetamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone.","_key":"059640affc600"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"e49c915ff5ca","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"d9eacc94e100"}]},{"style":"normal","_key":"976b06638dbc","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/abstract","_key":"4c843eeb0f89"}],"children":[{"_type":"span","marks":[],"text":"Additionally, he mentions the ","_key":"b0d684a351620"},{"_type":"span","marks":["4c843eeb0f89"],"text":"MAIA study","_key":"b0d684a351621"},{"_type":"span","marks":[],"text":" as an example where bispecifics were explored in a front-line setting. Banerjee states that although the study results thus far have shown some success, the risk of infections was found to be greater than he would like them to be, and he suggests the safety profiles of the drugs should be examined further.","_key":"b0d684a351622"}],"_type":"block"},{"style":"normal","_key":"82a01628945e","markDefs":[],"children":[{"marks":[],"text":"","_key":"cbce38a7848f0","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"text":"\"Even if tomorrow, teclistamab were to be approved for front-line therapy in any subset of patients, I would hazard a guess that 90% of Americans do not live within 30 minutes of a bispecific-capable center.\"","_key":"13fd846fa6880","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"014401dcbb2a"},{"_key":"583adbff2871","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"7e2abfa289500"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"Banerjee concludes the interview by recognizing the specific outpatient dosing they have access to but how this falls short on a global scale.","_key":"bc8775a279c60","_type":"span"}],"_type":"block","style":"normal","_key":"a9648d4137ad"},{"markDefs":[],"children":[{"_key":"d52f591db5c90","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"0a6f95fabcbf"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"\"I do want to put a very clear note of caution there that we need to look before we leap into this world of BCMA [B-cell maturation antigen] as front-line therapy.\"","_key":"eb63f0ae57bb0"}],"_type":"block","style":"normal","_key":"ffc86c96d22c"}],"contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"summary":"Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, University of Washington, dissects the limited data on T-cell therapies for multiple myeloma, infectious complications, and access to specialized treatment centers. ","_type":"article","authorMapping":[{"_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","biography":[{"_key":"3da8fced8696","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"marks":["superscript"],"text":"®","_key":"f546acb0aa91","_type":"span"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"text":"AJMC","_key":"843f7d4e787d","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe","_type":"span","marks":[]},{"marks":["superscript"],"text":"®","_key":"8ddca200bc46","_type":"span"},{"text":".","_key":"ba3cca6122e3","_type":"span","marks":[]}],"_type":"block","style":"normal"}],"profileImage":{"alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"},"_type":"mainImage"},"firstName":"Cameron","lastName":"Santoro","_rev":"sgy4yN0CjmArmRDnE2KiNm","_updatedAt":"2024-05-20T19:28:22Z","url":{"current":"cameron-santoro","_type":"slug"},"displayName":"Cameron Santoro","_createdAt":"2023-11-22T18:35:06Z","_type":"author"},{"firstName":"Aislinn","lastName":"Antrim","displayName":"Aislinn Antrim","_createdAt":"2023-03-16T17:42:50Z","_type":"author","_id":"401d7aa2-c737-425a-8a3e-6a8587b363ef","_updatedAt":"2023-03-16T17:42:50Z","_rev":"cejbFjqp0SNu6k7v9JvYJx","url":{"_type":"slug","current":"aislinn-antrim"}}]},{"link":"/view/creating-equitable-ai-models-for-multiple-myeloma","contentCategory":{"_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z"},"seoTag":["artificial intelligence","IMS","multiple myeloma","systemic racism"],"is_visible":true,"_rev":"dB2TH3ETy51FRPfE8alLpO","authorMapping":[{"_createdAt":"2023-11-22T18:35:06Z","_type":"author","_updatedAt":"2024-05-20T19:28:22Z","url":{"current":"cameron-santoro","_type":"slug"},"displayName":"Cameron Santoro","lastName":"Santoro","_rev":"sgy4yN0CjmArmRDnE2KiNm","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","biography":[{"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"marks":["superscript"],"text":"®","_key":"f546acb0aa91","_type":"span"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"text":"AJMC","_key":"843f7d4e787d","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe","_type":"span","marks":[]},{"marks":["superscript"],"text":"®","_key":"8ddca200bc46","_type":"span"},{"text":".","_key":"ba3cca6122e3","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"3da8fced8696","markDefs":[]}],"profileImage":{"alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"},"_type":"mainImage"},"firstName":"Cameron"}],"ExcludeFromPubMedXML":false,"_id":"4289c42c-d19c-4624-b1f7-9c80d4dc226b","articleType":"Commentary","source":null,"_updatedAt":"2024-09-25T18:49:58Z","documentGroup":{"_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference"},"title":"Creating Equitable AI Models for Multiple Myeloma","url":{"current":"creating-equitable-ai-models-for-multiple-myeloma","_type":"slug"},"published":"2024-09-26T16:18:00.000Z","_createdAt":"2024-09-25T16:18:16Z","summary":"Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, proposes AI-based solutions to address health care disparities, emphasizing systemic racism and phenotypic variations.","updatedOn":null,"taxonomyMapping":[{"_createdAt":"2020-03-30T19:06:53Z","_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference","_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z","identifier":"conference"},{"_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh"},{"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","summary":[{"_type":"block","style":"normal","_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}]}],"identifier":"multiple-myeloma"}],"_type":"article","thumbnail":{"asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/f1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png","size":2194636,"assetId":"f1df35f419ab459055c6d9a978f09de3f2488375","_type":"sanity.imageAsset","mimeType":"image/png","_rev":"NEmhylHz7zejTih5tt0QTP","_updatedAt":"2024-09-25T16:23:19Z","_createdAt":"2024-09-25T16:23:19Z","uploadId":"Vj9sRqfPxNBexgSmi604SFjrwNjJAWdR","path":"images/0vv8moc6/ajmc/f1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png","sha1hash":"f1df35f419ab459055c6d9a978f09de3f2488375","_id":"image-f1df35f419ab459055c6d9a978f09de3f2488375-2846x1611-png","originalFilename":"Screenshot 2024-09-19 at 11.19.40 AM.png","extension":"png","metadata":{"blurHash":"M=MQ|txu%MoLMx~qRjofofWBs;WBRQj[tQ","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"title":"#000","population":1.53,"background":"#ebfcf0","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"background":"#102122","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.14},"lightMuted":{"background":"#b2c0cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.01},"vibrant":{"background":"#51a8ad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"dominant":{"population":1.53,"background":"#ebfcf0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"_type":"sanity.imagePalette","darkMuted":{"background":"#56362c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"muted":{"title":"#fff","population":0.02,"background":"#9c6459","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAALCAYAAAB/Ca1DAAAACXBIWXMAABYlAAAWJQFJUiTwAAADCElEQVQokS2M3U+bdQCF3z/BG+/0wguNmdONDBdHmFZXhpJusQ0QxwZuFtoSnbCRCiY6/GDTaIcCUQYzLdDSOCdIMhI1MQQHS0Cw20qgDXSMUrq2KS20pR+0b3+Poe4kJyfPSc6RskKQEwL5cWaEIClyxOUUkVSEUHyD8E6AeDZBVsgIIUCIQuYLzv/fPZa0KwR7pzKCHII9zog8STlDeCeMx7/MwuoinkdetpM75PP5wnDvRM7L5ORcodtjIfJIsd0dEtk0ydwuKTlLOp8lLbJspWPML93DcsPKtz3f02sZYOLODMHNCDlZJpfPkcwkiacSJDMp0rtp0pkUkndznY1ogGA8zGYyylZmm3gujjfswz76C81N59GfOUWzTkfHlW/4c3KaSCxGJpshEosSjIaJxreIJWIFS671JZb9KzwMreGLbhBMBIlkIixveBiwWmgzNNBSrablnUqa9Aa6+80sejxsbkfxBvw88K3jCwbwh0L4Q0GkhQdOXF43K/5VHobW8UUfEUiEcfk82OxWWvU6DCdVaFUV1NfU0PH1V0xMT+J0LzB738HU3BxT/8wyNTPL7ZkZpLtuJ84VN4urHpbWVlnyreEO+LjrcWG3DWLUvkdd+XE0itepOXmCT9ouMmTrY3T8JvaxX+m32/jBYqZ/cADzsA3pjsPB9LyD23MOJuf/ZfKegymXk7/vzzE8cJ1Pte9yruwYb5ccofINBfWnNTRfqKet3Yjxy0voPjJS98H7NBpbaP28Henm+Dg3xm4xPPIbQyOjDN0a4+e/fmdk4g/6rvXQdPoUFYdfpnT/fpRHiqkoK6WsvBSlSklZlRqFRo1CrUZVe4ZqfQOS2Wqm96d+OkwmPr58mfbOq5iu99FrHaKzu4uG2lqOHizi0L59vKVUUFWl4tjxV3mh+CWeKTrA8yUlvKbRUGnQo9HVI1kGr3G1y0TjxQucO/8hbV90cKWzC1P3j5i+66FRZ+DooWJeOXgAbV0Nn11qRdtQx4uHi3ji6ad48tnnKC5/kxNnz6KsruI/5/CeMz1dyU0AAAAASUVORK5CYII=","dimensions":{"width":2846,"aspectRatio":1.766604593420236,"height":1611,"_type":"sanity.imageDimensions"},"isOpaque":true}}},"body":[{"disableAutoPlayVideo":false,"source":"brightcove","_key":"f47590081a4e","videoObject":{"_type":"videoDetails","videoTitle":"Anant Madabhushi, PhD","thumbnail":{"asset":{"_ref":"image-f1df35f419ab459055c6d9a978f09de3f2488375-2846x1611-png","_type":"reference"},"_type":"image"},"videoDuration":"PT2M54S","videoDescription":"Anant Madabhushi, PhD"},"_type":"video","caption":"Anant Madabhushi, PhD.","videoID":"6362446486112"},{"children":[{"marks":[],"text":"The ","_key":"a98f93c5e1a40","_type":"span"},{"_type":"span","marks":["59e7bd1c11bc"],"text":"International Myeloma Society","_key":"a98f93c5e1a41"},{"_type":"span","marks":[],"text":"'s 21st annual conference is set to take place in Rio de Janeiro, Brazil, from September 25 to 27. This gathering will bring together leading experts in the field to discuss the latest advancements in myeloma research, covering fundamental, preclinical, and clinical aspects of the disease.\n","_key":"a98f93c5e1a42"}],"_type":"block","style":"normal","_key":"186a6e2b3487","markDefs":[{"_key":"59e7bd1c11bc","nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/conference/ims"}]},{"_type":"block","style":"normal","_key":"53c17d5757f7","markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"15fb77974f47"}],"children":[{"_key":"1108eff9e41c0","_type":"span","marks":[],"text":"Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, proposes using AI to address disparities in "},{"marks":["15fb77974f47"],"text":"multiple myeloma","_key":"f088e1ce541c","_type":"span"},{"_type":"span","marks":[],"text":" care. He argues that systemic racism contributes significantly to these disparities, but there may also be subtle phenotypic differences between populations that can be identified to develop more tailored treatment approaches.","_key":"864dbe5dac2c"}]},{"style":"normal","_key":"b1a9ae95941e","markDefs":[],"children":[{"marks":[],"text":"","_key":"ce9cc94aed4b","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"marks":["em"],"text":"This transcript has been lightly edited for clarity.","_key":"769a338eb5770","_type":"span"}],"_type":"block","style":"normal","_key":"2335b8176cbd"},{"style":"normal","_key":"3f173340cb04","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"d0e7e9787911"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"54bbe7c7b5ac0"}],"_type":"block","style":"normal","_key":"6b46ee6339b3"},{"_type":"block","style":"normal","_key":"27e27c896cae","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c6e67eaa3420"}]},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"How can AI help address disparities in multiple myeloma care and outcomes?","_key":"85210111e6fa0"}],"_type":"block","style":"normal","_key":"2f92b3120dc4"},{"style":"normal","_key":"04f32e0dfea7","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"548faa8a9993"}],"_type":"block"},{"_type":"block","style":"normal","_key":"c28ee0147ae6","markDefs":[],"children":[{"_type":"span","marks":[],"text":"I will react by saying that the issue of disparities in cancer care is well established. We know that there are several different reasons for the disparities that we observe across different populations in the context of cancer care. Let's call out the 800-pound gorilla in the room. A lot of it has been the issue of systemic racism that has caused significant disparities in access and subsequently outcomes for different populations, particularly populations of color. As we look to better understand the disease, and we're seeing this in other cancers and other diseases, that beyond the social determinants of health and beyond the socioeconomic factors and access, we also are starting to acknowledge that there are subtle differences in the phenotype of the disease across different populations. And our work in prostate cancer and endometrial cancer has shown that using technologies like AI, we can start to tease out very subtle differences in the appearance of the disease across different populations. For instance, in prostate cancer and endometrial cancer, our work has revealed that there are cellular-level differences in the pathology images of, say, Black patients and White patients in the context of endometrial cancer and prostate cancer.","_key":"70260210740c0"}]},{"markDefs":[],"children":[{"_key":"0a521e9fdba00","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"0b4194fdb87c"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Again, I will repeat what I initially said. I know very little about multiple myeloma and I'm looking to learn at this particular meeting but I think that there's an opportunity to really use powerful technologies like AI to start to dive into understanding phenotypic differences between populations. I'm not suggesting that there are necessarily differences, but if there are differences, then we need to be cognizant of those differences and try to start accounting for that, potentially in starting to create more tailored AI models.","_key":"98c04f43b1950"}],"_type":"block","style":"normal","_key":"3bfeca32011f"},{"_type":"block","style":"normal","_key":"04db5b94f6da","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"2bd9a88cbc0d0"}]},{"_type":"block","style":"normal","_key":"c5a25d8ecef2","markDefs":[],"children":[{"_type":"span","marks":[],"text":"One of the things that AI has been accused of, quite rightly, is the fact that it is very prone to bias. It is very prone to exacerbating inequity and the only way to really address that is to be intentional about the way we develop the AI. To do that, we have to look at these approaches to try to understand, first and foremost, are there differences in the appearance of the disease across different populations? If there are, let's celebrate those differences and account for those differences in creating a more unbiased, more equitable AI model, or if need be, create a more population specific AI model that is more geared and catered to specific populations.","_key":"b1b28e0174360"}]}],"factCheckAuthorMapping":null},{"documentGroupMapping":[{"_key":"628eef6fd79e","_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference"}],"thumbnail":{"asset":{"_createdAt":"2024-09-25T15:37:16Z","_updatedAt":"2024-09-25T15:37:16Z","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":2864,"aspectRatio":1.7527539779681762,"height":1634},"isOpaque":true,"blurHash":"MtH2ZjNGoIRjMx~qM|ayWBRjofWBafoLkC","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":7.29,"background":"#553e2f","_type":"sanity.imagePaletteSwatch"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.74,"background":"#91817b"},"lightVibrant":{"background":"#dce3f4","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.09},"darkVibrant":{"title":"#fff","population":2.26,"background":"#040514","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":5.27,"background":"#b8c5ce","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#3b6a84","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.05},"dominant":{"title":"#fff","population":7.29,"background":"#553e2f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true},"path":"images/0vv8moc6/ajmc/790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png","size":4623212,"_id":"image-790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634-png","_type":"sanity.imageAsset","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png","assetId":"790660959e556ef9c9d3b479bb627446ee9ecc80","originalFilename":"Screenshot 2024-09-23 at 2.24.02 PM.png","extension":"png","uploadId":"Sx7CAsCvpN5rOfk8tPbySDnAMfCtZAXP","_rev":"dB2TH3ETy51FRPfE8a93kc","sha1hash":"790660959e556ef9c9d3b479bb627446ee9ecc80"}},"articleType":"Commentary","link":"/view/mrd-as-a-new-paradigm-in-myeloma-treatment","source":null,"documentGroup":{"_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference"},"_createdAt":"2024-09-25T15:34:44Z","published":"2024-09-26T15:15:00.000Z","url":{"current":"mrd-as-a-new-paradigm-in-myeloma-treatment","_type":"slug"},"_updatedAt":"2024-10-15T17:45:53Z","is_visible":true,"_type":"article","title":"MRD as a New Paradigm in Myeloma Treatment","seoTag":["minimal residual disease","MRD"],"taxonomyMapping":[{"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3},{"_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference","_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z","identifier":"conference","_createdAt":"2020-03-30T19:06:53Z"},{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z","summary":[{"_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}],"_type":"block","style":"normal"}],"identifier":"multiple-myeloma","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357"}],"updatedOn":null,"authorMapping":[{"_rev":"sgy4yN0CjmArmRDnE2KiNm","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","biography":[{"_key":"3da8fced8696","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"marks":["superscript"],"text":"®","_key":"f546acb0aa91","_type":"span"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"text":"AJMC","_key":"843f7d4e787d","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe","_type":"span","marks":[]},{"marks":["superscript"],"text":"®","_key":"8ddca200bc46","_type":"span"},{"text":".","_key":"ba3cca6122e3","_type":"span","marks":[]}],"_type":"block","style":"normal"}],"profileImage":{"alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"},"_type":"mainImage"},"firstName":"Cameron","lastName":"Santoro","_type":"author","_updatedAt":"2024-05-20T19:28:22Z","url":{"current":"cameron-santoro","_type":"slug"},"displayName":"Cameron Santoro","_createdAt":"2023-11-22T18:35:06Z"},{"lastName":"Antrim","displayName":"Aislinn Antrim","_createdAt":"2023-03-16T17:42:50Z","_type":"author","_id":"401d7aa2-c737-425a-8a3e-6a8587b363ef","_updatedAt":"2023-03-16T17:42:50Z","firstName":"Aislinn","url":{"_type":"slug","current":"aislinn-antrim"},"_rev":"cejbFjqp0SNu6k7v9JvYJx"}],"contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"_rev":"KLVqzQL7KTVccOrMxooy3I","ExcludeFromPubMedXML":false,"summary":"Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual patient management, including decisions about continuing or stopping treatment.","_id":"1567f56f-402c-4bec-948a-04322f7c1d31","factCheckAuthorMapping":null,"body":[{"videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634-png","_type":"reference"}},"videoDuration":"PT6M09S","videoDescription":"Rahul Banerjee, MD, FACP","_type":"videoDetails","videoTitle":"Rahul Banerjee, MD, FACP"},"_type":"video","caption":"Rahul Banerjee, MD, FACP","videoID":"6362443723112","disableAutoPlayVideo":false,"source":"brightcove","_key":"c1a7c059f145"},{"children":[{"_type":"span","marks":[],"text":"Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, discussed the use of minimal residual disease (MRD) assessment in multiple myeloma. Banerjee went on to explain how MRD can be applied to guide treatment decisions and monitor response to therapy.\n","_key":"1273c5e7251f"}],"_type":"block","style":"normal","_key":"6e39a1b7b7d8","markDefs":[]},{"style":"normal","_key":"4b544b81ccd4","markDefs":[{"blank":true,"_type":"link","href":"https://www.myelomasociety.org/events/21st-ims-annual-meeting/","_key":"0e6f89a04ca2","nofollow":true}],"children":[{"marks":[],"text":"He is speaking at the 21st annual ","_key":"12c00a61bf8d0","_type":"span"},{"_type":"span","marks":["0e6f89a04ca2"],"text":"International Myeloma Society","_key":"12c00a61bf8d1"},{"_type":"span","marks":[],"text":" conference, being held in Rio de Janeiro, Brazil, September 25-27. The event will feature leading experts discussing the basic, preclinical, and clinical aspects of myeloma. ","_key":"a07acbecbbbe"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"386447259e9a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"4a87c97f9a02"},{"_type":"span","marks":[],"text":" spoke to him ahead of the IMS meeting.\n","_key":"c215ccbe12de"}],"_type":"block"},{"children":[{"_key":"10b9cb1106c70","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"473224fa551f","markDefs":[]},{"style":"normal","_key":"8910aee89676","markDefs":[],"children":[{"text":"This transcript has been lightly edited for clarity.","_key":"b1873f815b3c0","_type":"span","marks":["em"]}],"_type":"block"},{"style":"normal","_key":"fa675e4aea00","markDefs":[],"children":[{"text":"","_key":"ef4aee0a2750","_type":"span","marks":[]}],"_type":"block"},{"markDefs":[],"children":[{"_key":"30888a7799c70","_type":"span","marks":["strong","underline"],"text":"Transcript"}],"_type":"block","style":"normal","_key":"a64f54c70608"},{"_type":"block","style":"normal","_key":"58a46c3847b8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"9b6415a2ed40"}]},{"children":[{"_type":"span","marks":["strong"],"text":"How is MRD assessment being used to guide treatment decisions and monitor response in multiple myeloma? What are the implications of MRD negativity for long-term outcomes?","_key":"eaa69ebb97900"}],"_type":"block","style":"normal","_key":"0f629f1216b3","markDefs":[]},{"children":[{"text":"Banerjee:","_key":"c1513af828290","_type":"span","marks":["strong"]},{"_type":"span","marks":[],"text":" I would separate this question by clinical trials vs individual patients sitting in front of me. For clinical trials, we all were very excited earlier this year when the FDA approved, or at least gave its endorsement at an ODAC [Oncologic Drugs Advisory Committee] meeting to MRD being a primary end point for studies.","_key":"c1513af828291"},{"_type":"span","marks":["superscript"],"text":"1 ","_key":"1bfd5575b68c"},{"_type":"span","marks":[],"text":"To familiarize the audience, the idea behind MRD is that it basically gives us the best tools in 2024 to look for any residual myeloma cells hiding behind, not [just] myeloma cells, even MGUS [monoclonal gammopathy of undetermined significance]–like cells, anything that's clonally abnormal, lurking underneath the scenes here.","_key":"3c0cd8304f7e"}],"_type":"block","style":"normal","_key":"32a884464755","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"One of the tests, the next-generation sequencing test [or] the clonality assay, can pick up 1 in a million cells, typically even more than that, if you have more than a million cells that are collected from the bone marrow, from the first pill aspirate. This is wonderful.","_key":"5895f7fb50920"}],"_type":"block","style":"normal","_key":"d112283ed200"},{"style":"normal","_key":"8139b2aca138","markDefs":[],"children":[{"_type":"span","marks":[],"text":"MRD negativity is amazing as an end point for trials because it reads out very quickly. With CAR [chimeric antigen receptor] T therapy, you're often able to see pretty quickly, within 28 days, that some patients who are going to do well are the ones who are MRD negative. A good example is the BENEFIT study that was presented at the American Society of Clinical Oncology [annual meeting] and recently published in ","_key":"ea1527b128f80"},{"_type":"span","marks":["em"],"text":"Nature Medicine","_key":"ea1527b128f81"},{"_type":"span","marks":[],"text":".","_key":"ea1527b128f82"},{"_type":"span","marks":["superscript"],"text":"2 ","_key":"b66f519f0980"},{"_type":"span","marks":[],"text":"That was looking, for example, at Isa-VRd [isatuximab plus the triplet bortezomib, lenalidomide, and dexamethasone] vs Isa-Rd in newly diagnosed patients.","_key":"b7b6c644a15d"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The primary end point there was MRD negativity at 18 months and it worked. Isa-VRd [isatuximab plus bortezomib, lenalidomide, and dexamethasone] beat Isa-Rd [isatuximab plus lenalidomide and dexamethasone]. It's worth noting that that was actually, I would argue, pretty practice changing for me because I had no doubt that Isa-VRd would beat VRd. Actually, the CEPHEUS study being presented at IMS will show that Dara-VRd was up from VRd in transplant-ineligible patients.","_key":"44ac7f64d3fc0"},{"_type":"span","marks":["superscript"],"text":"3","_key":"49c8b8e18543"}],"_type":"block","style":"normal","_key":"9024dc0b9405"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The question would be for transplant-ineligible patients, we typically use the MAIA regimen,","_key":"7c258599b02e0"},{"_type":"span","marks":["superscript"],"text":"4","_key":"35452435fd99"},{"_type":"span","marks":[],"text":" which is dara-Rd [daratumumab plus lenalidomide and dexamethasone] or a CD38 plus [lenalidomide] plus [dexamethasone], \"does adding bortezomib once a week add on to that?\" Here, they actually found a substantial 18-month benefit and MRD negativity. Interestingly, if you look even at 12 months, there was a significant difference between the curve. Even at the 12-month mark, you're able to see that we're using MRD negativity, that there's a difference between these 2 [regimens]. Isa-VRd is better than Isa-Rd and that's been changing my management. Right now, I'm considering quadruplets for maybe some more of my patients that might have been more borderline for transplant eligibility vs not.","_key":"434322bcc6be"}],"_type":"block","style":"normal","_key":"ed17c90668cb"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"If we had to wait for PFS [progression-free survival], that would have taken 4 to 5 years. The MAIA regimen, like Dara-Rd, or in this case, Isa-Rd, works very well. Medium PFS would have easily been 5 years, so MRD is great from that perspective, I'm so happy to see the FDA gave us blessing to [use] MRD as an end point here.","_key":"4b66568ac6830"}],"_type":"block","style":"normal","_key":"71f9a5d5e147"},{"style":"normal","_key":"6cca8acae872","markDefs":[],"children":[{"_type":"span","marks":[],"text":"For the individual patient sitting in front of me, if they achieve MRD negativity, great, because that means that we can't even see 1 in a million cells left behind. Does that mean they're cured? Probably not, because even patients who achieve MRD negativity after CAR T, for example, I've had many who then go on to relapse years and years later.","_key":"7a82346f210c0"}],"_type":"block"},{"markDefs":[],"children":[{"text":"The tricky part is if someone is MRD positive, it doesn't necessarily mean that the myeloma is about to come back. There are studies showing that, for example...25% of patients who have MRD resurgence, where their bone marrow goes from negative to positive low level MRD, never had a relapse, despite living for years and years thereafter.","_key":"bdf085484c1a0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"ecc38a915392"},{"style":"normal","_key":"5791b70c9baa","markDefs":[],"children":[{"_type":"span","marks":[],"text":"I've had one patient who is now 9 years after transplant, still on maintenance, doing great, I checked MRD and she's still MRD positive. How is that possible? MRD will just tell you that the cells are abnormal, not that they're cancerous. There's this idea of an MGUS-like phenotype, MGUS is the pre-cancer condition, monoclonal gammopathy of undetermined significance, where you have the precancerous cells producing a protein. I can't say that these patients have MGUS, because MGUS is precancer and they're post-cancer, but it's MGUS-like. Just because these cells are there doesn't mean that they know how to cause kidney damage by cast nephropathy, doesn't mean that they know how to chew holes into the bones, etc.","_key":"fd6e634ee5b10"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"MRD positivity is not a death sentence by any means. Unfortunately, in the field I feel we've hyped it a lot. There was a nice British study last year showing that they actually interviewed patients before and after their bone marrow biopsy, and the patients who were MRD positive were so disappointed. Honestly, that's on us as a field that we've hyped MRD negativity too much for individual patients.","_key":"6b8f62597abb0"}],"_type":"block","style":"normal","_key":"30de5598cf30"},{"style":"normal","_key":"8c73f7816853","markDefs":[],"children":[{"_type":"span","marks":[],"text":"I make it very clear for patients for MRD assessments that it's great to see if it's MRD negative, wonderful, if it's MRD positive, I'm not going to escalate your treatment, I'm not going to freak out, I'm not going to do anything differently. We don't know what to do differently for these patients. For MRD-positive patients, I would never escalate therapy or try to force them to become MRD negative, because we don't know that that will make them live better or live longer.","_key":"079d2f2c11ed0"}],"_type":"block"},{"style":"normal","_key":"8141313d589f","markDefs":[],"children":[{"marks":[],"text":"For patients who are MRD negative, if they have sustained MRD negativity on more than one check, they've been MRD negative twice, [if] MRI is negative, those are patients where I may talk about stopping maintenance therapy entirely in the frontline setting. To be clear, if someone's having toxicities from frontline maintenance, like from lenalidomide, or financial toxicity, you should address that earlier or change therapies or try something different. Don't wait for MRD negativity if someone's having toxicities but the absence of that, I do think it's reasonable, based on the data from the master study showing that in the absence of 2 or more higher cytogenetics, for the patients who had 0 or 0 to 1 high-risk cytogenetic features, discontinuation of all therapy if they achieve sustained MRD negativity at 10-5 worked for those patients is great to see.","_key":"8a74c08c0aa70","_type":"span"}],"_type":"block"},{"_type":"block","style":"normal","_key":"e1cd24a200ee","markDefs":[],"children":[{"marks":[],"text":"The study alluded to earlier looking at daratumumab plus lenalidomide vs lenalidomide maintenance after transplant, had the second randomization, where of patients who achieve sustained MRD negativity after 2 years, do we continue all treatment, or do we stop all treatment?","_key":"571282d101210","_type":"span"}]},{"children":[{"_type":"span","marks":[],"text":"That would be really interesting. That is the kind of data that I'm really looking for, randomized data, not of MRD as an end point, but of MRD as a middle point of basically helping us decide what to do. Should we continue therapy or stop there for some MRD negative? That I think will be really interesting to see.","_key":"0248a73ea4310"}],"_type":"block","style":"normal","_key":"c4b6b9ee56dc","markDefs":[]},{"markDefs":[],"children":[{"marks":["strong"],"text":"References","_key":"e0aeab60c0bc0","_type":"span"}],"_type":"block","style":"normal","_key":"7ac70d9afe7a"},{"style":"normal","_key":"ca254d855587","listItem":"number","markDefs":[{"_type":"link","href":"https://www.onclive.com/view/fda-s-odac-recognizes-mrd-as-an-accepted-end-point-for-accelerated-approval-in-multiple-myeloma","_key":"7f704111b286"}],"children":[{"_type":"span","marks":[],"text":"Seymour C. FDA’s ODAC recognizes MRD as an accepted end point for accelerated approval in multiple myeloma. OncLive. April 12, 2024. Accessed October 15, 2024. ","_key":"5f4089e027c40"},{"_type":"span","marks":["7f704111b286"],"text":"https://www.onclive.com/view/fda-s-odac-recognizes-mrd-as-an-accepted-end-point-for-accelerated-approval-in-multiple-myeloma","_key":"5f4089e027c41"}],"level":1,"_type":"block"},{"markDefs":[],"children":[{"marks":[],"text":"Leleu X, Hulin C, Lambert J, et al Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. ","_key":"ff8aff3eb2b80","_type":"span"},{"text":"Nat Med.","_key":"ff8aff3eb2b81","_type":"span","marks":["em"]},{"marks":[],"text":" 2024;30(8):2235-2241. doi: 10.1038/s41591-024-03050-2.","_key":"ff8aff3eb2b82","_type":"span"}],"level":1,"_type":"block","style":"normal","_key":"5aa534bd3424","listItem":"number"},{"level":1,"_type":"block","style":"normal","_key":"e06bb688d3c3","listItem":"number","markDefs":[],"children":[{"_key":"a001af32d6440","_type":"span","marks":[],"text":"Usmani S. Daratumumab + bortezomib/lenalidomide/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: Results of the phase 3 CEPHEUS study. Presented at: International Myeloma Society 21st Annual Meeting \u0026 Exposition; Rio de Janiero, Brazil; September 25-28, 2024. Abstract OA – 63."}]},{"style":"normal","_key":"3e659ab91b3e","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Facon T, Kumar S, Plesner T, Orlowski R, et al. for the MAIA trial investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. ","_key":"6ade04a79e450"},{"_type":"span","marks":["em"],"text":"N Engl J Med.","_key":"6ade04a79e451"},{"text":" 2019;380(22):2104-2115. DOI: 10.1056/NEJMoa1817249","_key":"6ade04a79e452","_type":"span","marks":[]}],"level":1,"_type":"block"}]},{"_id":"74459e26-49c4-433f-b31c-0721073ae54f","articleType":"Commentary","thumbnail":{"asset":{"uploadId":"Kpfoi3MttLEtflwxr9X5aKzYOKFJSH9O","path":"images/0vv8moc6/ajmc/cda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg","assetId":"cda4a66773ecad35c99e0b776bda873d8dda6f50","originalFilename":"Leland Metheny TN.jpg","extension":"jpg","_type":"sanity.imageAsset","mimeType":"image/jpeg","size":113181,"_id":"image-cda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675-jpg","metadata":{"blurHash":"MGED9pIu00xV~qVBRjyFtQD@NjxuWFM|$t","_type":"sanity.imageMetadata","palette":{"vibrant":{"background":"#226cce","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.94},"dominant":{"foreground":"#fff","title":"#fff","population":5.94,"background":"#226cce","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"population":5.21,"background":"#474a38","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"title":"#fff","population":5,"background":"#979773","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.81,"background":"#a0c2e0"},"darkVibrant":{"population":0.02,"background":"#0f4cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#b8b7d1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.46}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.7777777777777777,"height":675},"isOpaque":true},"_rev":"VQouENO9NzBZ2PdWUKsDTq","_createdAt":"2024-08-23T14:45:13Z","_updatedAt":"2024-08-23T14:45:13Z","sha1hash":"cda4a66773ecad35c99e0b776bda873d8dda6f50","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/cda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675.jpg"}},"url":{"current":"new-car-t-trial-in-mm-aims-for-triple-receptor-targeting","_type":"slug"},"summary":"Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) that targets 3 receptors on cancer cells and uses electroporation vs the typical lentiviral vector delivery. ","_rev":"VQouENO9NzBZ2PdWUL0oU2","authorMapping":[{"displayName":"Maggie L. Shaw","_id":"author_51b2956e2bd42e0d6e35a66971fd60bc","biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.","_key":"abc0e18a29ce0"}],"_type":"block","style":"normal","_key":"643be033259e"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/","_key":"159c764717fb","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_type":"span","marks":[],"text":".","_key":"abc0e18a29ce2"}],"_type":"block","style":"normal","_key":"f4070c315fab"}],"_updatedAt":"2024-08-07T15:47:36Z","url":{"current":"maggie-l-shaw","_type":"slug"},"_createdAt":"2020-05-05T10:50:09Z","_rev":"4vyIlJfwMwqB8NbLEufdwW","_type":"author","profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}}}],"ExcludeFromPubMedXML":false,"_type":"article","published":"2024-08-24T14:00:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"taxonomyMapping":[{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","summary":[{"style":"normal","_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}],"_type":"block"}],"identifier":"multiple-myeloma","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma"},{"_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso","_type":"taxonomy","name":"News","_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_updatedAt":"2022-01-19T10:20:16Z","identifier":"news"},{"_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews"},{"_createdAt":"2020-05-04T23:46:13Z","_rev":"GQ2iWOdzjKwgYpKUFVt5oL","_type":"taxonomy","name":"Technology","_id":"topic_technology","_updatedAt":"2020-07-30T14:47:46Z","identifier":"technology","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"}},{"_type":"taxonomy","name":"Health Care Delivery","_id":"topic_healthcare-delivery","_updatedAt":"2022-11-29T18:34:57Z","identifier":"healthcare-delivery","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"52vAUxG62nnEnK65ZDo5dG"},{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2020-04-14T15:02:13Z","_rev":"GeM6ny2T6Y1Qp0cm9jBxeg","_type":"taxonomy","name":"Hematology","_id":"compendium_hematology","_updatedAt":"2020-07-30T14:48:10Z","identifier":"hematology"}],"body":[{"caption":"Leland Metheny, MD, University Hospitals Seidman Cancer Center ","videoID":"6360884167112","disableAutoPlayVideo":false,"source":"brightcove","_key":"d6518178a3fe","videoObject":{"videoTitle":"New CAR T Trial in MM Aims for Triple Receptor Targeting","thumbnail":{"_type":"image","asset":{"_ref":"image-cda4a66773ecad35c99e0b776bda873d8dda6f50-1200x675-jpg","_type":"reference"}},"videoDuration":"PT2M40S","videoDescription":"Interview with Leland Metheny, MD","_type":"videoDetails"},"_type":"video"},{"children":[{"_type":"span","marks":[],"text":"The phase 1 BAFF CAR T clinical trial is investigating a new way to deliver chimeric antigen receptor (CAR) T-cell therapy to its intended targets on 2 fronts: by targeting 3 cell receptors—BAFF receptors, B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI)—vs the typical single receptor (CD19) and using electroporation instead of lentiviral vector delivery. ","_key":"a8cabfa46b070"},{"_key":"a8cabfa46b071","_type":"span","marks":["em"],"text":"The American Journal of Managed Care® "},{"_type":"span","marks":[],"text":"spoke with lead investigator Leland Metheny, MD, about the trial goals and how targeting 3 receptors compared with 1 receptor works.","_key":"a8cabfa46b072"}],"_type":"block","style":"normal","_key":"53f21349bd44","markDefs":[]},{"_key":"012c7e443c87","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"1840f6256cd40"}],"_type":"block","style":"normal"},{"style":"normal","_key":"e952d6427d6b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Metheny is a hematologist-oncologist at University Hospitals Seidman Cancer Center and assistant professor of medicine at Case Western Reserve University School of Medicine in Cleveland, Ohio.","_key":"d797cd78412d0"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e08b04bbb46e0"}],"_type":"block","style":"normal","_key":"05f3d09fa973"},{"_key":"5b4ca0af8621","markDefs":[],"children":[{"text":"Transcript","_key":"398b573f746d0","_type":"span","marks":["strong","underline"]}],"_type":"block","style":"normal"},{"_key":"1888af2d708b","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"What are your primary and secondary outcomes of interest in the BAFF CAR T clinical trial?","_key":"931dc48333110"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"3d8ec22fc985","markDefs":[],"children":[{"_key":"3460bf03f2610","_type":"span","marks":[],"text":""}]},{"children":[{"_type":"span","marks":[],"text":"The BAFF CAR T phase 1 clinical trial, of course, is a phase 1 trial. We're looking at safety, that's the primary outcome. In addition to that, we want to look at effectivity and the length of effectivity, meaning how long can we affect a progression-free survival in patients with multiple myeloma. And there are some correlative outcomes that we are looking at: integration of the DNA, persistence of the CAR T cells in patients, and immune-kind of end points, focusing on how long people are immunosuppressed and things like that.","_key":"f19bad2c58470"}],"_type":"block","style":"normal","_key":"072a09c801c4","markDefs":[]},{"style":"normal","_key":"6ceca6880295","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"13696926069f0"}],"_type":"block"},{"markDefs":[],"children":[{"_key":"aa9887e8073f0","_type":"span","marks":["strong"],"text":"Can you explain how your triple target approach works?"}],"_type":"block","style":"normal","_key":"7f9c6602b795"},{"markDefs":[],"children":[{"_key":"3039cd5658e40","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"b03ab975c7bd"},{"_key":"e001361f100a","markDefs":[],"children":[{"_key":"e8c4f67eef340","_type":"span","marks":[],"text":"This CAR T cell is targeting 3 receptors on mature B cells and plasma cells. The typical CAR T cell will recognize 1. One of the most common is CD19, and that's used for the treatment of certain lymphomas. Another receptor that's being used in multiple myeloma is BCMA; that's a target for many CAR T cells for multiple myeloma."}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"","_key":"dfe7bc78720e0"}],"_type":"block","style":"normal","_key":"eabe158833ed","markDefs":[]},{"style":"normal","_key":"ee83262dbcaa","markDefs":[],"children":[{"_key":"4e8a41e78a4c0","_type":"span","marks":[],"text":"This target is a ligand-based target, meaning there are receptors on the cell surface that attach to ligands, and this CAR T cell acts as kind of a fake ligand and will attach to 3 receptors on cell surfaces. One is the BAFF receptor, one is BCMA, and one is TACI. The benefit of being able to recognize and attach and then, therefore, attack the cells that have those receptors is that it's much harder for a cancer cell that has those 3 receptors—like certain types of lymphomas and myeloma—to downregulate all 3 receptors rather than just one. And so, the immune escape is less likely to occur in that setting."}],"_type":"block"},{"_type":"block","style":"normal","_key":"b294b92b0606","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"b5d3723be2c10"}]}],"is_visible":true,"_createdAt":"2024-08-23T14:42:22Z","_updatedAt":"2024-08-23T16:16:18Z","seoTag":["multiple myeloma","BAFF receptors","BAFF CAR T clinical trial","University Hospitals Seidman Cancer Center ","triple receptor"],"source":null,"title":"New CAR T Trial in MM Aims for Triple Receptor Targeting","link":"/view/new-car-t-trial-in-mm-aims-for-triple-receptor-targeting","updatedOn":null,"factCheckAuthorMapping":null},{"_updatedAt":"2024-07-29T19:25:29Z","documentGroupMapping":[{"_ref":"f98d1039-9d7f-4219-b2f8-ef9a8614f50e","_type":"reference","_key":"778239ea670d"}],"is_visible":true,"source":null,"factCheckAuthorMapping":null,"thumbnail":{"asset":{"_rev":"bx9Hsg5wWMZGjFDaxJSgX9","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/f6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png","originalFilename":"mikhael.png","extension":"png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":false,"blurHash":"M5BgMYt001MH4#00=?.ANM?a0bIT}j%#Xh","_type":"sanity.imageMetadata","palette":{"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.35,"background":"#8f725b"},"lightVibrant":{"background":"#80c1f9","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0},"darkVibrant":{"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.71},"lightMuted":{"background":"#bac7d8","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.38},"vibrant":{"background":"#07599e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08},"dominant":{"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.71},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.09,"background":"#54303b","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true},"uploadId":"d7RewzmClhIZc8yTBV6JGp0LahW5mHCb","size":1585529,"_updatedAt":"2024-06-21T02:34:07Z","mimeType":"image/png","sha1hash":"f6b179d9974841eb0d393e097d87babad52e750c","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/f6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png","assetId":"f6b179d9974841eb0d393e097d87babad52e750c","_createdAt":"2024-06-21T02:34:07Z","_id":"image-f6b179d9974841eb0d393e097d87babad52e750c-1920x1080-png"}},"url":{"current":"beyond-eha-2024-promising-research-in-multiple-myeloma-to-watch","_type":"slug"},"updatedOn":null,"authorMapping":[{"lastName":"Mikhael","displayName":"Joseph Mikhael, MD","_rev":"yjGvHZtBnx3s6VRZ8ZWyfW","url":{"current":"joseph-mikhael-md","_type":"slug"},"firstName":"Joseph","_createdAt":"2021-11-01T13:42:06Z","_type":"author","_id":"f613206f-fc1a-4862-bba3-caf042bd5117","_updatedAt":"2021-11-01T13:42:06Z"}],"taxonomyMapping":[{"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"identifier":"multiple-myeloma","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","summary":[{"_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}],"_type":"block","style":"normal"}]},{"_updatedAt":"2021-05-14T15:31:15Z","identifier":"post-conference-perspectives","_createdAt":"2020-03-30T20:09:58Z","sortOrder":4,"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy","name":"Post Conference Perspectives","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e"}],"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"articleType":"Opinion","seoTag":["multiple myeloma","MM","early relapse multiple myeloma","early relapse MM","EHA 2024","EHA","early relapse multiple myeloma treatment","early relapse MM treatment","MM treatment","multiple myeloma treatment"],"title":"Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch","link":"/view/beyond-eha-2024-promising-research-in-multiple-myeloma-to-watch","summary":"Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues. ","ExcludeFromPubMedXML":false,"_type":"article","showSocialShare":true,"published":"2024-07-29T19:24:42.699Z","body":[{"videoObject":{"videoDescription":"Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch","_type":"videoDetails","videoTitle":"Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch","thumbnail":{"_type":"image","asset":{"_ref":"image-f6b179d9974841eb0d393e097d87babad52e750c-1920x1080-png","_type":"reference"}},"videoDuration":"PT3M40S"},"_type":"video","videoID":"6357252091112","disableAutoPlayVideo":false,"source":"brightcove","_key":"223ccc422443"},{"_key":"bdf3e2d9547e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"94d4573a6d19"}],"_type":"block","style":"normal"},{"children":[{"_key":"826bd019ca97","_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question:"}],"_type":"block","style":"normal","_key":"b5704dc12e01","markDefs":[]},{"level":1,"_type":"block","style":"normal","_key":"e625256dce8d","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Please discuss any other data in multiple myeloma released at EHA 2024 that you find noteworthy to share with colleagues.","_key":"3600e976b0df0"}]},{"children":[{"marks":[],"text":"Outside of EHA 2024 what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?","_key":"6797ca63e0530","_type":"span"}],"level":1,"_type":"block","style":"normal","_key":"624d6ca694c4","listItem":"bullet","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"What can we look forward to through the end of the year and beyond?","_key":"bcd686c761af"}],"level":1,"_type":"block","style":"normal","_key":"138a4798042b","listItem":"bullet"}],"documentGroup":{"_ref":"f98d1039-9d7f-4219-b2f8-ef9a8614f50e","_type":"reference"},"_rev":"4bzlbtE25UledjYM2GPKyW","_createdAt":"2024-07-29T19:23:17Z","_id":"e5455d3c-ce5a-4576-a483-049f0e26bf54"},{"factCheckAuthorMapping":null,"thumbnail":{"asset":{"_createdAt":"2024-06-21T02:34:07Z","_id":"image-f6b179d9974841eb0d393e097d87babad52e750c-1920x1080-png","mimeType":"image/png","sha1hash":"f6b179d9974841eb0d393e097d87babad52e750c","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/f6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png","assetId":"f6b179d9974841eb0d393e097d87babad52e750c","_rev":"bx9Hsg5wWMZGjFDaxJSgX9","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/f6b179d9974841eb0d393e097d87babad52e750c-1920x1080.png","originalFilename":"mikhael.png","_updatedAt":"2024-06-21T02:34:07Z","extension":"png","metadata":{"palette":{"darkMuted":{"background":"#54303b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"muted":{"population":2.35,"background":"#8f725b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"foreground":"#000","title":"#fff","population":0,"background":"#80c1f9","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.71},"lightMuted":{"background":"#bac7d8","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.38},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08,"background":"#07599e"},"dominant":{"population":9.71,"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":false,"blurHash":"M5BgMYt001MH4#00=?.ANM?a0bIT}j%#Xh","_type":"sanity.imageMetadata"},"uploadId":"d7RewzmClhIZc8yTBV6JGp0LahW5mHCb","size":1585529}},"ExcludeFromPubMedXML":false,"summary":"Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.","authorMapping":[{"firstName":"Joseph","_createdAt":"2021-11-01T13:42:06Z","_type":"author","_id":"f613206f-fc1a-4862-bba3-caf042bd5117","_updatedAt":"2021-11-01T13:42:06Z","url":{"current":"joseph-mikhael-md","_type":"slug"},"lastName":"Mikhael","displayName":"Joseph Mikhael, MD","_rev":"yjGvHZtBnx3s6VRZ8ZWyfW"}],"documentGroup":{"_ref":"f98d1039-9d7f-4219-b2f8-ef9a8614f50e","_type":"reference"},"link":"/view/eha-2024-highlights-overcoming-challenges-with-bispecific-antibodies-in-rrmm","title":"EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM","is_visible":true,"articleType":"Opinion","_id":"47324d89-2f76-485e-b04f-c488d6239070","url":{"current":"eha-2024-highlights-overcoming-challenges-with-bispecific-antibodies-in-rrmm","_type":"slug"},"_createdAt":"2024-07-25T13:09:11Z","updatedOn":null,"taxonomyMapping":[{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z","summary":[{"style":"normal","_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}],"_type":"block"}],"identifier":"multiple-myeloma","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357"},{"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy","name":"Post Conference Perspectives","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e","_updatedAt":"2021-05-14T15:31:15Z","identifier":"post-conference-perspectives","_createdAt":"2020-03-30T20:09:58Z","sortOrder":4}],"published":"2024-07-24T19:38:00.000Z","seoTag":["multiple myeloma","MM","early relapse multiple myeloma","early relapse MM","EHA 2024","EHA","early relapse multiple myeloma treatment","early relapse MM treatment","MM treatment","multiple myeloma treatment"],"contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"_updatedAt":"2024-07-25T13:15:21Z","body":[{"source":"brightcove","_key":"223ccc422443","videoObject":{"_type":"videoDetails","videoTitle":"EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM","thumbnail":{"asset":{"_ref":"image-f6b179d9974841eb0d393e097d87babad52e750c-1920x1080-png","_type":"reference"},"_type":"image"},"videoDuration":"PT6M20S","videoDescription":"EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM"},"_type":"video","videoID":"6357250808112","disableAutoPlayVideo":false},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"94d4573a6d19"}],"_type":"block","style":"normal","_key":"bdf3e2d9547e"},{"_key":"b5704dc12e01","markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question:","_key":"826bd019ca97"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Results from the phase 1/2 MonumenTAL-1 study and phase 1B MonumenTAL-2 study were also presented at EHA 2024. How do the results from these two trials contribute to the evolving role of talquetamab in multiple myeloma?","_key":"2e1753cb5d330"}],"level":1,"_type":"block","style":"normal","_key":"3524647b158e","listItem":"number"},{"_type":"block","style":"normal","_key":"f18a751faefd","listItem":"number","markDefs":[],"children":[{"_key":"cb98d94a15a20","_type":"span","marks":[],"text":"What is the value of long-term follow-up data in multiple myeloma? How does this impact use of treatment regimens?"}],"level":1},{"_type":"block","style":"normal","_key":"67da1787a1ad","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What challenges must be considered and overcome with bispecific antibody-containing regimens in RRMM?","_key":"d7ccb5bbf0b20"}],"level":1}],"source":null,"_rev":"hS25uTmEvsaaDM5BOrHHhU","showSocialShare":true,"_type":"article","documentGroupMapping":[{"_ref":"f98d1039-9d7f-4219-b2f8-ef9a8614f50e","_type":"reference","_key":"778239ea670d"}]},{"taxonomyMapping":[{"_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","summary":[{"_type":"block","style":"normal","_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}]}],"identifier":"multiple-myeloma","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_updatedAt":"2023-11-03T18:19:22Z"},{"identifier":"post-conference-perspectives","_createdAt":"2020-03-30T20:09:58Z","sortOrder":4,"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy","name":"Post Conference Perspectives","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e","_updatedAt":"2021-05-14T15:31:15Z"}],"_rev":"AGf4LvcO2r7q1La1cnvlOD","contentCategory":{"_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z"},"_id":"76114ccc-3f02-4773-b000-caec83d4936e","body":[{"_type":"video","videoID":"6355437591112","disableAutoPlayVideo":false,"source":"brightcove","_key":"f8f30a0bbab7","videoObject":{"videoDuration":"PT3M46S","videoDescription":"Future Directions in the Management of Multiple Myeloma","_type":"videoDetails","videoTitle":"Future Directions in the Management of Multiple Myeloma","thumbnail":{"_type":"image","asset":{"_ref":"image-3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080-png","_type":"reference"}}}},{"style":"normal","_key":"b5231d180f7c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"8d803ce622ae"}],"_type":"block"},{"_type":"block","style":"normal","_key":"fccac98c837a","markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following questions:","_key":"2c854263fb33"}]},{"_type":"block","style":"normal","_key":"3cf178e25826","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Please discuss any other data in multiple myeloma released at ASCO 2024 that you find noteworthy to share with colleagues. ","_key":"63dc67d628aa0"}],"level":1},{"markDefs":[],"children":[{"marks":[],"text":"Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma? What can we look forward to through the end of the year and beyond?","_key":"cf28959689810","_type":"span"}],"level":1,"_type":"block","style":"normal","_key":"2db08140b2d1","listItem":"number"}],"articleType":"Opinion","updatedOn":null,"_createdAt":"2024-07-25T12:44:15Z","is_visible":true,"authorMapping":[{"url":{"current":"alfred-l-garfall-md","_type":"slug"},"firstName":"Alfred","lastName":"Garfall","_createdAt":"2024-07-17T19:51:04Z","_type":"author","displayName":"Alfred L. Garfall, MD","_rev":"aqoly2OlphftVMTTVbXxHr","_id":"a0bf29d9-6da0-4217-b86f-d223ee867db9","_updatedAt":"2024-07-17T19:51:04Z"}],"title":"Future Directions in the Management of Multiple Myeloma ","showSocialShare":true,"summary":"Alfred L. Garfall, MD, discusses his hopes for the future treatment landscape of multiple myeloma. ","thumbnail":{"asset":{"_type":"sanity.imageAsset","sha1hash":"3517b8da479dc604439ff19b860b70a91bcd483b","extension":"png","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MAFPZ{Mb04?Y00tTacM{kEtR01Rk]~j@_M","_type":"sanity.imageMetadata","palette":{"dominant":{"title":"#fff","population":13.51,"background":"#bebfae","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"_type":"sanity.imagePalette","darkMuted":{"background":"#2e4558","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.12},"muted":{"title":"#fff","population":0.92,"background":"#a27166","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":0.96,"background":"#daa087","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"population":13.07,"background":"#045281","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"title":"#fff","population":13.51,"background":"#bebfae","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"title":"#fff","population":0.43,"background":"#116491","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png","_id":"image-3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080-png","_updatedAt":"2024-06-25T21:02:57Z","uploadId":"FPKTrYOtqnmBG2vFyhJIbmRMxvmwK8ma","_rev":"qzf0PkWIytRxftv8XaKu0J","size":1372116,"originalFilename":"GarfallHS.png","_createdAt":"2024-06-25T21:02:57Z","path":"images/0vv8moc6/ajmc/3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png","assetId":"3517b8da479dc604439ff19b860b70a91bcd483b"}},"url":{"current":"future-directions-in-the-management-of-multiple-myeloma","_type":"slug"},"documentGroup":{"_ref":"7021f7df-d5d2-474a-81ac-5e72ca401b54","_type":"reference"},"link":"/view/future-directions-in-the-management-of-multiple-myeloma","source":null,"factCheckAuthorMapping":null,"ExcludeFromPubMedXML":false,"published":"2024-07-24T12:44:00.000Z","_updatedAt":"2024-07-25T12:51:15Z","_type":"article","seoTag":["multiple myeloma","MM","tocilizumab","teclistamab","ASCO 2024","ASCO","2024 ASCO","multiple myeloma treatment","prophylactic tocilizumab with teclistamab","prophylactic tocilizumab"],"documentGroupMapping":[{"_ref":"7021f7df-d5d2-474a-81ac-5e72ca401b54","_type":"reference","_key":"253f43951da8"}]},{"summary":"Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.","thumbnail":{"asset":{"extension":"png","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAALCAYAAAB/Ca1DAAAACXBIWXMAAAPoAAAD6AG1e1JrAAAC8UlEQVQokUXR20/aBwDF8Z9blraOWn1pQvewZNmSXZJle1mySzeXXR5mi3MqeEMBS6bNRARFROQyAQGFWd1EwFKEX8dV5VIuopTapm2a7H/6LvXFh/P6yck5wrt9Oj4bN/Pp2DzSHi1dP2u43jOFtPcPbgwtcePOBtLpbaS/byLVeJGq3EgnvUjvrCPVBrg+GUCiXKdN4UN4nas/aHjn9jTfTs4h1+sZ1uuYMC0wZXeg9wWY345gCsUxhxMsR5Os3Bexx9PY93M4EgcYo1luLke5otxAUPgR2r4a5dqPagaMFnZiQeKJANGol3DYQ3R3DTHsJxsNcPQwRK2aotkqcvasxtOXp7z874zKs8eo7qXoUP2FMLSOIHw5cg6OLTvJlxKcnqYplx6QEje5v+Ug7pwjY9NxGLRSyexyUk/TPMnTahV4/rxGuVljIpCkQxW8aNj5kwaldZXDSoqzp0UajRxHhzGSO2vsLd4lMashv2qgnLhHrSxSq6SoVNPUj/OIR1kGXZHzHQW59wIcX3FTrOd48aJKq1WkUhZJhrxEFqYQZzUUXAaKsQ2qxQSNeobj4yyNkwMeFnIMroaRjPkQBj0XoNrhpdos8OrVMU+elCiVRPZCa/y9dBfRpCXnm2c/5CGTClN59C/14xzNx0Uyjwoo3FGujq4h9LsuwBGLm3g+Ra6YI55Osr0XwuFzYTHqCC5ME/ab2frHzW5sEzEdIX+4T71xRKpSQu6OIBl2IfQ5Ed74euz8lG6tGfWSF/WiD5XJy6jRTe+0jR6VkckZA1a3FXvgT1a3vPh21vFv+YmKMULZA3odu7ytcCL02hDe/GaM9u4J3pNN8clvM3wom+GjPj0fy818MGTn/WEbX2jt/DK3gsxgoW/RRr/Zya1ZCwNLHobdIT7XBbnUv4Jw2/IaVPLWTSXt3eNIvlfR/t0EV7rVXO4xcknh4fKIH8mwm2v9Zjplerp+NdA1YKJjwEyHwkrnqJN2uZ02mQXhlpn/Aa+KDZ/62dpfAAAAAElFTkSuQmCC","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MAFPZ{Mb04?Y00tTacM{kEtR01Rk]~j@_M","_type":"sanity.imageMetadata","palette":{"lightMuted":{"foreground":"#000","title":"#fff","population":13.51,"background":"#bebfae","_type":"sanity.imagePaletteSwatch"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.43,"background":"#116491"},"dominant":{"background":"#bebfae","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":13.51},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.12,"background":"#2e4558","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"foreground":"#fff","title":"#fff","population":0.92,"background":"#a27166","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"background":"#daa087","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.96},"darkVibrant":{"population":13.07,"background":"#045281","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}}},"_type":"sanity.imageAsset","sha1hash":"3517b8da479dc604439ff19b860b70a91bcd483b","_id":"image-3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080-png","_updatedAt":"2024-06-25T21:02:57Z","uploadId":"FPKTrYOtqnmBG2vFyhJIbmRMxvmwK8ma","_rev":"qzf0PkWIytRxftv8XaKu0J","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png","size":1372116,"originalFilename":"GarfallHS.png","path":"images/0vv8moc6/ajmc/3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080.png","assetId":"3517b8da479dc604439ff19b860b70a91bcd483b","_createdAt":"2024-06-25T21:02:57Z"}},"articleType":"Opinion","link":"/view/asco-2024-dreamm-8-study-of-belantamab-mafodotin-pomalidomide-and-dexamethasone","updatedOn":null,"showSocialShare":true,"body":[{"_type":"video","videoID":"6355439365112","disableAutoPlayVideo":false,"source":"brightcove","_key":"f8f30a0bbab7","videoObject":{"videoDuration":"PT6M05S","videoDescription":"ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone","_type":"videoDetails","videoTitle":"ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone","thumbnail":{"_type":"image","asset":{"_ref":"image-3517b8da479dc604439ff19b860b70a91bcd483b-1920x1080-png","_type":"reference"}}}},{"_key":"b5231d180f7c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"8d803ce622ae"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"fccac98c837a","markDefs":[],"children":[{"text":"Video content above is prompted by the following questions:","_key":"2c854263fb33","_type":"span","marks":["strong","em"]}]},{"level":1,"_type":"block","style":"normal","_key":"531dbfdbec72","listItem":"number","markDefs":[{"_type":"link","href":"https://meetings.asco.org/abstracts-presentations/234910","_key":"2e43e7dd4493"}],"children":[{"marks":[],"text":"Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (","_key":"9ab409a13fad0","_type":"span"},{"marks":["2e43e7dd4493"],"text":"Abstract","_key":"311e77a70fd9","_type":"span"},{"_type":"span","marks":[],"text":")","_key":"f95aa1e109f9"}]},{"_type":"block","style":"normal","_key":"f28765dff94e","listItem":"number","markDefs":[],"children":[{"text":"What was the objective of this study?","_key":"ff8fed9af97b0","_type":"span","marks":[]}],"level":2},{"listItem":"number","markDefs":[],"children":[{"marks":[],"text":"How was this study designed/what methodology was used?","_key":"d004cac44cf30","_type":"span"}],"level":2,"_type":"block","style":"normal","_key":"1dac90334cdf"},{"level":2,"_type":"block","style":"normal","_key":"4a37963d7473","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What results were presented?","_key":"0e1d0e54d1a70"}]},{"children":[{"_type":"span","marks":[],"text":"N=155","_key":"df66383b86cb0"}],"level":3,"_type":"block","style":"normal","_key":"72a9700b5eeb","listItem":"number","markDefs":[]},{"style":"normal","_key":"80196aaa2dfc","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Median follow-up: 21.78 months","_key":"df0db2fc8f020"}],"level":3,"_type":"block"},{"style":"normal","_key":"bad17003ea31","listItem":"number","markDefs":[],"children":[{"marks":[],"text":"PFS","_key":"e67a388d3d160","_type":"span"}],"level":3,"_type":"block"},{"children":[{"text":"ORR","_key":"c856ee6eb3700","_type":"span","marks":[]}],"level":3,"_type":"block","style":"normal","_key":"7f9ded6e394f","listItem":"number","markDefs":[]},{"_key":"51ecf00e029e","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Median duration of response","_key":"791f8737cb5c0"}],"level":3,"_type":"block","style":"normal"},{"_key":"09ad8c74b847","listItem":"number","markDefs":[],"children":[{"text":"OS","_key":"d8db6bc403700","_type":"span","marks":[]}],"level":3,"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"Safety","_key":"7e021c1748ca0","_type":"span"}],"level":3,"_type":"block","style":"normal","_key":"32ce9a7879ee","listItem":"number"},{"children":[{"_key":"afcf2d35bdd20","_type":"span","marks":[],"text":"Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?"}],"level":1,"_type":"block","style":"normal","_key":"67f7437506d8","listItem":"number","markDefs":[]},{"children":[{"text":"Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?","_key":"213bdfda70ff0","_type":"span","marks":[]}],"level":1,"_type":"block","style":"normal","_key":"39303dafd90c","listItem":"number","markDefs":[]}],"authorMapping":[{"_updatedAt":"2024-07-17T19:51:04Z","displayName":"Alfred L. Garfall, MD","_rev":"aqoly2OlphftVMTTVbXxHr","_id":"a0bf29d9-6da0-4217-b86f-d223ee867db9","_type":"author","url":{"current":"alfred-l-garfall-md","_type":"slug"},"firstName":"Alfred","lastName":"Garfall","_createdAt":"2024-07-17T19:51:04Z"}],"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_updatedAt":"2024-07-22T15:55:27Z","_type":"article","factCheckAuthorMapping":null,"seoTag":["multiple myeloma","MM","tocilizumab","teclistamab","ASCO 2024","ASCO","2024 ASCO","multiple myeloma treatment","prophylactic tocilizumab with teclistamab","prophylactic tocilizumab"],"documentGroup":{"_ref":"7021f7df-d5d2-474a-81ac-5e72ca401b54","_type":"reference"},"url":{"current":"asco-2024-dreamm-8-study-of-belantamab-mafodotin-pomalidomide-and-dexamethasone","_type":"slug"},"_createdAt":"2024-07-22T15:44:14Z","is_visible":true,"documentGroupMapping":[{"_ref":"7021f7df-d5d2-474a-81ac-5e72ca401b54","_type":"reference","_key":"253f43951da8"}],"title":"ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone","_id":"65708a6f-51f5-4510-a310-4eca2b3cd303","ExcludeFromPubMedXML":false,"_rev":"hS25uTmEvsaaDM5BOphQXr","published":"2024-07-19T19:50:00.000Z","source":null,"taxonomyMapping":[{"_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","summary":[{"style":"normal","_key":"f1088709f836","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_key":"4063e54b1813","_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."}],"_type":"block"}],"identifier":"multiple-myeloma","cmeType":"per","_updatedAt":"2023-11-03T18:19:22Z","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu"},{"name":"Post Conference Perspectives","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e","_updatedAt":"2021-05-14T15:31:15Z","identifier":"post-conference-perspectives","_createdAt":"2020-03-30T20:09:58Z","sortOrder":4,"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy"}]}],"topArticlesData":[{"thumbnail":{"asset":{"_type":"reference","_ref":"image-6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080-jpg"},"_type":"mainImage","alt":"Don M. Benson, MD, PhD, James Cancer Hospital"},"updatedOn":null,"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"_id":"a494245c-a60e-434d-91d7-e8fc5e45eb35","title":"Balancing Life and Myeloma: A Patient-Centered Approach","url":"balancing-life-and-myeloma-a-patient-centered-approach","factCheckAuthors":null,"summary":"In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.","published":"2024-11-22T13:00:00.000Z","source":null},{"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-c93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645-png","_type":"reference"}},"summary":"Coverage from the IVBM Regional event in Denver, Colorado.","published":"2024-11-21T17:23:00.000Z","authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"factCheckAuthors":null,"_id":"3ab0a249-35da-4929-895b-bc3bc50fe93c","title":"Elevating Value in Cancer Care With Innovations, Accessibility, Equity","url":"elevating-value-in-cancer-care-with-innovations-accessibility-equity","updatedOn":null,"source":null},{"title":"OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM","url":"os-better-with-belantamab-mafodotin-triplet-vs-daratumumab-in-r-r-mm","source":null,"factCheckAuthors":[{"displayName":"Jason M. Broderick","url":"jason-m-broderick"}],"authors":[{"displayName":"Jordyn Sava","url":"jordyn-sava"}],"_id":"b2dc2b22-f734-439e-944e-5bd9fd39038d","thumbnail":{"_type":"mainImage","alt":"Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com","asset":{"_ref":"image-80e6c85b19f91f7e54b4708b48cf74f795adc108-1200x738-jpg","_type":"reference"}},"summary":"The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).","published":"2024-11-19T23:00:00.000Z","updatedOn":null},{"thumbnail":{"_type":"mainImage","alt":"Don M. Benson, MD, PhD, James Cancer Hospital","asset":{"_ref":"image-9b9874b28b21d52d6b1aa78689e72d7eb07fb979-1200x677-jpg","_type":"reference"}},"summary":"Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.","source":null,"_id":"869a71d0-ad13-49af-9ca2-8f893ef79b95","title":"Elevating Myeloma Care Amidst Complex Treatment Choices","updatedOn":null,"authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null,"url":"elevating-myeloma-care-amidst-complex-treatment-choices","published":"2024-11-15T20:33:22.902Z"},{"updatedOn":null,"source":null,"title":"Eque-Cel CAR T Shows Strong Results for Multiple Myeloma","url":"eque-cel-car-t-shows-strong-results-for-multiple-myeloma","published":"2024-11-07T16:00:00.000Z","authors":[{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null,"_id":"82e9c996-5af0-47d1-a41a-956031888493","thumbnail":{"_type":"mainImage","alt":"Neon CAR T graphic | Image Credit: © kalpis-stock.adobe.com","asset":{"_type":"reference","_ref":"image-d6cda65715e52774e2cab34d922cdd302167b243-1200x738-jpg"}},"summary":"Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease progression following standard-of-care therapies that include immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies."}],"features":[{"_rev":"3pz5VXlyDK36YPI8AhGpHx","_createdAt":"2024-07-03T17:28:42Z","feature_title":"EHA 2024: Highlights in Multiple Myeloma","feature_alt":"Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.","hide_title_body":false,"sortOrder":1,"_updatedAt":"2024-07-03T17:28:54Z","feature_img":{"asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/2c39f10d15ac4c73885940b5265e347b27a026ea-492x300.png"}},"_id":"47b4132e-e53a-471f-ba12-ca401220b2a3","is_active":true,"_type":"feature","feature_body":"Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.","feature_url":"/compendium/multiple-myeloma","feature_link":"https://bit.ly/4cuqjYm"},{"_updatedAt":"2024-07-03T17:38:01Z","feature_title":"ASCO 2024: Updates in Multiple Myeloma","feature_img":{"asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/63104dfe74df304623abca580f162e1a8614d01f-492x300.png"}},"_id":"1dca5ee3-17cc-49d0-9d39-0f60829a3936","feature_body":"Alfred L. Garfall, MD, shares insights to recent data surrounding the multiple myeloma treatment landscape as presented at ASCO 2024 in Chicago, Illinois.","feature_url":"/compendium/multiple-myeloma","_createdAt":"2024-07-03T17:38:01Z","is_active":true,"hide_title_body":false,"_type":"feature","feature_alt":"Evan J. Lipson, MD, from Johns Hopkins University School of Medicine contributes key updates in melanoma treatment presented at ASCO 2024 in Chicago, Illinois.","feature_link":"https://bit.ly/3xIxcGa","_rev":"3pz5VXlyDK36YPI8AhHY4e"}],"cmeData":{"msg":"","data":[{"id":"355d9b46-713d-4d48-84a7-2968d82157e5","brandName":"Ajmc","dataType":"ptce","title":"ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/s7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png","description":"December 18, 2024 | 1:00 PM \u0026 8:00 PM ET","releaseDate":"2024-07-18T04:00:00.000Z","expirationDate":"2024-12-19","creditType":"Live","creditAmount":"1.0","created_at":"2024-11-12T12:05:52.433765+00:00","TI_id":"eae2665d-bf7f-42eb-a26a-99bbfbf06427","slug":"ash-annual-meeting-coverage-highlighting-the-recent-updates-in-tki-use-in-the-treatment-of-cml-insights-and-application-for-managed-care","delReference":true,"contentTypeLabel":"Webinar Registration","activity-type":null,"specialty":"[\"Oncology\",\"Hematology\",\"Hematologic Cancer\"]","creditCertificate":null,"courseEndDate":"2024-12-19T04:59:59.999+00:00","cventUrl":""},{"id":"3b3937de-a7a5-4ebd-bb5c-6192a7da7102","brandName":"Ajmc","dataType":"ptce","title":"Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/d051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png","description":"1.0 Credits / Hematologic Cancer, Oncology","releaseDate":"2023-12-21T05:00:00.000Z","expirationDate":"2024-12-22","creditType":"On-Demand","creditAmount":"1","created_at":"2024-11-12T12:05:53.299762+00:00","TI_id":"5568bba0-655c-4a88-afe5-febf5a5e9fc3","slug":"recent-advances-in-bcma-directed-treatment-in-multiple-myeloma-insights-and-application-for-managed-care-enduring","delReference":true,"contentTypeLabel":"On-Demand Webinar","activity-type":null,"specialty":"[\"Hematologic Cancer\",\"Oncology\"]","creditCertificate":null,"courseEndDate":"2024-12-22T04:59:59.999+00:00","cventUrl":""},{"id":"9453bbb8-c0d5-459e-9058-a97e9e0cdb97","brandName":"Ajmc","dataType":"ptce","title":"Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/hvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png","description":"1.5 Credits / Oncology, Hematology, Hematologic Cancer","releaseDate":"2024-05-03T04:00:00.000Z","expirationDate":"2025-05-04","creditType":"On-Demand","creditAmount":"1.5","created_at":"2024-11-12T12:05:53.144574+00:00","TI_id":"e2a1de76-f5f4-4393-85a1-e17a243a9853","slug":"keeping-pace-with-new-developments-in-multiple-myeloma-updates-and-strategies-to-optimize-bispecific-antibodies-and-car-t-cell-therapy-tcdv","delReference":true,"contentTypeLabel":"On-Demand Virtual Symposium","activity-type":null,"specialty":"[\"Oncology\",\"Hematology\",\"Hematologic Cancer\"]","creditCertificate":null,"courseEndDate":"2025-05-04T03:59:59.999+00:00","cventUrl":""},{"id":"54fbd28a-f02c-44b9-8d31-f0863e5d2455","brandName":"Ajmc","dataType":"ptce","title":"Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png","description":"1.5 Credits / Hematology, Hematologic Cancer, Oncology","releaseDate":"2024-05-03T04:00:00.000Z","expirationDate":"2025-05-04","creditType":"On-Demand","creditAmount":"1.5","created_at":"2024-11-12T12:05:53.222033+00:00","TI_id":"3f5fc85c-88a5-4d21-9e76-047d384b88f2","slug":"addressing-the-gaps-and-clinical-challenges-in-chronic-lymphocytic-leukemia-updates-and-strategies-for-managed-care-dxq5","delReference":true,"contentTypeLabel":"On-Demand Virtual Symposium","activity-type":null,"specialty":"[\"Hematology\",\"Hematologic Cancer\",\"Oncology\"]","creditCertificate":null,"courseEndDate":"2025-05-04T03:59:59.999+00:00","cventUrl":""}],"fail":false},"videoData":{}},"queryString":{"slug":["compendium","multiple-myeloma"]}},"host":"www.ajmc.com"},"__N_SSP":true},"page":"/[...slug]","query":{"slug":["compendium","multiple-myeloma"]},"buildId":"jIKMoC-9mMyLq4v4Ma7Tv","isFallback":false,"gssp":true,"appGip":true,"scriptLoader":[]}</script></body></html>